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Here are the young men, 
                                  a weight on their shoulders 
                                  Here are the young men, 
                                  well where have they been? 
                                  We knocked on the doors 
                                  of hell's darker chambers 
                                  Pushed to the limits 
                                  we dragged ourselves in 
                                  Watched from the wings as 
                                  the scenes were replaying 
                                  We saw ourselves now as 
                                  we never have seen 
                                  Portrayal of the traumas and degeneration 
                                  The sorrows we suffered 
                                  and never were freed 
                                  Where have they been? 
 
                                  Weary inside, now our hearts 
                                  lost forever 
                                  Can't replace the fear 
                                  or the thrill of the chase 
                                  These rituals showed up the door 
                                  for our wanderings 
                                  Opened and shut, then slammed 
                                  in our face 
                                  Where have they been?  
 
 
Joy Division – Decades 
© Deborah Curtis, 1995 
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Chapter 1 
Migraine 
1.1 Epidemiology and diagnostic criteria 
Migraine is defined as an idiopathic, paroxysmal neurological disorder with moderate to 
severe attacks of unilateral, throbbing headache exacerbated by physical activity.  The 
migraine attack is accompanied by associated features such as nausea, vomiting, 
photophobia and phonophobia (Headache Classification Committee of the International 
Headache Society, 1988).  Since migraine is a common illness, it imposes a tremendous 
health burden on both patient and society (Solomon & Price, 1997).  Prevalence rates of 
migraine vary geographically and its occurrence is dependent on age (most common from 
age 25-55 years), gender (three times more common in women than in man) and income 
(affecting lower socio-economic groups more, see Lipton & Stewart, 1997; Silberstein & 
Lipton, 1996).  In about one third of patients (Rasmussen & Olesen, 1992), an aura may 
precede the migraine headache within one hour (migraine with aura), consisting of focal 
neurological (scintillating scotoma), sensory (pins or needle feeling or numbness) and/or 
motor (weakness or paralysis) symptoms.  The majority of patients, however, do not 
present such symptoms (migraine without aura) (Ferrari, 1998). 
 Migraine attacks per se are not necessarily an abnormal feature, considering that 
anyone may experience one or two migraine attacks in life.  Migraine patients are 
therefore defined as individuals who have had at least two attacks with aura or at least five 
attacks without aura.  To study migraine scientifically, the International Headache Society 
(IHS) provided some strict and uniform criteria to determine whether a patient is suffering 
from migraine (Headache Classification Committee of the International Headache Society, 
1988) (see Table 1.1 for migraine with and without aura). 
 
1.2 Pathophysiology 
Migraine attacks seem to involve physiological mechanisms, which can be divided in 
three distinct phases: an initiating trigger, an aura and finally the headache (Ferrari, 1998).  
Attacks occur when the threshold is reduced or when the triggers are strong and frequent.  
Genetic factors, such as a P/Q-type calcium channel dysfunction (Ophoff et al., 1996), 
seem to act as predisposing factors.  Internal and environmental  
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Table 1.1 IHS classification and diagnostic criteria for migraine without aura and 
migraine with aura (Headache Classification Committee of the International Headache 
Society, 1988). 
 
Migraine without aura 
A. At least five attacks fulfilling B-D 
B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated) 
C. Headache has at least two of the following characteristics: 
1. Unilateral location 
2. Pulsating quality 
3. Moderate or severe intensity 
4. Aggravation by walking upstairs or similar routine physical activity 
D. During headache at least one of the following: 
1. Nausea and/or vomiting 
2. Photophobia and phonophobia 
E. At least one of the following: 
1. History, physical and neurological examinations do not suggest associated head trauma, vascular or 
non-vascular intracranial disorders, exposure to or withdrawal from (toxic) substances, non-
cephalic infection, metabolic disorders or cranial or facial disorders 
2. History and/or physical and neurological examinations do suggest such disorder, but is ruled out by 
appropriate investigations 
3. Such disorder is present, but migraine attacks do not occur for the first time in close temporal 
relation to the disorder 
 
 
Migraine with aura 
A. At least two attacks fulfilling B 
B. At least three of the following four characteristics: 
1. One or more fully reversible aura symptoms indicating focal cerebral cortical and/or brain stem 
dysfunction 
2. At least one aura symptom develops over more than 4 minutes, or two or more symptoms occur in 
succession 
3. No aura symptom lasts more than 60 minutes.  If more than one aura symptom is present, accepted 
duration is proportionally increased 
4. Headache follows aura with a free interval of less than 60 minutes.  (It may also begin before or 
simultaneously with the aura) 
C. At least one of the following: 
1. History, physical and neurological examinations do not suggest associated head trauma, vascular or 
non-vascular intracranial disorders, exposure to or withdrawal from (toxic) substances, non-
cephalic infection, metabolic disorders or cranial or facial disorders 
2. History and/or physical and neurological examinations do suggest such disorder, but is ruled out by 
appropriate investigations 
3. Such disorder is present, but migraine attacks do not occur for the first time in close temporal 
relation to the disorder 
Chapter 1 
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factors, such as hormonal fluctuations, fatigue, relaxation after stress, meteorological 
changes and substance abuse may modulate this threshold (Rasmussen, 1993). 
 
Migraine generator 
Although there is limited information available about the trigger phase of migraine, there 
are indications that the initial trigger involves the brainstem as ‘migraine generator’.  
Positron emission tomography studies demonstrated that during the headache phase 
cerebral blood flow increased in cortical sensory association areas and unilaterally in the 
brainstem and that this activation persisted after complete relief from headache (Diener & 
May, 1996; Weiller et al., 1995).  In healthy volunteers, capsaicin-provoked headache 
failed to demonstrate this brainstem activation (May et al., 1998). 
 
Migraine aura 
As mentioned above, in about one third of migraine patients an aura is experienced before 
the headache phase.  The aura is associated with a reduction in cerebral blood flow 
(Olesen et al., 1981) that falls below a critical value.  This decrease in cerebral blood flow 
may induce a ‘cortical spreading depression’, a short-lasting depolarisation wave starting 
at the occipital cortex and moving across the cortex at a speed of 3-5 mm/min, followed 
by a depression of neuronal activity (Lauritzen, 1994).  Although cortical spreading 
depression has been demonstrated in animal models (Moskowitz et al., 1993; Read et al., 
1997), definite evidence that this mechanism also applies in humans is lacking. However, 
the aura symptoms and the cortical spreading depression share characteristics, such as the 
velocity of its spread and the patterns of changes in blood flow, suggesting that both 
phenomena have a similar neurobiological origin. 
 
Headache phase 
The reduction in cerebral blood flow is followed by the headache phase, which is 
characterised by a vasodilatation of extracerebral large arteries and arteriovenous 
anastomoses (e.g. in the dura mater, base of the skull and scalp).  This vasodilatation is 
probably due to changes in activity of the neurones innervating these blood vessels, with 
subsequent release of vasodilator peptides and transmitters.  Immunohistochemical studies 
have demonstrated the presence of several vasodilators in perivascular nerve fibres 
supplying intracranial blood vessels, including vasoactive intestinal peptide (VIP), nitric 
oxide (NO), substance P, neurokinin A and calcitonin gene related peptide (CGRP) (for 
Introduction: Migraine 
6 
review see Gulbenkian et al., 1999).  Dilated cranial blood vessels lead to enhanced blood 
volume following each cardiac stroke and rapid diastolic runoff, with a consequent 
augmentation in pulsations within the affected blood vessel.  These pulsations may well be 
responsible for the throbbing nature of the headache during a migraine attack.  The 
augmented pulsations can then be sensed by ‘stretch’ receptors in the vessel wall 
activating perivascular afferent terminals of the trigeminal sensory nerve, which in turn, 
may also release neuropeptides.  This release can consequently reinforce vasodilatation 
and perivascular sensory nerve activity, intensifying the migraine attack (see Saxena, 
1994).  Axonal conduction transmits nociceptive information towards the trigeminal 
nucleus caudalis and higher brain centres such as thalamus and hypothalamus for the 
registration of pain, photo- and phonophobia and nausea (Figure 1.1).  
 
1.3 Current antimigraine drugs 
Mild to moderate migraine attacks may be treated with specific and non-specific drugs 
including rapidly absorbable NSAIDs (aspirin, naproxen, diclofenac and tolfanemic acid), 
analgesics (paracetamol), narcotics (codeine, pethidine and morphine) or combination 
preparations (Diener et al., 1998; Ferrari, 1998; Limmroth & Diener, 1998).  Antiemetic 
compounds such as metoclopramide and domperidone are able to speed up the gastric 
emptying and may thus, when taken early in the migraine attack, improve the absorption 
of other drugs (Diener et al., 1998; Ferrari, 1998).  The choice of drug, dose and route of 
administration depends on the characteristics and frequency of the attack and on the 
specific preferences and contraindications of the patient (Ferrari, 1998).   
Chapter 1 
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Figure 1.1 Diagram showing putative changes in migraine. For details see text.  Based 
on De Vries et al., 1999 and Saxena, 1994. 
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Prophylactic drugs 
The most important indications to start preventive treatment are headache frequency of 
more than two attacks per month, no or inappropriate response to, contraindication to, or 
overuse of acute therapy, or when optimal abortive therapies have produced intolerable 
side effects.  The goals of migraine preventive therapy are to: (1) reduce attack frequency, 
severity and duration; (2) improve responsiveness to treatment of acute attacks: and (3) 
improve function and reduce disability.  The mode of action of prophylactics is mostly 
unknown (Goadsby, 1997), and animal models to test the efficacy of the drugs are not 
available.  Furthermore, while most modern clinical trials of acute migraine treatment rely 
on uniform endpoints with minor variations, endpoints in migraine prevention trials are 
more diverse (for review see Ramadan et al., 2000).  In general, prophylactic treatment 
has a limited efficacy (Ramadan et al., 1997) and includes the α2-adrenoceptor agonist 
clonidine (Louis et al., 1985), the β-blockers propranolol and metoprolol, the 5-HT2 
receptor antagonists methysergide, pizotifen and lisuride and the calcium channel blocker 
flunarizine (Diener et al., 1998). 
 
Ergot alkaloids 
For decades, ergot alkaloids have been the only specific drugs for the acute treatment of 
migraine.  Although these drugs are widely used, their efficacy has been poorly 
demonstrated (Dahlöf, 1993; Meyler, 1996) mostly due to methodological flaws in the 
clinical trials, which, since 1991 have been improved and are now standardised by the IHS 
(International Headache Society Committee on Clinical Trials in Migraine, 1991).  
Ergotamine and dihydroergotamine are vasoconstrictors, but they also inhibit the 
neurogenic plasma extravasation in the rat (Buzzi et al., 1992).  Ergotamine and 
dihydroergotamine display affinity for a high number of receptors, which include 
α-adrenoceptors, dopamine receptors and 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1F and 5-HT2 
receptors (Pauwels, personal communication).  This lack of selectivity probably explains 
the side-effect potential of the drugs such as nausea, vomiting, vertigo, gastric symptoms, 
dry mouth, restlessness and chest symptoms (Meyler, 1996).  In addition, incidental 
overdose or chronic overuse may induce ergotism leading to cyanosis, necrosis and 
infarctions of the heart and brain (Tfelt-Hansen et al., 1995).  Both ergot alkaloids have a 
low oral and rectal bioavailability, resulting in a large interpatient variability in the 
amount of drug reaching the circulation (Humbert et al., 1996; Little et al., 1982).  
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Furthermore, the clinical response is not related to the plasma concentration of the drug 
(Martin et al., 1995; Tfelt-Hansen & Paalzow, 1985), which is probably due to the 
formation of active metabolites and the slow washout of the compounds from their 
receptor biosphere (MaassenVanDenBrink et al., 1998; Martin et al., 1995).  Despite the 
number of potential side effects the ergot alkaloids are still widely used (for review and 
consensus see Tfelt-Hansen et al., 2000). 
 
Sumatriptan 
In the last decade of the twentieth century, tremendous progress was made in the acute 
therapy of migraine.  Sumatriptan (for chemical structure see Figure 1.2), a member of a 
new class of drugs known as 5-HT1B/1D (previously 5-HT1-like) receptor agonists, has 
provided the lead (Humphrey et al., 1990; Humphrey et al., 1988).  The introduction of 
sumatriptan by Humphrey and colleagues was based on the findings that: (1) urinary 
excretion of 5-hydroxyindole acetic acid (5-HIAA) increases (Sicuteri et al., 1961), while 
platelet 5-HT decreases during migraine attacks (Hinterberger et al., 1968); (2) migraine-
like symptoms can be precipitated by reserpine and alleviated by 5-HT: and (3) 
ergotamine and methysergide elicit a selective carotid vasoconstriction (at least partly via 
5-HT1-like receptors), which is confined to cephalic arteriovenous anastomoses that seem 
to be involved in migraine pathophysiology (De Vries et al., 1999; Ferrari & Saxena, 
1993; Saxena & Tfelt-Hansen, 2000).  Based on the above, tryptamine derivatives were 
synthesised to achieve selectivity at craniovascular 5-HT1-like receptors and this 
culminated in the design of sumatriptan (Humphrey & Feniuk, 1991). 
 The discovery of the relatively selective 5-HT1 (i.e. 5-HT1B, 5-HT1D, 5-HT1F and to 
a minor extent 5-HT1A, see Table 1.2) receptor agonist sumatriptan was a major 
improvement in the acute treatment of migraine.  The drug is highly effective and is 
generally well tolerated (Brown et al., 1991; The Subcutaneous  Sumatriptan  
International Study Group, 1991).  Despite its great utility in migraine treatment, 
sumatriptan has certain limitations such as low oral bioavailability (14%), high frequency 
of headache recurrence (20-40%, Fowler et al., 1991; Lacey et al., 1995), possibly due to 
a short half-life, and adverse events of which heaviness, pressure or tightness in the chest 
are reported in up to 15% of patients (Brown et al., 1991). Furthermore, the drug is 
contraindicated in patients with coronary artery disease because of its potential to constrict 
coronary arteries (see Chapter 3).  These shortcomings of sumatriptan, in addition to the 
excellent sales potentials in migraine, have prompted several pharmaceutical companies to 
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develop 5-HT1B/1D receptor agonists (the so-called ‘second generation’ triptans), which 
would be at least as effective as sumatriptan, but devoid of its shortcomings. 
 
Second generation triptans 
As mentioned above, several companies developed 5-HT1B/1D receptor agonists (for 
chemical structures see Figure 1.2) with a particular aim for a higher oral bioavailability, a 
longer duration of action with lower headache recurrence, greater selectivity for the 
carotid over the coronary vascular bed and with fewer if any chest related symptoms.  
Since the introduction of sumatriptan, five second-generation triptans have been marketed 
(zolmitriptan, naratriptan, rizatriptan, eletriptan and almotriptan), while frovatriptan is still 
awaiting approval by the Food and Drug Administration and European Medicines 
Evaluation Agency (Palmer & Dalton, 1999).  Donitriptan (F11356, John et al., 1999) and 
IS-159 (Dingemanse et al., 2000) are still in the earlier phases of investigation.  The 
clinical development of a few others has been discontinued because of lack of advantage 
compared to sumatriptan (alniditan and BMS181885) or because of severe alteration in 
hepatic function (avitriptan).  In general, the second-generation triptans display a higher 
affinity at the 5-HT1B and 5-HT1D receptors than sumatriptan, whereas for other 5-HT 
receptors the binding affinity profile varies (see Table 1.2 and Chapter 2 for details on the 
pharmacology of the triptans).  Pharmacokinetically, the second-generation triptans 
display improved oral properties compared to sumatriptan (see Table 1.3), oral 
bioavailability is much higher and more consistent and they proclaim a substantial 
increased lipophilicity and thus can cross the blood brain barrier for a possible central 
action (see Chapter 2).  Clinical efficacy data obtained in randomised clinical trials with 
and between the triptans are currently under evaluation (for reviews on clinical data see 
Deleu & Hanssens, 2000; Goadsby, 1998; Roon, 2000; Saxena & Tfelt-Hansen, 2000) and 
show that the second-generation triptans display similar pharmacotherapeutic properties as 
compared to sumatriptan.  Furthermore, all triptans caused typical adverse events, or 
so-called triptan symptoms (Mathew, 1997), which vary for the different triptans but all 
include heaviness, and pressure or tightness in the chest (Saxena & Tfelt-Hansen, 2000).  
As was observed with sumatriptan, all second-generation triptans have the propensity to 
contract the human isolated coronary artery and are, therefore, contraindicated in patients 
with coronary artery disease (Saxena & Tfelt-Hansen, 2000).   
 Overall, more head to head clinical trials are needed to determine the place of each 
of these 5-HT1B/1D receptor agonists.  Although differences among the triptans appear to 
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be small, the pharmacokinetics vary and, therefore, the availability of effective therapeutic 
options may improve the management of individual patients. 
 
 
Figure 1.2  Chemical structure of triptans 
 
N H 
S 
N H 
C H 3 
N
CH3 CH3
O O 
N H 
S 
O O 
N
CH3
H 
Sumatriptan Zolmitriptan 
Naratriptan Rizatriptan 
Eletriptan Almotriptan 
Frovatriptan 
NH
N 
C H 3 C H 3 
O
NH
O
N H 
N H 2 
S 
O O 
N
CH3
NH
N
N 
CH 3 C H 3 
N
N
N H 
NH
CH3N H 2 
O 
NH
O N H 2 
N
N
C
O
N
NH
S
O O
N
N 
C H 3 C H 3 
 Vernalis   
 Centre de  Recherche  Pierre  Fabre 
            Pfizer  Almirall Prodesfarma 
GlaxoSmithKline   
GlaxoSmithKline   
    Merck Sharp &    Dohme  
Zeneca
Donitriptan 
  
 
Chapter 2 
13 
Chapter 2 
Mechanisms of action of antimigraine drugs 
2.1 5-HT1 receptor agonists 
The introduction of sumatriptan resulted in extensive research investigating the 
therapeutic targets of acutely acting antimigraine drugs.  The vascular theory launched by 
Wolff suggested that the migraine aura is caused by intracranial vasoconstriction, which is 
countered by a reactive vasodilatation of the large extracranial arteries causing the 
headache (Wolff, 1963).  Furthermore, the observations as mentioned in Chapter 1.3 
(increase of 5-HIAA urinary excretion, precipitation of migraine symptoms by reserpine 
and alleviation by 5-HT and a selective carotid vasoconstriction by ergotamine) suggest a 
pivotal role for 5-HT in arterial vasoconstriction (see Saxena, 1990) and was the rationale 
behind the introduction of sumatriptan.  Although originally developed to induce 
contraction of putatively distended cranial blood vessels via postsynaptic 5-HT1 receptors 
(Humphrey et al., 1990; Humphrey & Feniuk, 1991), sumatriptan was also found to 
interact with presynaptic receptors on trigeminovascular afferents, whose activation is 
important in the development of meningeal neurogenic inflammation (Humphrey & 
Goadsby, 1994, for details see below).  Since then, sumatriptan-sensitive sites of action in 
the pain-transmitting pathways have been identified centrally, suggesting an additional 
mechanism of action within the central nervous system (Goadsby, 1997, for details see 
below).  
 
Receptor-binding profile 
Sumatriptan, a closely related 5-HT derivative, was developed as the first cranioselective 
vasoconstrictor, designated as a 5-HT1-like receptor agonist (Humphrey et al., 1990; 
Humphrey et al., 1988) devoid of the peripheral vasoconstrictor properties mediated via 
the 5-HT2 receptor (Bradley et al., 1986).  Since the introduction of sumatriptan the 
5-HT1-like receptors have been characterised and subdivided in 5-HT1A, 5-HT1B 
(previously known as 5-HT1Dβ), 5-HT1D (5-HT1Dα), 5-HT1E, 5-HT1F and 5-HT7 receptors 
(Hoyer et al., 1994; Hoyer & Martin, 1997; Martin & Humphrey, 1994).  Sumatriptan and 
the second-generation triptans display a high affinity at the 5-HT1B and 5-HT1D receptors 
(Table 1.2), with sumatriptan and rizatriptan being the weakest at the 5-HT1B receptor. All 
triptans have a moderate affinity at the 5-HT1A receptor.  Similarly, the compounds have a 
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moderate to high affinity for the 5-HT1F receptor, except donitriptan, IS-159 and the 
non-triptan alniditan (Leysen et al., 1996).  A high degree of selectivity is observed over 
the other 5-HT receptors, although some triptans display affinity at the 5-HT7 receptor, 
which mediates smooth muscle relaxation (Eglen et al., 1997; Saxena et al., 1998).  
Finally, it is worth mentioning that donitriptan displays a moderate affinity at the 5-HT2A 
receptor. 
 
Craniovascular 5-HT1 receptors 
As shown in Table 1.4 and further described in Chapter 3, a number of human isolated 
blood vessels contract in response to second-generation triptans with a potency that is 
similar to that of sumatriptan (Bou et al., 2000; Kaumann et al., 1993; Longmore et al., 
1998; MaassenVanDenBrink et al., 2000; Nilsson et al., 1999; Parsons et al., 1998; 
Razzaque et al., 1999; van den Broek et al., 2000).  Comparative pharmacological studies 
revealed a positive correlation between the vascular 5-HT1 receptor, mediating cerebral 
artery contraction, and the cloned human 5-HT1B, but not the 5-HT1D, receptor. This latter 
observation indicates that the 5-HT1B receptor is the target for the triptans in cranial blood 
vessels (Hamel & Bouchard, 1991; Hamel et al., 1993; Nilsson et al., 1999; Razzaque et 
al., 1999).  Other studies demonstrated expression of the 5-HT1B, but not 5-HT1D, receptor 
mRNA (Bouchelet et al., 2000; Hamel et al., 1993; Razzaque et al., 1999; Verheggen et 
al., 1998) and protein (Longmore et al., 1998; Nilsson et al., 1999) in human cranial 
vessels.  In addition to 5-HT1B receptors, expression of 5-HT1F receptor mRNA has been 
detected (Bouchelet et al., 2000).  But, as was observed for the cloned 5-HT1D receptor, no 
correlation between the vascular 5-HT1 and the 5-HT1F receptor was observed (Hamel et 
al., 1993; Kaumann et al., 1993). Furthermore, the lack of contractile effects of the 
selective 5-HT1F receptor agonists LY334370 and LY344864 in human isolated cerebral 
arteries (Bouchelet et al., 2000; Elhusseiny & Hamel, 2001) imply that this receptor does 
not mediate vasoconstriction.  Interestingly, LY334370 seems to be effective in the 
treatment of migraine (Gossen et al., 2000; Granier et al., 2000), suggesting that 5-HT1B 
receptor-induced vasoconstrictor activity may not be required for antimigraine activity.  
Unfortunately, it has not been demonstrated that the plasma concentrations reached after 
administration of LY334370 are devoid of vasoconstrictor activity, based on its moderate 
affinity for the 5-HT1B receptor (pKi: 6.87; Johnson et al., 1997).  In addition, no data are 
available on vasoactive metabolites as is the case for zolmitriptan (Peck et al., 1998) and 
rizatriptan (Goldberg et al., 2000).  Be that as it may, the effectivity of LY334370 in 
Chapter 2 
15 
migraine has no bearing on the importance of the 5-HT1B receptor in mediating the 
therapeutic action of the triptans, as illustrated by the clinical efficacy the non-triptan, 
alniditan (Roon et al., 1999), which has little affinity for the 5-HT1F receptor (Leysen et 
al., 1996). 
 
Peripheral 5-HT1 receptors on trigeminovascular afferents 
Moskowitz and colleagues extensively studied the implication of the trigeminovascular 
system in the manifestation of migraine pain, suggesting a possible neuronal locus of 
action of sumatriptan that involves blockade of nociceptive information (Moskowitz et al., 
1979).  The trigeminal fibres innervating human cerebral vessels contain vasodilator 
neuropeptides substance P, neurokinin A and CGRP (Edvinsson, 1991), of which the latter 
is released after depolarisation of the trigeminovascular ganglion or its perivascular nerve 
terminals (Goadsby et al., 1988).  The release of vasodilator neuropeptides subsequently 
leads to the development of a neurogenic inflammation.  Furthermore, CGRP is released 
into the extracerebral circulation during a migraine attack (Goadsby et al., 1990) and these 
levels are normalised after administration of sumatriptan in parallel with headache relief 
(Goadsby & Edvinsson, 1993).  Sumatriptan may block the release of neuropeptides and 
the subsequent dural plasma protein extravasation through inhibitory presynaptic 5-HT1 
receptors, located on trigeminovascular afferents (Buzzi et al., 1992; Buzzi & Moskowitz, 
1991).  Interestingly, mRNAs encoding for the 5-HT1B and 5-HT1D receptor (Bouchelet et 
al., 1996), as well as the receptor proteins (Longmore et al., 1997) are present on human 
trigeminal ganglia.  Peripherally located nerve terminals, however, only contain the 
5-HT1D receptor (Longmore et al., 1997), indicating that this presynaptic receptor is most 
likely the target for sumatriptan in controlling neurogenic inflammation.  Indeed, the 
triptans (although yet to be established for frovatriptan and IS-159) inhibit plasma protein 
plasma extravasation following stimulation of the trigeminal nerve (Limmroth et al., 2001; 
Gras et al., 2000; Gupta et al., 2000; Hargreaves & Shepheard, 1999; Limmroth et al., 
1999) in animal models.  However, angiography techniques failed to demonstrate plasma 
protein extravasation in patients during a migraine attack (May et al., 1998).  Interestingly, 
the selective 5-HT1D receptor agonist PNU-142633 (McCall, 1999), as well as other potent 
plasma protein extravasation inhibitors, such as the endothelin receptor antagonist 
bosentan (May et al., 1996) and the Neurokinin-1 receptor antagonist lanepitant 
(Goldstein et al., 1997), proved to be ineffective in the treatment of migraine.  
Furthermore, CP122288, a restricted sumatriptan derivative that has superior efficacy in 
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inhibiting plasma protein extravasation compared to sumatriptan (over a thousand fold, 
see Shepheard et al., 1997), was ineffective in the treatment of migraine at doses devoid of 
vasoconstrictor action (Roon et al., 2000).  Another receptor active in plasma protein 
extravasation is the 5-HT1F receptor. The selective 5-HT1F receptor agonists LY334370 
and LY344864 inhibit plasma protein extravasation in rat and guinea pig (Johnson et al., 
1997; Phebus et al., 1997).  These observations, together with the antimigraine activity of 
LY334370 (see above), may prove that the 5-HT1F receptor is an interesting new 
presynaptic target for the acute treatment of migraine.  As mentioned in the previous 
paragraph, the effective antimigraine drug alniditan lacks affinity at the 5-HT1F receptor, 
indicating that antimigraine efficacy does not require activation of this receptor. 
 
Central 5-HT1 receptors in the trigeminal nucleus caudalis 
An additional level of interest in the acute treatment of migraine has been the cells located 
centrally in the trigeminal nucleus caudalis that transduce intracranial noiciceptive 
information to higher integrative centres.  These cells represent an attractive neuronal 
therapeutic target that could be dissociated from vascular effects.  Interestingly, binding 
sites that recognise 5-HT1 receptor ligands, such as sumatriptan, have been localised at 
this level in humans (Pascual et al., 1996).  Goadsby and colleagues have demonstrated 
that intravenous administration of zolmitriptan (Goadsby & Edvinsson, 1994), naratriptan 
(Goadsby & Knight, 1997) or eletriptan (Goadsby & Hoskin, 1999) inhibited action 
potentials generated in the trigeminal nucleus caudalis after superior sagittal sinus 
stimulation, as well as c-fos mRNA expression, indicating neuronal activity (Hoskin et al., 
1999).  Similarly in rats, rizatriptan (Cumberbatch et al., 1997) and eletriptan (Knyihar-
Csillik et al., 2000) inhibit such potentials evoked by dural stimulation.  However, due to 
its poor brain penetration, intravenous sumatriptan did not alter trigeminal evoked activity 
(Kaube et al., 1993), nor did it affect c-fos expression in the trigeminal nucleus caudalis 
following trigeminal ganglion stimulation (Shepheard et al., 1995).  This raises the 
question of whether central trigeminal inhibition is a key factor in the action of 5-HT1B/1D 
receptor agonists.  On the other hand, it remains to be clarified whether during migraine 
headaches the blood-brain barrier is partly disrupted.  Indeed, after infusion of 
hyperosmolar mannitol, which disrupts the blood-brain barrier, both trigeminal evoked 
activity (Kaube et al., 1993) and c-fos expression (Shepheard et al., 1995) were inhibited 
by sumatriptan.  Additional 5-HT1 receptors in the nucleus tractus solitarus and area 
prostrema (Pascual et al., 1996), regions that are devoid of blood-brain barrier, could be 
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accessible even to non-brain-penetrant compounds such as sumatriptan and potentially 
explain some of their antiemetic effects.  The exact nature of the 5-HT1 receptor subtype 
involved in the central inhibition in human remains to be clarified.  On the basis of 
receptor mRNA and protein localisation in the trigeminal nucleus caudalis (see above) one 
can argue for the 5-HT1D receptor (Longmore et al., 1997) or even the 5-HT1F receptor.  
5-HT1F receptor involvement is supported by observations in rat, where LY334370 
inhibited activation of second-order neurons in the trigeminal nucleus caudalis produced 
by electrical stimulation of the dura mater (Shepheard et al., 1999).  The recent and 
forthcoming development of 5-HT1 receptor subtype-specific compounds will help to 
further identify which receptor subtype is involved in the central action of the triptans. 
 
2.2 5-HT2B receptor antagonists 
Although the exact role of 5-HT in the pathogenesis of migraine headache remains 
unknown, it has been hypothesised that migraine is a low serotonergic syndrome, 
primarily based on physiological studies on the evaluation of auditory evoked potentials.  
The amplitude of these evoked potentials is inversely related to central serotonergic 
transmission and in migraine patients a marked increase in amplitude was observed 
between attacks (Wang et al., 1996).  This latter finding supports a low 5-HT transmission 
and abnormal cortical processing of sensory information (Hegerl & Juckel, 1993).  It has 
been suggested that the optimal goal in migraine management may be to stabilise 5-HT 
neurotransmission (Raskin, 1993) since both neuronal and platelet stores of 5-HT are 
mobilised during a migraine attack (Humphrey, 1991).  There is considerable 
circumstantial evidence that the 5-HT2B receptor on human cranial blood vessels is 
activated by release of 5-HT and causes vasodilatation followed by a sequence of events 
leading to the migraine headache (Fozard & Kalkman, 1994; Schmuck et al., 1996).  
Clinical evidence to support the role of the 5-HT2B receptors in the development of 
migraine comes from the characteristics of some of the most common used migraine 
prophylactics, such as pizotifen, methysergide, cyproheptadine, amitriptyline, mianserin, 
chlorpromazine and propranolol which are non-selective antagonists at the 5-HT2 receptor 
(Goadsby, 1997).  On the other hand, the effectiveness of these drugs in migraine has been 
debated (Tfelt-Hansen & Saxena, 2000).  However, administration of the 5-HT2B receptor 
agonist meta-chlorophenylpiperazine (mCPP), yielding plasma concentrations compatible 
with activation of this receptor, produces a throbbing migraine-like headache accompanied 
Introduction: Mechanisms of Action 
18 
by nausea, vomiting and photophobia (Brewerton et al., 1988; Leone et al., 2000).  
Endothelial NO formation, occurring as a consequence of 5-HT2B receptor activation, 
appears to play a pivotal role with regard to both vasodilatation and plasma protein 
extravasation (Fozard & Kalkman, 1994; Olesen et al., 1995; Schmuck et al., 1996).  
Furthermore, migraine sufferers appear to be supersensitive to NO (in the form of nitro-
glycerine or glyceryl trinitrate) exposure (Olesen et al., 1993; Olesen et al., 1994; 
Thomsen et al., 1993).  NO, once released from the endothelial cells, can diffuse into the 
smooth muscle layer to induce dilatation of pain-sensitive intracranial arteries and also has 
the potential to activate trigeminovascular sensory nerve terminals that contain 
substance P and CGRP (Wei et al., 1992).  The success of a non-selective NO synthetase 
inhibitor L-NG-methylarginine hydrochloride in the treatment of migraine headache 
(Lassen et al., 1998) supports this hypothesis.  It should be mentioned, however, that the 
mCPP- or nitro-glycerine-induced headache is at its peak 8-12 hours after administration 
(Brewerton et al., 1988; Olesen et al., 1993), suggesting a still unknown mechanism after 
the initial NO formation, following 5-HT2B receptor activation.  Based on the premise that 
the release of 5-HT and subsequent activation of endothelial 5-HT2B receptors are early 
and important steps in the pathogenesis of migraine headache, clinical trials with specific 
5-HT2B receptor antagonists could clarify the role for this link in migraine pathogenesis.   
 
2.3 5-HT7 receptor antagonists 
A putative role of the 5-HT7 receptor in the regulation of cerebrovascular tone and 
migraine has been postulated on the basis of the ability of 5-HT to produce smooth muscle 
relaxation, through an endothelium-independent mechanism, in dog cerebral arteries 
(Terron, 1998; Terron, 1998; Terron & Falcon-Neri, 1999) via a receptor with a 
pharmacological profile that resembles the 5-HT7 receptor.  Furthermore, there is a high 
expression of 5-HT7 transcripts in animal and human brain vessels (Schmuck et al., 1996; 
Schoeffter et al., 1996; Ullmer et al., 1995).  The 5-HT7 receptor is positively coupled to 
adenylate cyclase (Tsou et al., 1994), increasing cyclic adenosine monophosphate (cAMP) 
in cultured smooth muscle cells from human brain vessels (Cohen et al., 1996).  It is thus 
possible that a similar relaxant mechanism operates in human brain vessels (via 
serotonergic nerve terminals located at the adventitial-medial border) by eliciting a direct 
dilatation of meningeal blood vessels without an interaction with the endothelial cells.  
Interestingly, most antimigraine prophylactics display a relatively high affinity at the 
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cloned 5-HT7 receptor (Terron, 1998) and are able to block 5-HT7 receptor-induced 
relaxation (Terron & Falcon-Neri, 1999).  The recent development of selective 5-HT7 
receptor antagonists (Forbes et al., 1998; Lovell et al., 2000) may fully elucidate the role 
of the 5-HT7 receptor in human cranial vessels and its function in the development of 
migraine headache. 
 
2.4  CGRP receptor antagonists  
Calcitonin gene-related peptide (CGRP) is a 37-amino acid peptide produced by 
alternative processing of calcitonin gene transcripts (Amara et al., 1982). CGRP 
containing nerves are closely associated with blood vessels and upon release of CGRP, a 
pronounced vasodilator response is observed in cerebral arteries (Edvinsson et al., 1987; 
Jansen et al., 1992).  Furthermore, CGRP released from sensory fibres originating in the 
trigeminal ganglia, dilates cerebral arteries (Goadsby & Edvinsson, 1993) and during a 
migraine attack, levels of CGRP are increased (Goadsby et al., 1990).  It has been 
postulated that inhibition of CGRP release (presynaptic) or prevention of CGRP-induced 
dilatation of cranial blood vessels (postsynaptic) leads to attenuation of a migraine attack.   
Furthermore, elevated levels of CGRP are normalised on administration of sumatriptan, 
concomitant with relief of headache pain (Goadsby & Edvinsson, 1993).  This action of 
sumatriptan may be related to prejunctional 5-HT1B/1D receptors located on trigeminal 
terminals, preventing CGRP release and subsequent inhibition of neurogenic 
vasodilatation (Humphrey & Feniuk, 1991).  The mode of action of CGRP and the clinical 
application of CGRP antagonists are of great interest in migraine pathophysiology and 
therapy, but the lack of non-peptidergic or stable CGRP antagonists has hampered both 
fundamental and clinical investigations. CGRP exerts its effects through 
G-protein-coupled receptors, which have been classified into CGRP1 and CGRP2 receptors 
(van Rossum et al., 1997).  Two forms of CGRP, termed α- and β-CGRP, are expressed in 
humans (Amara et al., 1985) and display very similar biological activities but can be 
pharmacologically distinguished by their agonist potency at CGRP1 and CGRP2 receptors, 
respectively (Jansen et al., 1992; Nilsson et al., 1992).  In vitro pharmacological 
determination of CGRP receptors involved in cranial artery dilatation has been hampered 
due to the lack of a potent CGRP antagonist. The weak CGRP1 peptidergic antagonist 
h-α-CGRP(8-37) only displays moderate affinity for this receptor (Chiba et al., 1989; Rist et 
al., 1998) with a possible residual partial agonist activity (Longmore et al., 1994; Poyner, 
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1995).  Furthermore, the clinical implication of this antagonist in migraine is poor due to 
its peptidergic structure. In this light, the introduction of the novel and chemically stable 
CGRP antagonist BIBN4096BS (Doods et al., 2000), may further clarify the importance 
of CGRP and its receptors in the pathogenesis of migraine.  Currently, this compound is 
under clinical investigation for the acute treatment of migraine headache and the results 
are awaited with great interest. 
 
2.5 Cortical spreading depression inhibitors 
As described in Chapter 1, cortical spreading depression is characterised by a transient, 
reversible depression of electrocephalographic activity originally linked to the aura phase.  
The role of cortical spreading depression in humans is controversial because of difficulties 
in demonstrating this phenomenon clinically. In animal models however, cortical 
spreading depression leads to cranial vasodilatation, partly caused by the release of CGRP 
and NO (Wahl et al., 1994).  Interestingly, sumatriptan appeared to decrease the amplitude 
of NO release, after locally applied depolarisation in both cats and rats (Read & Parsons, 
2000). Inhibition of this vasodilator response seems to be a novel avenue for the 
development of antimigraine drugs devoid of vasoconstrictor action.  Several compounds 
with distinct pharmacological properties have been described to block cortical spreading 
depression, such as the diuretic furosemide (Read et al., 1997), melatonin (Ebert et al., 
1999), the inhibitor of organic anion transport probenecid (Taylor et al., 1997) and the 
calcium channel antagonist lomerizine (Hara et al., 1998).  The antiepileptic drug 
lamotrigine, a glutamate receptor antagonist blocking voltage-sensitive sodium channels, 
inhibits cortical spreading depression and is effective in preventing migraine aura 
symptoms together with affecting headache frequency (Lampl et al., 1999).  Another 
study indicated that lamotrigine was ineffective in migraine prophylaxis (Steiner et al., 
1997).  Particular interest lays in the development of the anticonvulsant SB220453 (Chan 
et al., 1999), currently under investigation in clinical trials in migraine prophylaxis.  
SB220453 potently inhibits cortical spreading depression-evoked NO release via a yet 
unknown mechanism (Read et al., 2000; Smith et al., 2000) but is devoid of 
vasoconstrictor properties (this thesis and MaassenVanDenBrink et al., 2000). 
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Chapter 3 
Human blood vessels as in vitro models in migraine 
3.1 General 
As described in Chapters 1 and 2, migraine attacks are known to involve alterations in the 
regulation of tone of intra- and/or extra-cranial arteries. The subsequent dilatation of these 
cranial blood vessels then induces the headache (Humphrey et al., 1990; Humphrey & 
Feniuk, 1991; Saxena, 1990; Saxena, 1994).  There are several models, both in human and 
animal, to study the effects and mechanisms of antimigraine drugs on cranial blood 
vessels, both in vivo and in vitro.  Experimentally induced headaches, in healthy 
volunteers or migraine patients, provide possibilities to study headache mechanisms in 
various ways.  Arterial reactions can be studied using transcranial Doppler and 
high-frequency ultrasound imaging to measure regional cerebral blood flow and volume. 
Blood samples taken before and after a migraine attack can be compared to evaluate 
biochemical alterations in amines and neuropeptides (Goadsby et al., 1988; Goadsby et 
al., 1990).  Furthermore, experimental headache induction may be useful in the early 
investigation of novel pharmacologic compounds for migraine and pharmacologic 
intervention can be a useful tool in the study of headache mechanisms (Olesen, 1995).  It 
should be mentioned, however, that setting up in vivo measurements in man is limited in 
view of ethical and practical reasons.  Several experimental models representing features 
of migraine pathophysiology have been clarified in laboratory animals (for review see De 
Vries et al., 1999).  However, animals do not have migraine or at least cannot express 
whether they have a migraine or not, nor are there any biological markers that indicate 
whether an animal has migraine.  Furthermore, there are marked differences between the 
various species and humans, regarding neuronal transmission and receptor pharmacology 
and localisation in tissues (Hoyer & Middlemiss, 1989; Parsons, 1991).  In the light of the 
above, it is meaningful to apply in vitro techniques to blood vessels from man to obtain 
information about the vascular pathophysiology and evaluation of potential drugs in 
migraine treatment.  The study of contraction and relaxation in ring segments of blood 
vessels important in migraine therapy is a straight forward method used to examine the 
vascular effects of drugs and together with molecular biology techniques provides an 
excellent tool in understanding migraine pharmacology.  This chapter will mainly focus on 
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the effects of acute antimigraine drugs (i.e. triptans) in human isolated blood vessels 
important in migraine therapy. 
 
3.2 In vitro organ bath pharmacology 
Pre-experimental considerations 
Many methods have been developed for studying the mechanical responses of blood 
vessels in vitro involving vascular segments. The experimental conditions and methods 
depend on the size of the vessel, the desired response and equipment available. The first 
consideration is the choice of the buffer solution used in the experiments with the Krebs 
bicarbonate solution as the most widely used.  In particular the concentration of Ca2+ ions 
(Godfraind & Kaba, 1972; Janssens & Verhaeghe, 1984) and the pH (Verbeuren et al., 
1978) can influence the reactivity of the isolated blood vessels.  The solution is often 
bubbled with a gas mixture of 5% CO2 (which will maintain a proper pH) and 95% O2 to 
prevent hypoxia and unwanted release of substances (Rubanyi & Paul, 1985; Rubanyi & 
Vanhoutte, 1985).  The temperature is another factor that must be controlled, as it affects 
vascular reactions and the apparent affinity of certain receptors for agonists and 
antagonists (Arner & Hogestatt, 1990; Flavahan & Vanhoutte, 1986; Padilla et al., 1998; 
Padilla et al., 1997). 
 Another consideration is whether or not the endothelium should remain intact, since 
it can profoundly influence both the resting tone and pharmacological reactivity of a drug.  
A large number of studies have shown that activation of the endothelium leads to release 
of NO, prostacyclins, prostanoids and endothelins, which can obscure the true behaviour 
of the drugs acting at vascular smooth muscle receptors.  Similarly, receptors present in 
the smooth muscle can also be present in endothelial cells, which could alter the response 
to drugs.  Leaving the endothelium intact, however, may resemble the physiologic reality 
closer but requires criteria that define its functional integrity (such as observing relaxation 
to substance P).  Once suspended in organ baths, each individual blood vessel segment 
should be stretched to a level of maximum responsiveness, the degree of stretch necessary 
for this condition can be determined by measuring the maximal response with several 
degrees of pre-stretch.  In practise this can be time consuming and an average degree of 
stretch is determined in pilot experiments and used in subsequent experiments using the 
same type of blood vessel.  After initial resting tension is obtained, a reference contraction 
should be introduced, which can be used as an internal standard.  In general, 
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potassium-induced depolarisation is applied, but this reference contraction can also be 
obtained by applying by a well described receptor agonist, preferably without influence on 
the mechanisms investigated to avoid unwanted receptor activation or desensitisation.  
Once all pre-experimental conditions have been determined, concentration response 
curves can be constructed by either single drug concentration exposure or cumulative drug 
additions of which the latter can be designed with either a single curve or a multiple curve 
protocol in each segment preparation (for review on pre-experimental considerations see 
Janssens, 1995; Lew & McPherson, 1996; Martin & Giles, 1996). 
 
Pharmacological parameters  
Studying the effect of drugs in human isolated blood vessels can produce valuable 
parameters.  Concentration response curves can be described by fitting the constructed 
cumulative concentration response curve of a drug, using a non-linear regression analysis, 
into a concentration effect curve by using the following equation: 
 
E = Emax/(1 + (EC50/[agonist])nH) 
 
Or, when logarithmically transformed: 
 
E = Emax/(1 + 10((pEC50-[agonist])*nH)) 
 
Where E is the effect of an agonist, which is expressed either as an absolute  (i.e. mN or 
grams) or as a relative value (i.e. % of contraction evoked by the agonist or compared to 
an internal standard).  From this non-linear regression analysis three distinct parameters 
can be extracted.  Firstly, information can be obtained from the Emax value or 
maximal-induced contraction by an agonist, which is described as the efficacy or activity 
of an agonist.  In general, an agonist whose maximal response corresponds to the response 
of a known and well described full agonist in a certain blood vessel is known as a full 
agonist (intrinsic activity = 1), those whose maximal response falls short of this full 
response are known as partial agonists (intrinsic activity < 1, Ariëns, 1954).  Secondly, the 
EC50 value can be determined, which is described as that concentration of agonist needed 
to obtain a half-maximal effect of an agonist, also known as the affinity or potency of an 
agonist; the negative logarithm of EC50 is depicted as pEC50.  Thirdly, the slope factor or 
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Hill slope (nH) can be determined, this Hill slope describes the steepness of a 
concentration response curve, which, when the agonist-receptor system follows the law of 
mass-action of a single binding site, equals unity (Clark, 1937).  A Hill Slope different 
from unity may be indicative of agonist action at two distinct receptors.  Interpretation of 
the calculated parameters depends on the definition of the parameter and the goal of the 
experiments.  When experiments in isolated blood vessels are performed to predict the 
effects of an agonist in man, the potency of a drug is based on the half maximal effect this 
compound, regardless the mechanisms and receptors involved in mediating this 
contraction.  In other words, the (p)EC50 for the overall effect.  Functional pharmacology 
in isolated blood vessels can also be used to determine which receptors and mechanisms 
are involved in mediating the effects of a drug.  In this latter case, potency is described by 
the combined effect of the agonist affinity for a receptor (i.e. tendency to bind to the 
receptor) and efficacy (i.e. ability, once bound, to initiate an effect).  In this case, potency 
is described as the (p)EC50 for the receptor mediating the effect. 
 Agonist rank orders of potency and efficacy have long been used in receptor 
classification but show various limitations.  It should be recognised that efficacy of a 
given agonist is tissue-dependent, since its value depends on the receptor density and the 
efficiency of the receptor-effector coupling, i.e. a certain agonist can behave as a full 
agonist in one tissue and manifests partial agonism in another tissue.  On the other hand, 
the potency of an agonist greatly depends on the amount of spare receptors or receptor 
reserve of a certain tissue, i.e. the higher the receptor reserve the lower concentrations of 
agonist are required to elicit 50 % of the maximal response.  When comparing agonists to 
provide reliable information on receptor classification, all agonists need to achieve the 
same maximal effect and Hill slopes should be similar.  Only when these conditions are 
met, true agonist potency-ratios can be determined via partial receptor inactivation by, for 
example, alkylation (Furchgott & Bursztyn, 1967).   
Another way to characterise and classify the receptors and mechanisms involved in 
agonist-induced effects is via the use of specific receptor antagonists.  A receptor 
antagonist binds to a receptor without inducing an effect (i.e. intrinsic activity = 0) and can 
be classified by its kinetics of interaction with receptors.  The most commonly used and 
mathematically described interaction is called competitive reversible antagonism, which is 
the condition when an antagonist binds reversibly to the same recognition sites on the 
receptor as does the agonist and thus competes for such sites.  To describe the effects of a 
competitive antagonist on the responses to a range of agonist concentrations, the concept 
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of dose (or better concentration) ratios is useful.  Dose ratios, which can be determined 
experimentally, are defined as the ratio of the concentration of agonist required to elicit an 
equal effect in the presence and absence of the antagonist. An empirical scale for 
antagonist potencies based on dose ratios, termed pA scale, was introduced by Schild 
(1968), from which the most widely used parameter has been pA2 (the negative logarithm 
of the concentration of antagonist required to produce a two-fold shift to the right of an 
agonist concentration response curve).  However, pA2 is an empirical measure of 
antagonist potency that provides no information on the nature of antagonism.  By contrast, 
an estimate of KB, the antagonist-receptor dissociation equilibrium constant, can be 
calculated for antagonists that compete with agonists for unoccupied receptors in a simple, 
reversible manner. This KB is a chemical term derived from the rates of onset and offset of 
antagonist binding to the receptor and is independent of receptor function and location.  
Arunlakshana and Schild mathematically described the relation between the magnitude of 
agonist curve rightward shift (i.e. dose ratio) and antagonist concentration (Arunlakshana 
& Schild, 1959) using the following Schild regression equation: 
 
Log (r-1) = n*log [B] + pKB 
 
Where r represents the dose ratio, n the slope of the Schild plot, log [B] the logarithm of 
molar concentration of antagonist and pKB the negative logarithm of the KB.  When the 
Schild plot yields a straight line with slope of unity (i.e. n=1) the intercept of the abscissa 
reflects the pKB, and since the zero value on the ordinate is obtained when r=2, the pKB 
corresponds to the pA2.  It bears emphasis that when the Schild plot slope is not unity, the 
slope of the Schild regression should be constrained to unity in order to provide an 
estimate of pKB.  When this constraint is not applied, the value of the intercept still 
provides an estimate of the pA2, but is no longer valid to estimate pKB.  To estimate a 
valid antagonist potency against a receptor, three well defined criteria should be regarded. 
Firstly, increasing concentrations of antagonist should produce successive, parallel 
rightward displacements of the agonist concentration effect curve with no depression of 
maximal effect. Secondly, the antagonist affinity should be independent of the 
concentration used so that the data in the form of a Schild plot yield a slope of unity.  In 
case only one or two concentrations of antagonist are used to construct a Schild plot the 
respective pKB or pA2 is depicted as an apparent value.  Thirdly, the antagonist affinity 
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should be independent of the agonist used, because the agonist simply titrates receptor 
sites unoccupied by the antagonist.  When all these criteria are met and the Schild 
regression analysis reveals a slope of unity one can provide a clear and solid 
pharmacologic receptor classification (for review on analysis of concentration response 
curves see Kenakin, 1993; Martin & Giles, 1996). 
 
3.3  Human cranial arteries as models for therapeutic site of action 
As described in Chapter 2, the therapeutic activity of acutely acting antimigraine drugs is 
most probably mediated by constriction of dilated cranial arteries.  Therefore, 
measurements of contraction in human cranial arteries are an excellent tool for the 
evaluation of potential drugs for the treatment of migraine as well as investigating the 
mechanisms involved in craniovascular contraction and thus, unravel cerebrovascular 
pathophysiological changes during a migraine attack. As described below, three distinct 
arteries are commonly used as therapeutic models, the middle meningeal (an extracerebral 
intracranial artery), the intracerebral (basilar and cerebral artery) and extracranial artery 
(temporal artery).  
 
Middle meningeal artery 
The human middle meningeal artery (Figure 3.1) is the largest of the arteries that supply 
the dura mater, a pain-sensitive, richly vascularised and innervated tissue that is 
implicated in various cephalalgias, including vascular headache. Sumatriptan has been 
shown to constrict the human middle meningeal artery in vivo, with subsequent relief of 
migraine headache (Henkes et al., 1996).  The middle meningeal artery is innervated by 
afferent sensory fibres containing substance P, neurokinin A and CGRP, most of which 
originate in the trigeminal ganglion, and sympathetic fibres containing noradrenaline and 
neuropeptide Y (NPY), emanating predominantly from the superior cervical ganglion 
(Gulbenkian et al., 1999).  The presence of mast cells over the entire dural connective 
tissue and dural blood vessels, with their vasoactive constituents, including 5-HT, makes 
these blood vessels intriguing with regard to their potential role in regulation of vascular 
tone, inflammation and migraine. The middle meningeal artery can be obtained in 
conjunction with neurosurgical operations where a part of the skull needs to be removed to 
obtain access to disorders such as aneurysms or meningeomes.  By opening the skull a 
redundant part of the middle meningeal artery may be damaged and subsequently removed 
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from the dural sheath after which the obtained piece of artery can be used for in vitro 
organ bath experiments.   
 As mentioned above, construction of cumulative concentration response curves to 
antimigraine drugs can be used to determine its potency and efficacy in migraine.  Indeed, 
sumatriptan and the second-generation triptans tested in this preparation all induced 
concentration-dependent contractions, indicating therapeutic activity, with marginal 
differences in both efficacy and potency (Table 1.4 for references), except for donitriptan, 
which appears to be 50-fold more potent than sumatriptan (Chapter 5).  The triptans have 
a high binding affinity at the human 5-HT1B and 5-HT1D receptors (Table 1.2) and 
moderate to low affinity for various other receptor types.  The vasoconstrictor potency of 
5-HT receptor agonists in the middle meningeal artery is positively correlated with 
measurements of affinity obtained in cell lines expressing the human 5-HT1B receptor, but 
not the 5-HT1D or 5-HT1F receptor (Razzaque et al., 1999).  Due to the lack of specific 
subtype-selective receptor antagonists, the functional identification of the receptor 
involved in the triptan-induced contraction has long been hampered.  Studies using the 
non-selective 5-HT1B/1D receptor antagonists GR125743 (reversible) and GR127935 
(irreversible) revealed that sumatriptan-induced contraction was potently blocked 
(Razzaque et al., 1999), but failed to discriminate between the 5-HT1B and 5-HT1D 
receptors.  Eletriptan-induced contraction was similarly blocked by GR125743 as 
compared to sumatriptan (Chapter 7), indicating that eletriptan and sumatriptan contract 
the middle meningeal artery via the same mechanisms.  Indications that sumatriptan elicits 
its action predominantly via the 5-HT1B receptor came from the finding that the 5-HT2 
receptor antagonist ketanserin, which also has a high affinity for the 5-HT1D receptor, 
failed to block sumatriptan-induced contractions (Jansen et al., 1992).  Indeed, as 
described in Chapter 8, the first selective 5-HT1B receptor antagonist SB224289 blocked 
sumatriptan-induced contractions, whereas the selective 5-HT1D receptor antagonist 
BRL15572 failed to block this contraction.   
 In parallel with functional in vitro organ bath experiments, molecular biological 
studies revealed dense and predominant 5-HT1B (and only trace amounts of 5-HT1D) 
receptor protein and mRNA in the smooth muscle and endothelium of the middle 
meningeal artery suggesting a role for the 5-HT1B receptor in antimigraine activity 
(Longmore et al., 1998; Longmore et al., 1997; Schmuck et al., 1996).  Apart from 
5-HT1B receptor mRNA, 5-HT1F, 5-HT2A, 5-HT2B, 5-HT4 and 5-HT7 receptor mRNA has 
been detected in homogenates of the human middle meningeal artery (Schmuck et al., 
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1996). While the 5-HT1F receptor does not seem to be involved in regulation of blood 
vessel tone both 5-HT2B and 5-HT7 receptors regulate blood vessel dilatation (see 
Chapter 2).  The 5-HT2A receptor mediates contractile responses to 5-HT in this 
preparation, since the latter is competitively blocked by ketanserin (Jansen et al., 1993).  
Due to the fact that the 5-HT1B/1D receptor agonists reveal a similar intrinsic activity as 
compared to 5-HT, both the 5-HT1B as well as the 5-HT2A receptor mediate serotonergic 
vasoconstriction in this preparation. 
 
 
 
Figure 3.1 Middle meningeal artery and its projection on the dura mater (Edvinsson & 
Dahl, 2000). 
 
Cerebral arteries 
The major cerebral arteries supplying the brain consist of the internal carotid system and 
the vertebrobasilar system that communicate with one another to form an anastomotic 
arterial system called the circle of Willis.  Branches from the major cerebral (i.e. anterior, 
middle and posterior) arteries extend along the surface of the brain and then penetrate the 
pia mater to become the intraparenchymal (pial) vessels that supply the neural tissue of the 
brain. Immunocytochemical studies have revealed that the large cerebral arteries are 
innervated with nerve fibres containing NPY, vasoactive intestinal peptide (VIP), 
substance P, neurokinin A and CGRP, originating from the superior cervical ganglion and 
small local ganglia at the base of the skull.  Sensory fibres seem to derive from the 
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trigeminal ganglion and from dorsal root ganglia (Gulbenkian et al., 1999; Edvinsson et 
al., 1987; Edvinsson et al., 1994; Uddman & Edvinsson, 1989).  Using transcranial 
Doppler sonography (for review see, May & Goadsby, 1999) is has been demonstrated 
that blood flow velocity in middle cerebral artery is significantly higher on the headache 
side, which returns to normal values after administration of sumatriptan (Humphrey et al., 
1991).  On the other hand, although administration of sumatriptan increased regional 
cerebral blood flow velocity in middle cerebral arteries and basilar artery, no differences 
were found between the headache and non-headache side as well as between migraine and 
headache free periods (Limmroth et al., 1996).  Despite the differences in observations 
regarding cerebral blood flow, this intracranial artery can be used as a model to predict 
antimigraine activity.  It has been shown that sumatriptan and other triptans constrict 
human isolated cerebral arteries (Bouchelet et al., 2000; Jansen et al., 1993; Nilsson et al., 
1999) with similar potencies as compared to the isolated middle meningeal arteries (see 
Table 1.4).  Similarly, sumatriptan is blocked by 5-HT1B/1D receptor antagonists, whereas 
the 5-HT2 receptor antagonist ketanserin was without effect (Bouchelet et al., 2000; 
Jansen et al., 1993; Nilsson et al., 1999).  In contrast to middle meningeal artery, 
contraction to 5-HT is not blocked by ketanserin, suggesting that the 5-HT1B receptor 
exclusive mediates serotonergic vasoconstriction in this preparation.  Furthermore, 
selective 5-HT1D and 5-HT1F receptor agonists failed to constrict the middle cerebral 
artery (Bouchelet et al., 2000).  Immunocytochemical studies revealed the presence of 
5-HT1B receptor mRNA and protein whereas that of 5-HT1D receptor was absent 
(Bouchelet et al., 1996; Hamel et al., 1993; Nilsson et al., 1999).  Some middle cerebral 
arteries also expressed the 5-HT1F receptor mRNA (Bouchelet et al., 1996).  
 
Temporal artery 
The superficial temporal artery (a. temporalis superficialis), the smaller of the two 
terminal branches of the external carotid artery, appears, from its direction, to be the 
continuation of that vessel.  It begins in the substance of the parotid gland, behind the neck 
of the mandible, and crosses over the posterior root of the zygomatic process of the 
temporal bone and divides into two branches, a frontal and a parietal temporal artery.  
Immunocytochemical studies have revealed that the majority of the nerve fibres displayed 
immunoreactivity for tyrosine hydroxylase and NPY.  A moderate supply of perivascular 
nerve fibres displayed either acetylcholinesterase activity or immunoreactivity for VIP and 
CGRP.  Only a few nerve fibres displayed substance P and neurokinin A 
Introduction: Human Blood Vessels 
30 
immunoreactivity (Jansen Olesen et al., 1995).  In their pioneer work, Graham and Wolff 
(1938) observed an increase in the amplitude of the superficial temporal artery pulsations 
during the headache phase of migraine, explaining the throbbing nature of the migraine 
headache.  Furthermore, after administration of ergotamine, the amplitude of the 
pulsations was reduced and pain was concomitantly relieved.  From these data they 
reasoned that migraine headache is caused by stretching of extracranial arteries and that it 
is alleviated by vasoconstriction.  As was observed in measuring regional cerebral blood 
flow, more recent studies revealed conflicting results.  Using a high-resolution ultrasound 
equipment it has been demonstrated that, during an attack, the temporal artery diameter on 
the headache side is larger (Iversen et al., 1990).  On the other hand, it was observed that 
only in a minority of patients, dilatation of the superficial temporal artery contributed to 
the migraine headache (Drummond & Lance, 1983).  Despite these conflicting results, this 
extracranial artery constricts to various antimigraine drugs and therefore, can be used as a 
model to predict antimigraine activity.  Sumatriptan constricted the isolated temporal 
artery with a similar potency and efficacy as compared to both human middle meningeal 
and cerebral arteries (Jansen et al., 1992; Jansen et al., 1993).  Furthermore, sumatriptan is 
potently blocked by the 5-HT1B receptor antagonist SB224289 (Verheggen et al., 1998) 
and not by the 5-HT1D receptor antagonist BRL15572, whereas a 5-HT2 receptor mediated 
response at high concentrations is blocked by the 5-HT2 receptor antagonist mesulergine 
(Chapter 8). The 5-HT2 receptor appears to be the predominant contractile serotonergic 
receptor in this preparation since sumatriptan revealed a markedly lower intrinsic activity 
as compared to 5-HT (Jansen et al., 1993; Verheggen et al., 1996), which is not observed 
in middle meningeal and cerebral artery.  Indeed, 5-HT is potently blocked by the 5-HT2 
receptor antagonist ketanserin, whereas non-selective 5-HT1-like receptor antagonists 
show little (Verheggen et al., 1996) or no effect (Jansen et al., 1993).  Despite the 
functional role for the 5-HT2A receptor in this preparation, mRNA could not be detected in 
homogenised tissue, possibly due to an artery specific splice variant (Verheggen et al., 
1998).  The same study revealed mRNA expression for the 5-HT1B, 5-HT1D, 5-HT4 and 
5-HT7 receptors, whereas no 5-HT1F receptor mRNA was detected. 
 
3.4 Human Peripheral blood vessels as a model for side-effect potential 
Ever since the introduction of ergotamine and dihydroergotamine, various studies reported 
the occurrence of chest symptoms, such as substernal chest pain, discomfort and even 
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myocardial infarction (Meyler, 1996; Roithinger et al., 1993; Slob et al., 1988; Wayne, 
1986), in a proportion of patients using antimigraine drugs.  In order to avoid side-effects 
related to peripheral vasoconstriction, sumatriptan was introduced as a potent 
cranioselective indole derivative, but as was the case with the ergots, sumatriptan 
administration revealed similar chest symptoms in up to 15% of patients (Ottervanger et 
al., 1997; Plosker & McTavish, 1994).  In addition, there are some reports on myocardial 
infarction after the use of sumatriptan (Ottervanger et al., 1997).  These findings suggest 
that coronary artery constriction is responsible for the reported side-effects.  In order to 
investigate the potential side-effects, the human isolated coronary artery can be used as a 
model to predict coronary side-effect potential of sumatriptan and the newly developed 
antimigraine drugs. Similarly, the human isolated saphenous vein can also be used as 
model for the coronary artery as well as a predictive preparation for possible peripheral 
effects of these antimigraine drugs. 
 
Coronary artery 
To investigate the side-effect potential of antimigraine drugs in vitro, the right epicardial 
coronary artery is most commonly used.  In our laboratory, this artery is obtained from 
‘heart-beating’ organ donors, who died of non-cardiac disorders, within 24 hours after 
explantation. The right coronary artery arises from the right anterior aortic sinus.  It passes 
at first between the conus arteriosus and the right auricula and then runs in the right 
portion of the coronary sulcus.  Immunohistochemistry revealed that the proximal part of 
epicardial arteries possesses a relatively sparse supply of nerve fibres forming a loose 
network in the adventitia, whereas the perivascular network increases in density as the 
vessels are followed distally.  In both proximal and distal regions, the majority of nerve 
fibres display neuropeptide Y and tyrosine hydroxylase immunoreactivity.  CGRP- and 
substance P-immunoreactive nerve fibres are very sparse in the proximal region of the 
arteries and increase in number distally.  Only a few scattered VIP-immunoreactive nerve 
fibres are found in both arterial regions (Gulbenkian et al., 1993). 
 As was observed in the cranial vasculature, ergotamine reduced myocardial blood 
flow and increased coronary resistance in migraine patients (Gnecchi-Ruscone et al., 
1998), which is caused by vasoconstriction of the coronary arteries.  Similarly, it has been 
demonstrated, via angiography, that subcutaneously administered sumatriptan caused a 
significant rise in systemic pressure with a reduction of coronary artery diameter 
(MacIntyre et al., 1993).  In vitro studies revealed that sumatriptan constricted the 
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coronary artery with a lower potency than its respective potency in cranial arteries (see 
Table 1.4), consistent with the cranioselective nature of this compound 
(MaassenVanDenBrink et al., 2000; Parsons et al., 1998; van den Broek et al., 2000).  
This propensity of sumatriptan to constrict the coronary artery was one of the reasons 
behind developing the second-generation triptans but all, except eletriptan, are equally or 
slightly more potent in human isolated coronary artery as compared to sumatriptan (Ferro 
et al., 1995; Longmore et al., 1996; Longmore et al., 1997; MaassenVanDenBrink et al., 
1998; MaassenVanDenBrink et al., 2000; Saxena et al., 1997; van den Broek et al., 2000).  
All triptans, except donitriptan (see Chapter 5), constrict the coronary artery with a similar 
efficacy, whereas they evince a lower efficacy than 5-HT (Bax et al., 1993; Ferro et al., 
1995; MaassenVanDenBrink et al., 2000) and their respective efficacies in human cranial 
arteries (MaassenVanDenBrink et al., 2000; Parsons et al., 1998; van den Broek et al., 
2000).  The relatively high intrinsic activity of 5-HT indicates that the 5-HT2 receptor is 
the most important receptor in this preparation. Indeed, contraction to 5-HT is 
predominantly blocked by 5-HT2 receptor antagonists whereas only a small proportion is 
blocked by 5-HT1 receptor antagonists (Bax et al., 1993; Connor et al., 1989; Kaumann et 
al., 1994).  Contraction to sumatriptan is blocked by non-selective 5-HT1B/1D receptor 
antagonists (MaassenVanDenBrink et al., 2000; van den Broek et al., 2000), whereas the 
5-HT1B receptor antagonist SB224289 partially blocked this contraction (Chapter 8).  The 
5-HT1D receptor antagonist BRL15572 failed to block sumatriptan-induced contraction.  
These data indicate that the 5-HT1B receptor is responsible for the contraction to the 
triptans in this preparation although other unknown receptors cannot be excluded (see 
Chapters 7 and 8).  Thus, as long as the 5-HT1B receptor is required for the therapeutic 
efficacy of antimigraine drugs, they will also have the propensity to constrict the coronary 
artery.  Immunocytochemical RT-PCR techniques have revealed predominant mRNA 
expression coding for the 5-HT1B, 5-HT2A and 5-HT2B receptor, while little or no 5-HT1A, 
5-HT1D, 5-HT1E, 5-HT2C and 5-HT7 receptor mRNA was detected in human epicardial 
coronary arteries (Ishida et al., 1999; Nilsson et al., 1999).  Conflicting results have been 
obtained for 5-HT1F receptor mRNA, where one study demonstrated strong expression 
(Nilsson et al., 1999) and two studies showed little or no expression (Bouchelet et al., 
2000; Ishida et al., 1999).  Using selective antibodies against 5-HT1B and 5-HT1D 
receptors, the 5-HT1B receptor protein (Nilsson et al., 1999) has been localised in smooth 
muscle and endothelium, whereas little or no 5-HT1D receptor protein could be detected.  
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Similar results were obtained with immunohistochemical techniques used to localise the 
receptor mRNAs (Chapter 8). 
 
Saphenous vein 
The human saphenous vein is frequently used as a graft in coronary bypass surgery. 
Leftover pieces can be obtained intra-operatively and may be used as a tool in 
investigating peripheral vasoconstriction.  Various experiments have been performed in 
animal (i.e. canine and rabbit) isolated saphenous veins to screen for antimigraine efficacy 
(Bou et al., 2000; Cohen & Schenck, 1999; Humphrey et al., 1989; John et al., 1999; 
Martin et al., 1997; Slassi et al., 2000), whereas these preparations are also predictive of 
human coronary artery constriction (Cohen et al., 1997) and thus can be used to screen for 
side-effect potential.  The great saphenous vein (v. saphena magna), the longest vein in the 
body, begins in the medial marginal vein of the dorsum of the foot and ends in the femoral 
vein about 3 cm below the inguinal ligament. Immunohistochemical methods revealed a 
peptidergic innervation mainly localised along the vasa vasorum and associated with 
immunoreactivity of substance P and CGRP (Herbst et al., 1992).  
 Studies in human isolated saphenous vein have demonstrated that sumatriptan, as 
well as eletriptan, constricted this preparation with a potency that is more closely related 
to the respective values in coronary artery as opposed to middle meningeal artery 
(MaassenVanDenBrink et al., 2000; van den Broek et al., 2000, see Table 1.4).  The 
efficacy profile of these antimigraine drugs, however, appears to be more closely related 
to the latter preparation, but both compounds have a lower intrinsic activity than 5-HT 
(Bax et al., 1992; MaassenVanDenBrink et al., 2000; van den Broek et al., 2000). 
Non-selective 5-HT1 receptor antagonists blocked sumatriptan-induced contractions (Bax 
et al., 1992; van den Broek et al., 2000) but only weakly antagonised eletriptan- (van den 
Broek et al., 2000) and 5-HT- (unpublished results) induced contractions. The selective 
5-HT1B receptor antagonist SB224289 potently blocked sumatriptan-induced contractions, 
whereas the 5-HT1D receptor antagonist BRL15572 was without effect (Chapter 8).  The 
5-HT2 receptor antagonist ketanserin potently blocked 5-HT-induced contraction but it 
was ineffective against sumatriptan (Bax et al., 1992).  Based on these results the human 
saphenous vein is likely to contain both contractile 5-HT1B and 5-HT2 receptors.  No 
immunocytochemical studies have been reported for 5-HT receptor proteins, but 5-HT1B, 
in contrast to 5-HT1D, receptor mRNA, has been localised in smooth muscle and 
endothelium of this preparation (Chapter 8). 
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3.5 Summary 
Based on pharmacological in vitro and immunohistochemical studies it is apparent that the 
5-HT1B receptor is responsible for mediating contraction by the triptans (see Tables 1.4 
and 1.5).  One of the key characteristics of this constriction to antimigraine drugs is the 
fact that they are cranioselective, but they also constrict peripheral blood vessels. It is, 
therefore, important to examine the effects of antimigraine drugs in models mimicking the 
therapeutic site of action (i.e. cranial arteries) and potential coronary side-effects (i.e. 
coronary artery) to provide an index of efficacy and safety, respectively. 
 
 
 
 
 
 
 
 
Aims of the thesis 
Based on the questions that were addressed in the previous chapters, the aims of the thesis 
were:  
 
1. To determine the effects of several current and prospective antimigraine drugs on 
human isolated blood vessels of relevance to therapeutic activity and side-effect potential 
(see part II of the thesis). 
2. To investigate and characterise which receptors/mechanisms are involved in vascular 
responses elicited by antimigraine drugs (see part III of the thesis). 
  

  
Tables 
Table 1.2 Receptor binding properties (pKi values) of the triptans at human 5-HT receptors. 
 
Receptor Sumatriptan Zolmitriptan Naratriptan Rizatriptan Eletriptan Almotriptan Frovatriptan Donitriptan IS-159 
5-HT1A 6.0 – 6.9a,b,c 6.5 – 6.6c,d 7.1 – 7.6b,c 6.4c 7.4c 6.3f 7.3g 7.6h  
5-HT1B 7.4 – 8.5a,c,i 7.7 – 8.1c,d,i 8.1 – 9.3c,e,i 6.9 – 8.1c,i, 7.8 – 8.0c,i 8.0f 8.2 – 8.6g,i 9.4h 8.5k 
5-HT1D 8.0 – 8.7a,c,i 8.9 – 9.7c,d,i 8.3 – 9.2c,e,i 7.9 – 8.6c,i, 8.8 – 8.9c,i 8.0f 8.2 – 8.6g,i 9.3h 8.8k 
5-HT1E 5.6 – 4.8a,c,j 7.7 – 8.0c,i 7.7c 6.8c 7.3c  <6.0g 5.9h  
5-HT1F 7.6 – 7.9a,c,j 7.2 – 7.5c,d,i 8.2 – 8.4c,i 6.8 – 6.9c,i 7.7 – 8.0c,i  7.0 – 7.2g,i 5.5h <5.0k 
5-HT2A <5.5c <5.5c <5.5c <5.5c <5.5c  <5.3g 6.7h  
5-HT2B 6.9* 7.2*  6.6*      
5-HT7 5.9c 7.0c <5.5c 5.7c 6.7c <6.5f 6.7g 6.4h  
          
Data taken from: a, Leysen et al., 1996; b, Newman-Tancredi et al., 1997; c, Napier et al., 1999; d, Martin et al., 1997; e, Connor et al., 1997;  
f, Bou et al., 2000; g, Xu et al., 1999; h, John et al., 1999; i, Pauwels & John, 1999; j, Adham et al., 1993; k, Hamel, 2000; *, P. Gupta, 
personal communication. 
  
Table 1.3 Pharmacokinetic parameters for triptans 
 
Drug Dose (mg) Tmax (h) T1/2 (h) Bio 
availability 
(%) 
Cmax (nM) Plasma 
protein 
binding (%) 
Free Cmax 
(nM) 
LogDpH 7.4 
Sumatriptan 6 (s.c.) 0.2 2.0 96 244 – 261 14 – 21 193 – 224 -1.5 
 100 (p.o.) 1.5 2.0 14 142 – 183  112 – 157  
Zolmitriptan 2.5 (p.o.) 1.5 2.5 39 9 25* 7 -1.0 
 5 (p.o.) 1.5 3.0 46 17  13  
Naratriptan 2.5 (p.o.) 2.0 5.5 74 38 20* 30 -0.2 
Rizatriptan 10 (p.o.) 1.0 2.0 40 74 – 93 14* 64 – 80 -0.7 
Eletriptan 40 (p.o.) 1.8  50 213 85* 32 +0.5 
 80 (p.o.) 1.4 6.3 50 643  96  
Frovatriptan 2.5 (p.o.) 3.0 25.7 30 29 15# 25 -1.0 
Almotriptan 12.5 (p.o.) 2.5 3.1 80 148 30† 104  
 
Data taken from: Saxena & Tfelt-Hansen, 2000. *, A. McHarg, personal communication; #, P. Buchan, personal communication; †, J. Gras, 
personal communication. LogDpH 7.4: measure of lipophilicity with increasing numbers indicating greater lipid solubility, s.c.: subcutaneous, 
p.o.: oral. 
 
  
Table 1.4 pEC50 values of contraction to triptans in human isolated blood vessels. 
 
 Sumatriptan Zolmitriptan Naratriptan Rizatriptan Eletriptan Almotriptan Frovatriptan Donitriptan IS-159
Middle 
meningeal 
artery 
 
6.9 – 7.6 
a,b,c,d,e 
7.4a  7.0b 7.3c,d 7.5f  9.1e  
Cerebral/ 
Basilar 
Artery 
 
6.4 – 6.8g,i 7.2g 7.0g   5.4f 7.9h  6.8i 
Coronary 
artery 
5.7 – 6.7 
c,d,e,j,k,l,m 
6.3 – 7.3j,k 6.8j,l 6.0 – 6.4j,k,m 5.5 – 5.7c,d 5.3f 7.4h 7.6e  
Saphenous 
vein 
6.1 – 6.2c,d    5.9 – 6.1c,d     
 
Data taken from: a, Razzaque et al., 1999; b, Longmore et al., 1998; c, MaassenVanDenBrink et al., 2000; d, van den Broek et al., 2000;  
e, Chapter 5; f, Bou et al., 2001; g, Nilsson et al., 1999; h, Parsons et al., 1998; i, Bouchelet et al., 2000; j, MaassenVanDenBrink et al., 1998;  
k, Martin et al., 1997; l, Connor et al., 1997; m, Longmore et al., 1997.  pEC50 values for basilar artery in italics. 
  
Table 1.5 Presence of mRNAs of various 5-HT receptor subtypes in blood vessels important in migraine. 
 
 5-HT1A 5-HT1B 5-HT1D 5-HT1F 5-HT2A 5-HT2B 5-HT4 5-HT7 
Middle 
meningeal 
artery 
 
  
++ 
 
± 
 
+ 
 
+ 
 
+ 
 
+ 
 
+ 
Middle 
cerebral 
artery 
 
  
++ 
 
   
 
± 
    
Temporal 
artery 
 
  
++ 
 
+ 
 
 
   
+ 
 
+ 
Coronary  
artery 
 
 
 
 
+ 
 
 
 
  / ± / + 
 
++ 
 
+ 
  
 
 
For references see Chapter 3. ++, dense; +, normal; ±, little; , no expression of receptor mRNA. 
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Chapter 4 
Craniovascular selectivity of eletriptan and sumatriptan in human 
isolated blood vessels 
Summary - Eletriptan is a 5-HT1B/1D receptor agonist with proven efficacy in the acute 
treatment of migraine.  The objective of this study was to assess the craniovascular 
selectivity of eletriptan and sumatriptan in blood vessels predictive of therapeutic efficacy 
(human middle meningeal artery) and adverse coronary side effects (human coronary 
artery and human saphenous vein). 
We obtained coronary artery from organ donors (n=9), middle meningeal artery 
from patients (n=11) undergoing craniotomy, and saphenous vein from patients (n=9) 
undergoing coronary bypass surgery.  Concentration-response curves to eletriptan and 
sumatriptan were constructed to obtain measurements of efficacy (maximum contraction, 
Emax) and potency (concentration eliciting 50% of Emax, EC50).  The contraction that is 
likely to be induced at the maximal free plasma concentration (Cmax) was determined by 
calculating Cmax/EC50 ratios and by interpolation of the concentration-response curves. 
 Eletriptan and sumatriptan induced concentration-dependent contractions of 
meningeal artery, coronary artery, and saphenous vein.  Eletriptan was less potent than 
sumatriptan in coronary artery, whereas both compounds had similar potency in meningeal 
artery and saphenous vein.  However, the potency of eletriptan and sumatriptan was higher 
in meningeal artery than in coronary artery (86-fold for eletriptan and 30-fold for 
sumatriptan) or saphenous vein (66- and 25-fold).  The efficacy of eletriptan and 
sumatriptan was similar within tissues.  The predicted contraction by eletriptan (40 mg 
and 80 mg) and sumatriptan (100 mg) at free Cmax observed in clinical trials was similar in 
meningeal artery, whereas in coronary artery and saphenous vein it was lower for 40 mg 
eletriptan than for sumatriptan.  At therapeutic concentrations both eletriptan and 
sumatriptan contract middle meningeal artery more than coronary artery.  This suggests 
that in patients with healthy coronary arteries, they have a limited propensity to cause 
adverse coronary side effects.  However, both drugs remain contraindicated in patients 
with coronary artery disease. 
 
Based on:  MaassenVanDenBrink, A., van den Broek, R.W.M., de Vries, R., Bogers, A.J.J.C., Avezaat, C.J. 
& Saxena, P.R. (2000). Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood 
vessels. Neurology, 55, 1524-30. 
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4.1 Introduction 
The 5-HT1B/1D receptor agonist sumatriptan is effective in the treatment of migraine 
attacks (Ferrari, 1991; Ferrari & Saxena, 1993; Saxena & Tfelt-Hansen, 2000).  However, 
from a therapeutic perspective, sumatriptan has several limitations, including low oral 
bioavailability, variable absorption, and a short half-life.  Moreover, up to 15% of patients 
consistently report chest symptoms, including chest pressure, tightness and pain, often 
mimicking pectoral angina (Brown et al., 1991; Plosker & McTavish, 1994; Visser et al., 
1996).  Although extracardiac mechanisms have been invoked, chest symptoms may well 
be caused by coronary vasoconstriction, which has been observed after sumatriptan both 
in vivo (MacIntyre et al., 1992) and in vitro (Bax & Saxena, 1993; Chester et al., 1993; 
MaassenVanDenBrink et al., 1998).  Indeed, the use of sumatriptan, like that of 
ergotamine, (Galer et al., 1991; Yasue et al., 1981) has even been associated with 
myocardial infarction (O'Connor & Gladstone, 1995; Ottervanger et al., 1993) and cardiac 
arrest (Kelly, 1995).  These limitations have prompted the development of several new 
5-HT1B/1D receptor agonists with improved clinical and pharmacological profiles. 
The 5-HT1B/1D receptor agonist eletriptan appears to have several advantages over 
sumatriptan with regard to its pharmacological and pharmacokinetic characteristics.   
Eletriptan has a higher affinity for the human recombinant 5-HT1B and 5-HT1D receptor 
(pKi: 8.0 for 5-HT1B and 8.9 for 5-HT1D receptor) than sumatriptan (pKi: 7.4 for 5-HT1B 
and 8.0 for 5-HT1D receptor) (Napier et al., 1999).  Eletriptan has also been shown to be 
more rapidly and consistently absorbed from the gastrointestinal tract than sumatriptan 
(Morgan et al., 1997; Rance et al., 1997) and has a longer plasma half-life (Morgan et al., 
1997).  These features of eletriptan may contribute to its superior efficacy versus 
sumatriptan in comparative clinical trials (Goadsby et al., 2000; Pryse-Phillips & on 
behalf of the Eletriptan Steering Committee, 1999). 
Eletriptan is effective in preclinical models that are believed to be predictive of 
clinical effect.  For example, eletriptan effectively reduces carotid arteriovenous 
anastomotic blood flow in anesthetized pigs (Willems et al., 1998) and reverses 
established plasma protein extravasation in anesthetized rats with a potency and efficacy 
equivalent to sumatriptan (Gupta et al., 1996).  Eletriptan has also been shown to exhibit 
an improved selectivity compared to sumatriptan in reducing carotid artery blood flow 
when compared with coronary artery diameter and femoral arterial blood flow in the 
anesthetized dog (Gupta et al., 1996).  In vitro studies show that eletriptan elicits a potent 
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and concentration-dependent contraction of the dog isolated saphenous vein and basilar 
artery, where it acts as a partial agonist (Gupta et al., 1999). 
Vasoconstriction of the large cranial and extracranial blood vessels is considered to 
be a putative mechanism of the antimigraine action of sumatriptan (Ferrari & Saxena, 
1993; Saxena & Tfelt-Hansen, 2000).  Indeed, sumatriptan has been shown to potently 
contract the human isolated middle meningeal artery (Hamel et al., 1993; Jansen et al., 
1992).  Thus, contraction of the human isolated middle meningeal artery by eletriptan may 
be indicative of its therapeutic efficacy in migraine patients.  Similarly, contraction of the 
human isolated coronary artery (MaassenVanDenBrink et al., 1998) and, possibly, also of 
the saphenous vein (Cohen et al., 1998) to antimigraine drugs may predict the 
cardiovascular safety profile of the triptans in migraine patients without cardiovascular 
artery disease. 
In the present study, we determined the potency (EC50) and efficacy (Emax) of 
eletriptan and sumatriptan in contracting the human isolated middle meningeal artery, 
coronary artery and saphenous vein.  Contractions to serotonin (5-hydroxytryptamine; 
5-HT) were also studied as controls.  As described previously (MaassenVanDenBrink et 
al., 1998), we related our findings to the therapeutic free plasma concentrations of 
eletriptan and sumatriptan in migraine patients. 
 
4.2 Patients and methods 
Tissue preparations 
Human isolated middle meningeal artery 
Middle meningeal arteries were obtained from 11 patients (six men, five women; age 
26-73 years; mean age±s.e.mean: 50±5 years) undergoing craniotomy at the neurosurgical 
unit of the University Hospital 'Dijkzigt', Erasmus University Medical Centre, Rotterdam.  
During the surgical procedure, a part of the skull is temporarily removed and the dura 
mater, together with a small piece of the middle meningeal artery, is intentionally cut to 
obtain access to the brain.  This piece of the artery was placed in a plastic tube filled with 
ice-cold (0-4°C) physiological saline and immediately transported to the laboratory. 
After arrival at the laboratory, the middle meningeal artery was placed in a cold, 
oxygenated Krebs buffer solution of the following composition: 119 mM NaCl, 4.7 mM 
KCl, 1.3 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3 and 11.1 mM 
glucose; pH 7.4.  To avoid spontaneous contractions during the experiment, the 
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cyclo-oxygenase inhibitor indomethacin (0.1 µM) was added to the Krebs solution.  In the 
experiments where relaxation to eletriptan and sumatriptan was studied after a 
precontraction with 5-HT, the Krebs solution was enriched with a cocktail of antagonists 
and re-uptake inhibitors (atropine, mepyramine, mesulergine, prazosin and imipramine: all 
0.1 µM; corticosterone: 10 µM).  The artery was cleaned from connective tissue, and no 
attempt was made to remove the endothelium. 
 
Human isolated coronary artery 
The right epicardial coronary artery was obtained from nine heart beating organ donors 
who died of non-cardiac disorders less than 24 h before the tissue was taken to the 
laboratory (six cerebrovascular accident, three trauma of the head; six men, three women; 
age 5-57 years; mean age±s.e.mean: 37±6 years).  The hearts were provided by the 
Rotterdam Heart Valve Bank (Rotterdam, The Netherlands) after donor mediation by Bio 
Implant Services Foundation / Eurotransplant Foundation (Leiden, The Netherlands) after 
removal of the aortic and pulmonary valves for homograft valve transplantation.  The 
hearts were stored at 0-4°C in a sterile organ protecting solution (UW, EuroCollins, or 
HTK-Bretschneider) immediately following circulatory arrest.  After arrival in the 
laboratory, the right coronary artery was removed and placed in a cold, oxygenated Krebs 
buffer solution of the following composition: 118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 
1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3 and 8.3 mM glucose; pH 7.4.  Vessel 
segments containing macroscopically visible atherosclerotic lesions were excluded. 
 
Human isolated saphenous vein 
Leftover human saphenous vein was obtained postoperatively from nine patients 
(seven men, two women; age 60 - 78 years; mean age±s.e.mean: 69±2 years) undergoing 
coronary bypass surgery at the cardiothoracic surgical unit of the University Hospital 
'Dijkzigt', Erasmus University Medical Centre, Rotterdam.  The tissue was immediately 
placed in cold (0-4°C) physiological saline and transported to the laboratory within 
15 min.  After arrival at the laboratory, the vein was cleaned of connective tissue and 
placed in a cold, oxygenated Krebs buffer solution of the same composition as used for 
coronary artery. 
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Isometric tension measurements 
Vessels were cut into ring segments of approximately 3-4 mm length and suspended on 
stainless steel hooks in organ baths (10 ml for middle meningeal artery, 15 ml for 
coronary artery and saphenous vein), containing Krebs buffer solution as described above 
for each tissue.  The buffer was aerated with 95% O2 and 5% CO2 and was maintained at 
37°C.  The segments were allowed to equilibrate for at least 30 min and were washed 
every 15 min.  Changes in tension were measured with an isometric force transducer 
(EMKA Technology, Paris, France: middle meningeal artery; Harvard, South Nattick, 
Massachusetts, U.S.A: coronary artery and saphenous vein) and were recorded with IOX 
1.103 software (EMKA Technology, Paris, France: middle meningeal artery) or on a 
flatbed recorder (Servogor 124, Goerz, Neudorf, Austria: coronary artery and saphenous 
vein).  Preparations were stretched to a stable pretension of about 4 mN for middle 
meningeal artery, 15 mN for coronary artery or 10 mN for saphenous vein. 
 
Experimental protocols 
Human isolated middle meningeal artery 
Vessel segments were exposed two to three times to 0.1 µM prostaglandin F2α (K+ was 
avoided as it frequently increased basal tone; unpublished observations) to prime the 
tissue stable contractions.  Subsequently, the segments were contracted with 1 µM 
prostaglandin F2α and endothelial functional integrity was assessed by observing 
relaxation to substance P (10 nM).  Contractions were expressed as a percentage of 
contraction to 1 µM prostaglandin F2α.  After a 30-min incubation period, concentration 
response curves were constructed with eletriptan, sumatriptan and 5-HT (in all cases 
0.1 nM-100 µM).  Where enough segments could be obtained from one artery, 
experiments were performed in a paired parallel manner (i.e. all compounds were tested in 
different segments obtained from the same artery; n=4).  Otherwise, experiments were 
performed in a non-parallel manner (three arteries, resulting in n=1 for eletriptan, 
sumatriptan and 5-HT). 
Since high concentrations (>1 µM) of eletriptan and sumatriptan relaxed the 
middle meningeal artery (see Results), these relaxant responses were further investigated 
in segments precontracted with 100 µM 5-HT (n=4). 
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Human isolated coronary artery and saphenous vein  
Segments were exposed to K+ (30 mM) twice.  After precontraction with 
prostaglandin F2α (1 µM), the functional integrity of the endothelium was verified by 
observing relaxation to substance P (1 nM) in coronary artery or to bradykinin (1 µM) in 
saphenous vein (substance P is nearly inactive in saphenous vein).  Following washout, 
the tissue was exposed to K+ (100 mM) to determine the maximal contractile response to 
K+.  After a 30-min incubation period, concentration response curves to eletriptan, 
sumatriptan and 5-HT (all 1 nM-100 µM) were constructed in a paired, parallel set-up.  
The contractions were expressed as a percentage of contraction to 100 mM K+. 
 
Relation with clinical plasma concentrations 
The Emax represents the efficacy, and the EC50 the potency, of a drug in eliciting a 
response.  Thus, the lower the EC50 of a drug, the more likely it is to cause 
vasoconstriction at lower plasma concentrations; the Emax is only of importance when a 
drug is present in high enough concentrations, as dictated by its potency (see 
MaassenVanDenBrink et al. (1998).  To assess the ability of eletriptan and sumatriptan to 
contract the blood vessels during clinical use, we calculated the ratio between the maximal 
free (corrected for protein binding) plasma concentration (free Cmax) of these drugs after 
the clinically used oral dose (eletriptan: 40 mg and 80 mg, sumatriptan: 100 mg) (Ferrari, 
1998; Goadsby, 1998; Hettiarachchi, 1999; Saxena & Tfelt-Hansen, 2000) and the EC50 
value of the compounds.  In addition, we determined the contraction that would occur at 
free Cmax.  Free Cmax values were used because the fraction of a drug that is bound to 
plasma proteins only serves as a reservoir and is pharmacologically inactive (Du Souich et 
al., 1993; Proost et al., 1996; Wright et al., 1996). 
 
Data analysis and presentation 
The concentration response curves obtained with eletriptan, sumatriptan and 5-HT were 
analyzed using GraphPad software (GraphPad software Inc., San Diego, California, 
U.S.A.) to determine EC50 values.  In case a concentration response curve did not reach a 
plateau, the contraction in response to the highest concentration was considered as Emax.  
Contraction occurring at free Cmax was calculated by interpolation of the individual 
concentration response curves, using a sigmoidal function (SlideWrite Plus, Advanced 
Software Inc., Encinitas, California, U.S.A.). 
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EC50 values were transformed into pEC50 values (-10log EC50) before statistical analyses to 
obtain a normal distribution.  The EC50 values of the different compounds obtained in the 
three blood vessels were compared using analysis of variance, followed by Tukeys post 
hoc test (between tissue unpaired comparison).  Analysis of variance, followed by Tukeys 
post hoc test was also used to compare the EC50 and Emax values of the compounds (within 
tissue comparison).  Analysis of variance was performed in a paired manner for coronary 
artery and saphenous vein and in an unpaired manner for middle meningeal artery.   The 
relaxation of middle meningeal artery observed with eletriptan and sumatriptan was 
compared using an unpaired t-test. 
For analysis on the predicted contraction to eletriptan and sumatriptan at free Cmax, 
the mean of the reported Cmax (Lacey et al., 1995; Milton et al., 1998; Plosker & 
McTavish, 1994) and plasma protein binding (Scott, 1994) values of eletriptan and 
sumatriptan were used.  Since predicted contractions to eletriptan (40 or 80 mg) and 
sumatriptan (100 mg) at free Cmax were not normally distributed, as assessed with the 
Kolmogorov-Smirnov test, they were compared with non-parametric statistics.   In middle 
meningeal artery, Kruskal-Wallis test (within tissue unpaired comparison) was used, while 
in coronary artery and saphenous vein the predicted contractions were compared using 
Friedman test (within tissue paired comparison).  Both Kruskal-Wallis and Friedman tests 
were followed by Dunn multiple post hoc comparisons.  No comparison was made 
between predicted contractions induced by 40 and 80 mg eletriptan because these values 
were obtained from the same concentration-response curve and thus were not independent 
observations.  Data are presented as mean±s.e.mean in figures.  In all cases significance 
was assumed when P<0.05. 
 
Compounds 
Eletriptan hydrogen bromide and sumatriptan succinate (extracted from tablets) were a gift 
from Pfizer Limited (Sandwich, Kent, UK).  Prostaglandin F2α (tris salt), substance P 
acetate, bradykinin acetate and 5-hydroxytryptamine creatinine sulfate (serotonin; 5-HT) 
were purchased from Sigma Chemical Co. (St. Louis, Missouri, USA).  Indomethacin 
hydrochloride was obtained from the pharmacy of University Hospital 'Dijkzigt', Erasmus 
University Medical Centre, Rotterdam.  Indomethacin was dissolved in DMSO and further 
diluted in distilled water.  All other compounds were dissolved in distilled water. 
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Ethical approval 
The Ethical Committee of the Erasmus University Medical Centre Rotterdam approved 
this study. 
 
4.3 Results 
Basic contractile properties 
In vessel segments of middle meningeal artery, relaxation to substance P (10 nM) 
amounted to 40±9% of precontraction with 1 µM prostaglandin F2α (10±2 mN, n=11).  
Coronary artery segments relaxed in response to substance P (1 nM), the response 
amounting to 48±16% of precontraction (30±4 mN) induced by prostaglandin F2α (1 µM, 
n=9).  Coronary artery contraction to 100 mM K+ was 43±12 mN.  In segments of 
saphenous vein, relaxation to bradykinin (1 µM) was 42±7% of precontraction (10±3 mN) 
induced by 1 µM prostaglandin F2α (n=9).  Contraction to 100 mM K+ was 17±4 mN. 
 
Contractile responses to eletriptan, sumatriptan and 5-HT 
Human isolated middle meningeal artery 
As shown in Figure 4.1 (left panel), eletriptan, sumatriptan and 5-HT contracted the 
human isolated middle meningeal artery in a concentration-dependent manner up to a 
concentration of 1 µM.  Higher concentrations of the agonists relaxed the artery; at 
100 µM the relaxant response was 11±7% (5-HT), 31±7% (sumatriptan) or 87±9% 
(eletriptan) of their individual maximal contraction.  The Emax and EC50 of the contractile 
response to 5-HT, sumatriptan and eletriptan did not differ significantly (Table 4.1). 
To further investigate the relaxant responses to sumatriptan and eletriptan, the 
compounds were studied after precontraction with 5-HT (100 µM).  As shown in 
Figure 4.1 (right panel), the relaxation by eletriptan (134±29% of precontraction with 100 
µM 5-HT) was significantly higher than that by sumatriptan (20±5%). 
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Figure 4.1 Human middle meningeal artery.  Left panel: Contractile responses (n=5) to 
eletriptan (○), sumatriptan (□) and 5-HT (▲).  Right panel: Relaxant responses (n=4) to 
eletriptan (○) and sumatriptan (□) in vessel precontracted with 100 µM 5-HT. 
 
Human isolated coronary artery 
Eletriptan, sumatriptan and 5-HT all caused concentration-dependent contractions of the 
coronary artery (Figure 4.2).  The EC50 of eletriptan and sumatriptan was significantly 
higher (i.e. the potency was significantly lower) than that of 5-HT, whereas the Emax of 
these compounds was significantly smaller than that of 5-HT.  Furthermore, eletriptan was 
significantly less potent (i.e., the EC50 value was significantly smaller) compared to 
sumatriptan (Table 4.1). 
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Figure 4.2 Contractile responses to eletriptan (○), sumatriptan (□) and 5-HT (▲) in 
the human coronary artery (n=9). 
 
 
Human isolated saphenous vein 
Eletriptan, sumatriptan and 5-HT all caused concentration-dependent contractions of the 
saphenous vein (Figure 4.3).  The EC50 of both eletriptan and sumatriptan was 
significantly higher than that of 5-HT, whereas the Emax of these compounds was 
significantly lower than that of 5-HT (Table 4.1). 
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Figure 4.3 Contractile responses to eletriptan (○), sumatriptan (□) and 5-HT (▲) in 
the human saphenous vein (n=9). 
 
 
Comparison of contractile responses between blood vessels 
Both eletriptan and sumatriptan were significantly more potent (i.e. lower EC50) in the 
middle meningeal artery than in coronary artery or saphenous vein (Table 4.1).  This 
selectivity (i.e. EC50 middle meningeal artery divided by EC50 coronary artery or 
saphenous vein) for eletriptan was 86-fold for coronary artery and 66-fold for saphenous 
vein; for sumatriptan the cranioselectivity was 30-fold for coronary artery and 25-fold for 
saphenous vein for sumatriptan.  5-HT was also significantly more potent in the middle 
meningeal artery than in coronary artery (25-fold) or saphenous vein and (7-fold).  In 
addition, 5-HT was more potent in the saphenous vein than in coronary artery (Table 4.1).  
Because Emax values between different tissues may differ depending on the internal 
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standard used (prostaglandin F2α or K+), the Emax values were not compared between 
tissues. 
 
Predicted contraction at therapeutic plasma concentrations 
The maximal plasma concentrations (Cmax) attained at therapeutic doses of eletriptan and 
sumatriptan were corrected for plasma protein binding to obtain free Cmax values.  As 
described in detail earlier,(MaassenVanDenBrink et al., 1998) we calculated the ratio 
between the reported free plasma Cmax after administration of a clinically effective dose 
(see Table 4.2) and the EC50 value of the compounds in contracting the human isolated 
middle meningeal and coronary artery and saphenous vein (Figure 4.4).  The data show 
that the Cmax/EC50 ratios in middle meningeal artery are considerably higher than in 
coronary artery or saphenous vein.  Whereas in the middle meningeal artery the Cmax/EC50 
ratio of eletriptan (40 and 80 mg) and sumatriptan (100 mg) are similar, this ratio seems to 
be smaller for eletriptan in the coronary artery and saphenous vein. 
In addition to the analysis described above, we determined the contraction 
occurring at free Cmax by interpolation of the concentration response curves (see 'data 
analysis').  At free Cmax, the predicted contractions of middle meningeal artery to eletriptan 
(40 mg and 80 mg) and sumatriptan (100 mg) were similar.  In contrast, the predicted 
contraction of coronary artery and saphenous vein for the 40-mg eletriptan dose was 
significantly smaller than that for sumatriptan (Table 4.2). 
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Figure 4.4 Relationship between the reported Cmax concentration in patients  (see 
Table 4.2) and EC50 values of eletriptan (40 mg, hatched columns; 80 mg, filled columns) 
and sumatriptan (100 mg, open columns) in contracting human isolated middle meningeal 
artery, coronary artery and saphenous vein.  Note that a free Cmax/EC50 ratio of one 
indicates that, if same conditions were applicable in patients as in present in vitro 
experiments, the drug would elicit 50% of its maximum contraction.  In view of use of 
Cmax values from literature, data were not subjected to statistical analysis.  
  
 
Table 4.1  EC50 and Emax values of eletriptan, sumatriptan and 5-HT for the contraction of human blood vessels. 
Middle meningeal artery (n=5) Coronary artery (n=9) Saphenous vein (n=9) 
 EC50 (nM) 
 
Emax 
(% PGF2α) 
EC50 (nM) 
 
Emax (% K+) 
 
EC50 (nM) 
 
Emax (% K+) 
 
       
Eletriptan 50±28 98±6 4299±1624b,c 27±6 3299±1635c 62±9
 
       
Sumatriptan 53±21 103±13 1597±465a,c 35±18 1327±577c 71±11 
       
5-HT 21±11 123±7 529±166a,b,c 83±9a,b 138±30a,b,c,d 130±9
a,b 
 
aSignificantly different from the EC50 or Emax of eletriptan in the respective tissue (i.e. within tissue comparison). 
bSignificantly different from the EC50 or Emax of sumatriptan in the respective tissue (i.e. within tissue comparison). 
cSignificantly different from the EC50 in middle meningeal artery for the respective compound (i.e. between tissue comparison). 
dSignificantly different from the EC50 in coronary artery for the respective compound (i.e. between tissue comparison). 
  
 
Table 4.2 Cmax of eletriptan and sumatriptan following oral dose, plasma protein binding values and free Cmax for eletriptan and 
sumatriptan, as well as the predicted contraction occurring at free Cmax in middle meningeal artery, coronary artery and saphenous vein. 
Predicted contraction at free Cmax (range)  Oral dose Cmax (nM) Plasma 
protein 
binding (%) 
Free Cmax 
(nM) Middle 
meningeal artery 
(% PGF2α) 
Coronary artery 
(% K+) 
Saphenous vein 
(% K+) 
Eletriptan 40 mg 213* 83-88* 30 50 (29-74) 4 (0-25)d 7 (0-11)d 
 80 mg 643a  90 72 (43-92) 7 (2-44) 13 (1-23) 
        
Sumatriptan 100 mg 142-183b 14-21c 112-157 74 (46-113) 16 (0-125) 17 (2-44) 
*A.D. McHarg, personal communication. a, Milton et al., 1998;  b, Lacey et al., 1995; Plosker & McTavish, 1994; c, Scott, 1994. 
d Significantly different from sumatriptan in the respective blood vessel (i.e. within tissue comparison). No significant differences were 
observed between 80 mg eletriptan and sumatriptan in the respective blood vessel. 
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4.4 Discussion 
Contraction to eletriptan and sumatriptan 
In the present study, we investigated contraction elicited by eletriptan and sumatriptan in 
human isolated blood vessels predictive of therapeutic efficacy (middle meningeal artery) 
and coronary side-effect potential (coronary artery, saphenous vein).  Both eletriptan and 
sumatriptan contracted these blood vessels in a concentration-dependent manner and 
exhibited selectivity for contracting the human isolated middle meningeal artery relative to 
coronary artery (86-fold for eletriptan and 30-fold for sumatriptan) as well as saphenous 
vein (66-fold for eletriptan and 25-fold for sumatriptan).  Whereas there was no difference 
in potency between eletriptan and sumatriptan in the middle meningeal artery or 
saphenous vein, eletriptan was less potent than sumatriptan in coronary artery.  This is in 
accordance with another study at our laboratory, where eletriptan was significantly less 
potent than sumatriptan in contracting the human isolated coronary artery (Van den Broek 
et al., 1999). 
It is to be noted that, compared to sumatriptan, high concentrations of eletriptan 
elicited a more marked relaxation of middle meningeal artery (Figure 4.1).  This relaxant 
response may be mediated by the 5-HT7 receptor (Eglen et al., 1997; Hoyer et al., 1994; 
Saxena et al., 1998), since eletriptan has a higher affinity for the 5-HT7 receptor than 
sumatriptan (pKi: 6.7 for eletriptan and 5.9 for sumatriptan (Napier et al., 1999)).  On the 
other hand, eletriptan (and sumatriptan) did not relax coronary artery, where, at least, the 
5-HT7 receptor mRNA has been located (Nilsson et al., 1999; Ullmer et al., 1995).  We do 
not know whether the 5-HT7 receptor is expressed in saphenous vein, but, in any case, 
neither eletriptan nor sumatriptan induced a relaxation.  Irrespective of the mechanism 
involved, the relaxant response to eletriptan in middle meningeal artery is not clinically 
relevant because it was observed at a concentration of 100 µM, which is over a 1000-fold 
higher than its therapeutic plasma concentration (see Table 4.2).  In the middle meningeal 
artery, contraction to eletriptan and sumatriptan reached the same Emax as contraction to 
5-HT, whereas in the coronary artery and saphenous vein the maximum contraction to 
5-HT was 2- to 3-fold higher than that of eletriptan and sumatriptan.  This confirms that in 
the middle meningeal artery no or few 5-HT2 receptors are present (Hamel & Bouchard, 
1991; Hamel et al., 1993; Longmore et al., 1998), in contrast to coronary artery and 
saphenous vein where contraction to 5-HT is mainly mediated by 5-HT2 receptors (Bax et 
al., 1993; Bax et al., 1992; Connor et al., 1989).  The potency rank order of the 
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compounds obtained in the coronary artery and saphenous vein was similar, suggesting 
that the human isolated saphenous vein may serve as a model for human coronary artery 
contraction to antimigraine drugs. 
 
Predicted contraction at therapeutic plasma concentrations 
Both eletriptan and sumatriptan had a significantly lower EC50 (higher potency) in the 
middle meningeal artery than in the coronary artery or saphenous vein.  This higher 
potency in the middle meningeal artery is favorable for antimigraine drugs, conferring 
selectivity for cerebral over coronary blood vessels.  Indeed, the predicted contraction by 
eletriptan and sumatriptan at free Cmax was high in the middle meningeal artery, while 
contraction of the coronary artery and saphenous vein was generally low for both 
compounds (Table 4.2).  The comparison of the magnitude of contraction in middle 
meningeal artery versus coronary artery and saphenous vein is hampered by the fact that 
contractions in middle meningeal artery were expressed as percentage of contraction to 
1 µM prostaglandin F2α (K+ was avoided as it frequently increased basal tone), while in 
coronary artery and saphenous vein they were expressed as percentage of contraction to 
K+ (100 mM).  However, the contraction to 1 µM prostaglandin F2α in the coronary artery 
and saphenous vein was about 60-70% of the contraction obtained with 100 mM K+ (see 
Results, basic contractile properties).  Thus, the use of prostaglandin F2α- or K+-induced 
contraction for reference most probably does not account for the high efficacy of eletriptan 
and sumatriptan in contracting middle meningeal artery. 
The predicted coronary artery contraction at free Cmax was lower for 40 mg 
eletriptan than for sumatriptan (100 mg), whereas there was no difference in predicted 
middle meningeal artery contraction (see Table 4.2).  This data is supported by a recent 
study in patients without significant obstructive coronary artery disease who underwent 
diagnostic cardiac catheterisation.  Eletriptan was infused at 3.33 µg/kg/min (that resulted 
in a mean free Cmax equivalent to that observed after an oral dose of 40 mg) and it 
produced no significant changes in the mean proximal, middle or distal coronary artery 
diameters (Muir et al., 1999).  However, one of the ten patients investigated exhibited a 
segmental constriction of the proximal right coronary artery that may have been 
catheter-induced (Muir et al., 1999) or perhaps caused by the drug.  In contrast, 
intravenous infusion of sumatriptan (total dose of 48 µg/kg) reduced the coronary artery 
diameter significantly with 13% (MacIntyre et al., 1992).  It should, however, be noted 
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that the plasma concentration obtained with this infusion yielded 3-4 times the Cmax 
obtained with 100-mg oral dose of sumatriptan.  In summary, it appears that the 40-mg 
dose of eletriptan may have a low therapeutic burden, including coronary side effects, 
whilst retaining therapeutic efficacy. 
The interpretation of the above data may be influenced by certain factors, 
including the presence of circulating active metabolites of the parent drug 
(MaassenVanDenBrink et al., 1998).   In contrast to sumatriptan (Duquesnoy et al., 1998; 
Fowler et al., 1991), a pharmacologically active N-desmethyl metabolite has been 
described for eletriptan (Milton et al., 1996).  This metabolite is similar to the parent 
compound with respect the affinity at 5-HT1B and 5-HT1D receptors, but its plasma levels 
are 7-9 fold lower than eletriptan concentrations in humans (A.D. McHarg, personal 
communication).  Therefore, N-desmethyl eletriptan is unlikely to contribute to the 
pharmacological action of eletriptan during clinical use.  Further, the calculations of the 
predicted contraction to eletriptan and sumatriptan were based on plasma concentrations 
obtained outside migraine attacks.  Whereas it is known that the absorption of 100 mg oral 
sumatriptan is not significantly affected during migraine attacks (Cutler et al., 1991; 
Plosker & McTavish, 1994), no such data are available about Cmax values following 
therapeutic doses (40 or 80 mg) of eletriptan.  However, the Cmax following 30 mg oral 
eletriptan is reduced by 31% during migraine attacks (Johnson et al., 1997).  Extrapolation 
of this finding may mean that plasma concentrations following 40- and 80-mg doses of 
eletriptan are also decreased during a migraine attack.  This may lead to a reduced 
coronary artery constriction, but then the constriction of middle meningeal artery, 
probably mediating therapeutic efficacy, may also be reduced. 
In any case, the predicted coronary artery contraction to both doses of eletriptan as 
well as to sumatriptan is such that myocardial ischemia is unlikely to occur in patients 
with healthy coronary arteries.  This is consistent with data obtained in this laboratory for 
other triptans (MaassenVanDenBrink et al., 1998).  In contrast, in patients with 
pre-existing coronary artery lesions who have only a limited coronary reserve (Winbury & 
Howe, 1979), even a small coronary artery contraction could lead to myocardial ischemia.  
A similar phenomenon may also be observed in patients with "variant" angina pectoris, 
who have increased coronary artery sensitivity to 5-HT (McFadden et al., 1992).  
Therefore, both eletriptan and sumatriptan remain contraindicated in coronary artery 
disease. 
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4.6 Post-Publication Peer Review: Craniovascular selectivity of eletriptan 
and sumatriptan in human isolated blood vessels  
 
Determining safety and appropriate use of medications are key concerns in drug 
development. We therefore consider it necessary to correct any misconceptions that might 
arise from this article by VanDenBrink and colleagues. The authors rightly conclude that 
sumatriptan and eletriptan have limited propensity to cause adverse coronary side effects, 
but incorrectly imply that eletriptan is relatively more selective for meningeal vis-à-vis 
coronary arteries than sumatriptan. Their misleading conclusion is unfounded because of 
their use of inappropriate analyses, such that: 1. The contractions of human isolated 
coronary artery to both sumatriptan and eletriptan were both small and variable, with some 
S.E.M. values being greater than 50% of the mean. 2. Contractions to eletriptan, but not 
sumatriptan, continued to elevate with increasing concentration without plateauing. This 
distorts EC50 estimates which should only be used for comparison of agonist potencies 
when a response plateau has been clearly demonstrated for each agonists and the maxima 
are shown to be the same (reference 2, below). 3. It makes no sense to estimate separate 
EC50 values from the concentration- contraction curves for eletriptan and sumatriptan 
knowing that the two curves are statistically indistinguishable. 4. Comparison of 
contractile effects in vitro relative to estimated clinical plasma concentrations, provided by 
the authors, must be interpreted cautiously because of the lack of robustness of the 
quantitative data for both parameters. Because of extensive plasma protein binding of 
eletriptan, its free concentration has been calculated on the assumption that the protein 
binding involved is a linear phenomenon unaffected by other possible therapies, which is 
not the case in reality where non equilibrium kinetics apply.  
With either drug, the plasma concentrations normally achieved are associated with 
little or no coronary artery constriction. Further suggesting that there might be less 
contractile effects with eletriptan than sumatriptan are misleading. Thus, there is a general 
consensus that all the triptans have similar pharmacology and a similar but small degree of 
ability to constrict human conduit coronary arteries. This should not confound the view 
that all triptans have a good safety profile when used properly in appropriate patient 
populations, devoid of ishemic heart disease (reference 1).  
 
P.P.A. Humphrey Dr. W. Feniuk Dr. R. Salonen; Neurology 2001, 57: 162-a 
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1) Goadsby, PJ, Hargreaves, RJ. Mechanisms of action of serotonin 5- HT1B/1D agonists: insights into 
migraine pathophysiology using rizatriptan. Neurology, 55 (9 suppl 2):S8-14, 2000).  
2) Kenakin, T. pharmacologic analysis of drug-receptor interaction. Raven, New York, second edition 
(1993). 
 
 
4.6 Response to: Post-Publication Peer Review: Craniovascular selectivity 
of eletriptan and sumatriptan in human isolated blood vessels 
The overall conclusion and indeed the 'take-home' message in our paper 
(MaassenVanDenBrink et al.; reference 1) is that "at therapeutic concentrations both 
eletriptan and sumatriptan contract middle meningeal artery more than coronary artery, 
suggesting that in patients with healthy coronary arteries they have a limited propensity to 
cause adverse coronary side effects [, but] both drugs remain contraindicated in patients 
with coronary artery disease". While agreeing with this conclusion, Humphrey and 
colleagues term our analyses 'inappropriate' and our finding that eletriptan may be a little 
more selective for meningeal vis-à-vis coronary arteries than sumatriptan 'misleading' and 
'unfounded'. We believe that the choice of these adjectives is rather harsh and not borne by 
their critique, which we address in the same order. 1. We know that coronary artery 
contractions to sumatriptan often show a relatively large variability (references 2,3) and, 
therefore, our experiments were conducted in parallel, i.e. both eletriptan and  sumatriptan 
were studied in segments obtained from each of the 9 coronary arteries. Despite this 
variability, which was more conspicuous with sumatriptan (see Fig. 2; reference 1), the 
difference in the EC50 values was statistically discernible. 2. As pointed out in our paper, 
concentrations of eletriptan and sumatriptan higher than 10-4 M (which are some 500 times 
the Cmax values and produced contractions that were statistically not different) could not be 
used. One may argue whether or not the maximum coronary contraction (Emax) was 
reached with eletriptan, the 'distortion' of EC50 estimate is relatively small and, that too, to 
the 'disadvantage' of eletriptan, whose EC50 would then be still higher; this is supported by 
computer simulation with extrapolated Emax values. Moreover, comparable agonists 
maxima (which is in all likelihood the case here) may be a requirement when one is using 
agonists EC50 ratios for the purpose of receptor classification4, but are not essential for 
analyses of the kind used in the present case, in particular, the estimation of predicted 
contractions following drug Cmax. 3. The  concentration contraction curves for eletriptan 
and sumatriptan consist of a family of 9 paired curves and whether or not the mean curves 
were "statistically indistinguishable", it is strange that Humphrey et al. allege that "it 
makes no sense to estimate separate EC50 values from the concentration-contraction 
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curves for eletriptan and sumatriptan". Surely, the proximity of curves does not preclude 
estimation of EC50 values for the two compounds. 4. We are quite aware that one must be 
cautious with interpretation of in vitro experimental data for clinical situations, where 
laboratory conditions do not always apply (see Conclusion and the last part of Discussion; 
reference 1). There is nothing wrong in using therapeutic plasma concentration for our 
analyses. If this concentration is affected by concomitant medications, one may need to 
adjust the drug doses accordingly.  
Lastly, we like to point out that the methods and analyses applied here were very 
much the same as in our earlier publication (reference 3), dealing with human coronary 
artery contractions elicited by sumatriptan, ergots as well as some other triptans. One may 
perhaps also argue that the contraction to sumatriptan (10-4 M) had not reached a plateau 
(see Fig. 1; reference 3), but then we reported that "all [investigated] drugs  were more 
potent (lower EC50 values) than sumatriptan in contracting the human isolated coronary 
artery". Our sentiments expressed then (reference 3), now (reference 1) or elsewhere 
(references 5,6) remain the same: all triptans, including sumatriptan, have a good safety 
profile in otherwise healthy subjects, but they must remain contraindicated in patients with 
coronary artery disease.  
In conclusion, while we refute the critique expressed by Humphrey and colleagues, 
we feel consoled that this critique is from such reputed scientists as Humphrey and 
colleagues, who obviously agree with our 'take- home' message.  
 
P.R. Saxena, R.W.M. van den Broek, A. MaassenVanDenBrink; Neurology 2001, 57: 
163-a 
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Chapter 5 
Human middle meningeal and coronary artery contractions by 
donitriptan and sumatriptan: Prediction of therapeutic plasma 
concentration of donitriptan. 
Summary - Donitriptan is a potent, high efficacy agonist at 5-HT1B/1D receptors.  We 
investigated the contractile effects of donitriptan and sumatriptan on human isolated blood 
vessels of relevance to therapeutic efficacy in migraine (middle meningeal artery) and 
coronary adverse events (coronary artery).  Furthermore, using the concentration response 
curves in the middle meningeal artery, we predicted the plasma concentration needed for 
the therapeutic effect of donitriptan.  Both donitriptan and sumatriptan contracted the 
middle meningeal artery with similar apparent efficacy (Emax: 103±8% and 110±12%, 
respectively), but the potency of donitriptan (pEC50: 9.07±0.14) was significantly higher 
than that of sumatriptan (pEC50: 7.41±0.08).  In the coronary artery, the contraction to 
donitriptan was biphasic with a significantly higher maximal response (Emax: 29±6%) than 
sumatriptan (Emax: 14±2%; pEC50: 5.71±0.16), yielding two distinct pEC50 values 
(8.25±0.16 and 5.60±0.24).  Incubation with the 5-HT2 receptor antagonist ketanserin 
(10 µM) eliminated the low affinity component of the concentration response curve of 
donitriptan and the resultant Emax and pEC50 were 9±2% and 7.33±0.21, respectively.  
Ketanserin was without effect on the sumatriptan-induced contraction.  Based on the 
middle meningeal artery contraction, concentrations (Cmax) of donitriptan that may be 
expected to have a therapeutic efficacy equivalent to that of 50 and 100 mg sumatriptan 
are predicted to be around 2.5 and 4.3 nM, respectively.  Such concentrations are likely to 
induce only a small coronary artery contraction 2.9±1.5% and 3.8±2.0%, respectively; 
these are not different from those by Cmax concentrations of sumatriptan (1.7±0.4% or 
2.2±0.4%).  The present results suggest that, like sumatriptan, donitriptan exhibits 
cranioselectivity and would be effective in aborting migraine attacks with a similar 
coronary side-effect profile as sumatriptan. 
 
Based on: van den Broek, R.W.M., MaassenVanDenBrink, A., Mulder, P.G.M., Bogers, A.J.J.C., Avezaat, 
C.J. & Saxena, P.R. (2001). Comparison of donitriptan and sumatriptan-induced contractile responses in the 
human middle meningeal and coronary arteries. Eur. J. Pharm., submitted. 
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5.1 Introduction 
The introduction of the 5-HT1B/1D receptor agonist sumatriptan (Humphrey and Feniuk, 
1991) has been followed by a number of  second-generation triptans (Connor et al., 
1997; Martin, 1997; Parsons et al., 1998; Gupta et al., 1999), all of which effectively abort 
migraine headache (Goadsby, 1998; Diener and Limmroth, 1999; Deleu and Hanssens, 
2000; Millson et al., 2000; Tfelt-Hansen et al., 2000; Ferrari et al., 2001).  Despite the 
higher affinity at 5-HT1B/1D receptors, better oral bioavailability, increased brain 
penetration and longer plasma half-life, somewhat surprisingly, the newer triptans show 
only subtle differences with sumatriptan in the efficacy and tolerability (Goadsby, 1998; 
Deleu and Hanssens, 2000; Fox, 2000; Millson et al., 2000; Tfelt-Hansen et al., 2000; 
Ferrari et al., 2001).  In the light of the above, Centre de Recherche Pierre Fabre (Castres, 
France) have reported another triptan, donitriptan (F11356: hydrochloride salt or F12640: 
mesylate salt), which displays a uniquely high affinity and, more importantly, intrinsic 
efficacy at recombinant human 5-HT1B/1D receptors with negligible affinity for the 5-HT1F 
receptor (Table 5.1).  In animal experiments, donitriptan has been shown to have a long 
duration of action, to gain access to the brain and to be well-tolerated (John et al., 1999; 
2000).  The therapeutic potential of the drug is currently being evaluated in migraine 
patients. 
It is now generally accepted that the therapeutic action of sumatriptan and other 
triptans is mainly due to constriction of dilated intra- and extracranial blood vessels, 
although other mechanisms interfering with the trigeminovascular system may also be 
involved (De Vries et al., 1999; Tfelt-Hansen et al., 2000; Feniuk and Humphrey, 2001). 
The constriction of cranial blood vessels by triptans is much more marked than that of the 
peripheral arteries, such as the coronaries (Longmore et al., 1998; Parsons et al., 1998; 
MaassenVanDenBrink et al., 2000; Van den Broek et al., 2000).  Despite this 
cranioselectivity, the triptans do have a propensity to cause cardiovascular adverse events, 
including myocardial ischaemia and infarction in predisposed individuals (Kelly, 1995; 
Ottervanger et al., 1997; Main et al., 1998). 
In the present study, we have investigated the contractile effects of donitriptan and 
sumatriptan on human isolated blood vessels of relevance to therapeutic efficacy (middle 
meningeal artery) and coronary adverse events (coronary artery).  Furthermore, using the 
concentration response curves in the middle meningeal artery and the basic assumptions 
about the mechanism of action of triptans, we have made an attempt to predict the free 
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(protein-unbound) plasma concentration needed for therapeutic effect of donitriptan, 
which would shortly undergo clinical trials. 
 
5.2 Material and methods 
Tissue collection 
Human isolated middle meningeal artery 
Human middle meningeal arteries were obtained from 7 patients (3 male, 4 female; age 
20-72 years) undergoing craniotomy at the neurosurgical unit of the University Hospital 
'Dijkzigt', Erasmus University Medical Centre, Rotterdam.  During the surgical procedure, 
a part of the skull is temporarily removed and the duramater, together with a small piece 
of the middle meningeal artery, is cut to obtain access to the brain.  This piece of the artery 
was placed in a plastic tube filled with ice-cold (0-4 °C) physiological saline and 
immediately transported to the laboratory.  Upon arrival at the laboratory, the artery was 
placed in a cold oxygenated modified Krebs bicarbonate solution of the following 
composition (mM): NaCl 119, KCl 4.7, CaCl2 1.25, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25 
and glucose 11.1; pH 7.4.  The cyclo-oxygenase inhibitor indomethacin (0.1 µM) was 
added to the Krebs solution to prevent prostaglandin synthesis.  Excess tissue surrounding 
the artery was carefully removed and no attempt was made to remove the endothelium.  
The middle meningeal artery was stored overnight in cold oxygenated Krebs solution and 
was used the following day. 
 
Human isolated coronary artery  
The human right epicardial coronary artery was obtained from 7 heart-beating organ 
donors (5 male, 2 female; 12-65 years), who died of non-cardiac disorders.  The hearts 
were provided by the Heart Valve Bank, Rotterdam, The Netherlands after donor 
mediation by Bio Implant Services Foundation/Eurotransplant Foundation, Leiden, The 
Netherlands; for details, see MaassenVanDenBrink et al. (1998).  Upon arrival in the 
laboratory, the right coronary artery was cleaned from the surrounding tissue and placed in 
a cold, oxygenated Krebs bicarbonate solution of the following composition (mM): NaCl 
118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25 and glucose 8.3; pH 7.4.  
No attempt was made to remove the endothelium.  The artery was stored overnight in cold 
oxygenated Krebs solution and was used the following day. 
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Experimental protocol 
Human isolated middle meningeal artery 
The middle meningeal artery was cut into circular 3- to 4-mm long segments, which were 
mounted on metal prongs in 10-ml organ baths containing Krebs bicarbonate solution, 
aerated with 95% O2 and 5% CO2 and maintained at a temperature of 37 oC.  Changes in 
isometric tension were measured by a force displacement transducer and recorded with 
IOX 1.203h software (both EMKA Technology, Paris, France).  Segments were stretched 
to a passive tension of 4 mN and were allowed to stabilise at this level for 60 min (with 
replacement of Krebs solution every 15 min).  All segments were then exposed 2-3 times 
to 0.1 µM prostaglandin F2α (PGF2α) to demonstrate reproducibility of the evoked 
contractions.  Subsequently, the segments were pre-contracted with PGF2α (1 µM) and the 
relaxation response to substance P (10 nM) was used to evaluate the presence of a 
functional endothelium.  After washing, the segments were allowed to equilibrate for 
60 min, with replacement of buffer every 15 min.  The segments were then used, where 
possible, in a paired parallel experimental set-up and cumulative concentration response 
curves to either donitriptan (0.03 nM-1 µM) or sumatriptan (1 nM-10 µM) (both dissolved 
in 40% v/v polyethylene glycol) were constructed. 
 
Human isolated coronary artery  
Vessels were cut into ring segments of approximately 4-mm length and were suspended 
on stainless steel hooks in 15-ml organ baths containing Krebs bicarbonate solution 
aerated with 95% O2 and 5% CO2 and maintained at a temperature of 37 oC.  Vessel 
segments containing macroscopically visible atherosclerotic lesions were not used.  
Changes in tension were recorded using a Harvard isometric transducer (Harvard 
Apparatus, South Natick, MA, USA).  The segments were allowed to equilibrate for at 
least 30 min and were washed every 15 min.  Segments were stretched to a passive tension 
of 15 mN.  All segments were then exposed to KCl (30 mM) twice, to prime tissue 
reproducibility.  Subsequently, the functional integrity of the endothelium was verified by 
observing relaxation to substance P (1 nM) after pre-contraction with PGF2α (1 µM).  
After washout, the tissue was exposed to KCl (100 mM) to determine the maximal 
contractile response to KCl.  The tissue was washed and then was allowed to equilibrate 
for another period of 30 min.  After this equilibration period the segments were divided in 
a paired parallel experimental set-up and cumulative concentration response curves to 
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either donitriptan, sumatriptan (both dissolved in 40% v/v polyethylene glycol) or 
sumatriptan (dissolved in distilled water) were constructed.  In addition, we incubated half 
of the segments with the 5-HT2 receptor antagonist ketanserin (10 µM) for 30 min prior to 
constructing concentration response curves to donitriptan and sumatriptan. 
 
Data analysis 
Concentration response curves 
Contractile responses were expressed as percentage of the contractile response to 1 µM 
PGF2α (middle meningeal artery) or 100 mM KCl (coronary artery).  Initially, we 
calculated the mean value of the individual maximum contractile responses (Emax) to 
donitriptan and sumatriptan; in case the contractions did not reach a plateau the 
contraction induced by the highest agonist concentration was considered as Emax.  Except 
for donitriptan in the coronary artery, we analysed all concentration response curves with a 
non-linear regression fitting technique for sigmoidal functions with variable slope using 
Prism® 3.0 (GraphPad Software Inc., San Diego, CA, USA) to obtain pEC50 values for the 
agonists.  The mean concentration response curve to donitriptan in the coronary artery 
appeared to be biphasic in nature.  Indeed, the curve fitted significantly better to a model 
of two receptor populations than to a sigmoidal model (Goodness of Fit: R=0.99 and 0.97, 
respectively, P<0.05; Prism® 3.0).  Thus, two distinct pEC50 values of donitriptan-induced 
contractions in coronary artery were obtained. 
Cranioselectivity ratios were calculated as the inverse logarithmic difference 
between respective pEC50 values of donitriptan and sumatriptan in the middle meningeal 
and coronary arteries (see MaassenVanDenBrink et al., 2000; Van den Broek et al., 2000). 
 
Prediction of plasma concentration of donitriptan required for therapeutic activity 
The average free (protein-unbound) maximum plasma concentration (Cmax) in human 
volunteers following 50 mg and 100 mg oral sumatriptan is 81 nM and 135 nM, 
respectively (see MaassenVanDenBrink et al., 1998; Fox, 2000; MaassenVanDenBrink et 
al., 2000).  The extent of middle meningeal artery contractions elicited at these 
concentrations of sumatriptan was derived using individual concentration response curves 
(see Fig. 5.1).  Based on the assumption that constriction of dilated cranial blood vessels is 
the major mechanism of action of triptans in migraine (De Vries et al., 1999; Tfelt-Hansen 
et al., 2000; Feniuk and Humphrey, 2001), we have attempted to predict therapeutic Cmax 
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of donitriptan, i.e. the concentrations of donitriptan that would be needed to elicit a middle 
meningeal artery contraction equivalent to that caused by 81 nM or 135 nM of 
sumatriptan.  In two out of seven experiments with donitriptan in the middle meningeal 
artery, the predicted contraction was higher than the individual Emax of donitriptan, thus 
excluding these experiments from this analysis.  Therefore, we chose to analyse the mean 
concentration response curve of donitriptan to predict the mean therapeutic free Cmax and 
95% CI.  Lastly, the individual concentration response curves in the coronary artery were 
used to calculate the extent of coronary artery contraction that may be expected at the 
(predicted) therapeutic Cmax of sumatriptan and donitriptan. 
 
Statistical analysis 
Differences between Emax and pEC50 values of concentration response curves as well as 
the goodness of fit (sigmoidal or biphasic nature of donitriptan in the coronary artery) 
were analysed according to paired t-test or repeated measures one-way analysis of 
variance (ANOVA), followed where appropriate (coronary artery) by Tukeys multiple 
comparison t-test (Prism® 3.0).  The 95% confidence interval (95% CI) of 
cranioselectivity ratios obtained with donitriptan and sumatriptan was calculated and 
compared as described by Steel and Torrie (1980).  In all cases, statistical significance was 
assumed when P<0.05.  Except for cranioselectivity ratios and free Cmax values, where the 
geometric means with 95% CI are given, all other data are presented as mean±S.E.M. 
 
Ethical approval 
The Medical Ethics Committee of the Erasmus University Medical Centre Rotterdam, 
dealing with the use of human material for scientific experiments, approved the protocols 
for this investigation. 
 
Compounds 
Indomethacin hydrochloride, ketanserin tartrate, prostaglandin F2α tris salt and substance P 
acetate were purchased from Sigma Chemical Co. (St. Louis, MO, USA).  Donitriptan 
mesylate (F12640) was kindly supplied by Centre de Recherche Pierre Fabre (Castres-
Cedex, France).  Sumatriptan succinate (batch: C1008/122/1) was a gift from Glaxo 
Wellcome (Ware, Kent, UK).  Indomethacin was dissolved in 100% v/v dimethyl 
sulphoxide and further diluted in distilled water.  Donitriptan mesylate (F12640) was 
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dissolved in 40% v/v polyethylene glycol and sumatriptan was either dissolved in 40% v/v 
polyethylene glycol or distilled water.  All other compounds were dissolved in distilled 
water. 
 
5.3 Results 
Relaxation responses to substance P 
In vessel segments of the middle meningeal and coronary arteries (n=7 each) the 
relaxation to substance P amounted to 26±8% and 58±10% of precontraction to 
1 µM PGF2α, respectively. 
 
Human middle meningeal artery 
As shown in Fig. 5.1 and Table 5.2, both donitriptan (n=7) and sumatriptan (n=5) 
contracted the middle meningeal artery in a concentration-dependent manner with a 
similar efficacy (Emax: 103±8% and 110±12% of contraction to 1 µM PGF2α, 
respectively).  The potency (pEC50) of donitriptan was significantly higher than that of 
sumatriptan (9.07±0.14 and 7.41±0.08, respectively; P<0.0001).  This was also the case 
when only the 5 experiments with donitriptan performed in parallel with sumatriptan were 
considered (pEC50: 9.05±0.17).  The Hill slopes of the concentration response curves to 
donitriptan (1.2±0.3) and sumatriptan (1.1±0.3) did not significantly differ from each 
other, nor were they significantly different from unity. 
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Human coronary artery 
The human isolated coronary artery also contracted in response to donitriptan and 
sumatriptan in a concentration-dependent manner (Fig. 5.2 and Table 5.2).  Donitriptan 
contracted the coronary artery biphasically with an Emax of 29±6% of contraction to 100 
mM KCl.  The concentration response curves to donitriptan were fitted to a model of two 
receptor populations and revealed two distinct pEC50 values (8.25±0.16 and 5.60±0.24).  
Incubation with the 5-HT2 receptor antagonist ketanserin (10 µM) revealed a sigmoidal 
curve with a potency (pEC50) of 7.33±0.21 yielding a significant decrease in Emax (9±2% 
Figure 5.1 Cumulative concentration response curves to donitriptan (○; n=7) and
sumatriptan (□; n=5) in the human isolated middle meningeal artery.  Symbols and
vertical bars represent the means and S.E.M.  Arrows represent the prediction of the
contraction of the artery at the average free (protein-unbound) Cmax (81 or 135 nM) after
a therapeutic dose of sumatriptan (50 mg or 100 mg oral tablet, respectively) and the
predicted therapeutic Cmax of donitriptan needed to elicit a contraction equivalent to that
caused by 81 or 135 nM sumatriptan. 
α
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of contraction to 100 mM KCl) as compared to donitriptan in the absence of ketanserin 
(P<0.01).  The Hill slope of the concentration response curves to donitriptan in the 
presence of ketanserin was 0.8±0.1, which was not significantly different from unity. 
Sumatriptan, dissolved in distilled water, contracted the coronary artery with a 
potency (pEC50) of 5.71±0.16 and maximal effect (Emax) of 14±2% of contraction to 
100 mM KCl; these were significantly lower as compared to the pEC50 (high affinity 
component) and Emax of donitriptan.  The Hill slope of concentration response curves to 
sumatriptan (0.6±0.1) was significantly different from unity.  Incubation with the 5-HT2 
receptor antagonist ketanserin (10 µM) was without effect on either the Emax (11±3% of 
contraction to 100 mM KCl) or the pEC50 (5.76±0.14) of sumatriptan, whereas the Hill 
slope did not differ from unity (0.8±0.3). 
Due to the fact that donitriptan was dissolved in 40 v/v polyethylene glycol, we 
investigated whether the solvent influenced contraction to sumatriptan.  Sumatriptan 
dissolved in 40 v/v polyethylene glycol caused a similar contraction (Emax: 10±2% of 
contraction to 100 mM KCl; pEC50: 6.18±0.29; Hill slope: 0.8±0.3) as compared to 
sumatriptan dissolved in distilled water. 
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Cranioselectivity of donitriptan and sumatriptan 
The mean cranioselectivity ratios (inverse logarithm of the difference between the pEC50 
values in the middle meningeal and coronary arteries) and the respective 95% CI are 
shown in Table 5.2.  Due to the fact that donitriptan showed a biphasic response in the 
human coronary artery, the pEC50 value obtained in the lower (high affinity) part of the 
curve was used to calculate the cranioselectivity ratio, since the therapeutic concentration 
is expected to be in this range (see above).  Both donitriptan and sumatriptan were 
significantly more potent in the middle meningeal artery as compared to the coronary 
artery, whereas the cranioselectivity ratio for donitriptan was slightly lower than that for 
sumatriptan.  After treatment with ketanserin, both donitriptan and sumatriptan had similar 
cranioselectivity ratios (Table 5.2). 
Figure 5.2  Cumulative concentration response curves (n=7 each) to donitriptan 
in the absence (○) or presence of 10 µM ketanserin (●) and sumatriptan in the 
absence (□) or presence of 10 µM ketanserin (■).  Symbols and vertical bars 
represent the mean and S.E.M. 
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Prediction of plasma concentration of donitriptan required for therapeutic activity 
The mean therapeutic free Cmax following administration of a 50 mg or 100 mg oral tablet 
of sumatriptan has been reported to be 81 nM and 135 nM, respectively (see 
MaassenVanDenBrink et al., 1998).  As shown in Table 5.3, the contraction to 
sumatriptan that is predicted to occur at these concentrations was 79±8% and 89±9% of 
contraction to 1 µM PGF2α, respectively, in the middle meningeal artery and 1.7±0.4% 
and 2.2±0.4% of contraction to 100 mM KCl, respectively, in the coronary artery.  
Interpolating concentration response curves to donitriptan in the middle meningeal artery, 
the predicted therapeutic free Cmax values of donitriptan (i.e. concentration eliciting 79% 
or 89% of contraction to 1 µM PGF2α) were 2.5 nM (95% CI: 1.5-6.5 nM) and 4.3 nM 
(95% CI: 2.4-12.9 nM), respectively.  At these predicted free Cmax values, the contraction 
of donitriptan in the coronary artery may amount to 2.9±1.5% and 3.8±2.0% of 
contraction to 100 mM KCl, respectively; these were not significantly different from those 
calculated for sumatriptan (Table 5.3). 
 
  
 
 
Table 5.1 
Chemical structure and affinity and efficacy of donitriptan and sumatriptan at human 5-HT1B/1D/1F receptors. 
 Chemical structure Inhibition radioligand binding (pKi) Inhibition cAMP 
accumulation (pEC50) 
Enhancement 
[35S]GTPγS binding 
(pEC50) 
  5-HT1B 5-HT1D 5-HT1F 5-HT1B 5-HT1D 5-HT1B 5-HT1D 
Donitriptana  
 
 
9.4-10.1 9.3-10.2 5.5 8.91 9.57 8.74 9.08 
Sumatriptan  
 
7.8b 8.5b 7.9b 7.16c 8.79c 6.63c 7.75c 
Data from: a, John et al. (1999); b, Leysen et al. (1996); c, Pauwels et al. (1997).  pKi and pEC50 are expressed as Log M. 
NH
S
NH
CH3 N
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F12640: mesylate salt
F11356: hydrochloride
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N
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Table 5.2 Functional parameters obtained with donitriptan and sumatriptan in the 
absence or presence of ketanserin (10 µM) in the human isolated middle meningeal and 
coronary arteries.  Data are presented as means±S.E.M. or as mean (95% CI).  Except 
sumatriptan in the middle meningeal artery (n=5), the number of experiments were 7 in each 
case.  The Emax values are presented as % of contraction elicited by either 1 µM PGF2α 
(middle meningeal artery) or 100 mM KCl (coronary artery).  NP, Not performed. 
 
Middle meningeal artery Coronary artery  
Emax pEC50 Emax pEC50 
Cranioselectivity 
ratioa (95% CI) 
 
Donitriptan 103±8%  9.07±0.14b 29±6%b 8.25±0.16b,c 
5.60±0.24c 
7 (3-16)d,e 
Donitriptan + 
ketanserin 
NP NP 9±2% 7.33±0.21b  55 (19-162)d 
Sumatriptan 110±12%   7.41±0.08 14±2% 5.71±0.16 50 (22-113)d 
Sumatriptan + 
ketanserin 
NP NP 11±3% 5.76±0.14 45 (22-92)d 
a, Cranioselectivity ratio = Inverse logarithm [pEC50 (middle meningeal artery)  pEC50 
(coronary artery)]. 
b, Significantly different from respective values obtained with sumatriptan (P<0.05). 
c, Biphasic concentration response curves yielding two distinct pEC50 values. 
d, Significantly different from 1 (P<0.05). 
e, Significantly lower than sumatriptan (P<0.05). 
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Table 5.3 Predicted therapeutic free plasma Cmax of donitriptan and predicted 
contraction of middle meningeal and coronary arteries at free therapeutic Cmax of sumatriptan 
and donitriptan.  Data are presented as means±S.E.M. or as mean (95% CI).  Except 
sumatriptan in the middle meningeal artery (n=5), the number of experiments were 7 in each 
case. 
 Free therapeutic Cmax (nM) Predicted contraction at free Cmax 
 Knowna Predicted Middle 
meningeal artery 
(% PGF2α) 
Coronary artery 
(% KCl) 
Sumatriptan 
50 mg 
100 mg 
 
81 
135 
  
79±8 
89±9 
 
1.7±0.4 
2.2±0.4 
Donitriptan 
X mgb 
Y mgc 
  
2.5 (1.5-6.5) 
4.3 (2.4-12.9) 
 
79 
89 
 
2.9±1.5 
3.8±2.0 
a, see Fox, 2000; MaassenVanDenBrink et al., 1998. 
b, Values based on middle meningeal artery contraction induced by free Cmax after 50 mg 
sumatriptan. 
c, Values based on middle meningeal artery contraction induced by free Cmax after 100 mg 
sumatriptan. 
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5.4 Discussion 
Efficacy profile in the middle meningeal artery 
It is well known that acutely acting antimigraine drugs (ergots and triptans) have a 
vasoconstrictor effect, particularly on large cranial arteries and arteriovenous anastomoses 
(De Vries et al., 1999; Tfelt-Hansen et al., 2000).  Donitriptan contracted the human 
isolated middle meningeal artery with a similar maximal response as sumatriptan (see Emax 
values in Table 5.2).  The results are in accordance with those obtained in the rabbit 
isolated saphenous vein (John et al., 2000), an established model to detect agonist activity 
at 5-HT1B receptors (Valentin et al., 1996; Wurch et al., 1997), but are at variance with the 
high intrinsic activity of donitriptan at 5-HT1B/1D receptors demonstrated in other 
experimental models (John et al., 1999; 2000).  Indeed, like the rabbit saphenous vein 
model, the human middle meningeal artery preparation apparently does not distinguish 
between low and high efficacy 5-HT1B receptor agonists, suggesting the preparation is 
likely to express 5-HT1B receptors in a high density (Longmore et al., 1997; 1998).  It is 
noteworthy that high efficacy agonist activity is not necessarily observed in every model, 
and models that distinguish high from low efficacy agonists have a low receptor reserve, 
due to a relatively low receptor density and/or inefficient second-messenger coupling 
(Kenakin, 1993; John et al., 2000).  We concede that the Emax of donitriptan-induced 
coronary artery contraction in the presence of ketanserin (mediated by the 5-HT1B 
receptor) was not higher than that of sumatriptan (see Fig. 5.2), despite a low 5-HT1B 
receptor density in this vessel (Longmore et al., 1998), but we do not have data with 
regard to receptor coupling. 
There is now overwhelming evidence that cranial vasoconstrictor response to triptans is 
mediated via the 5-HT1B receptor (Bouchelet et al., 1996; Longmore et al., 1997; 1998; 
Van den Broek et al., 2000; Centurión et al., 2001).  Indeed, in accordance with the 
binding affinities at the human 5-HT1B receptor (see Table 5.1), donitriptan (pEC50: 
9.07±0.14) was 48-fold more potent than sumatriptan (pEC50: 7.41±0.08) in contracting 
the human middle meningeal artery. 
 
Efficacy profile in the coronary artery 
Concentration response curves to donitriptan in the human isolated coronary artery 
revealed a biphasic response with a significantly higher maximum contraction as 
compared to sumatriptan (Emax: 29±6% and 14±2% of the response to 100 mM KCl, 
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respectively).  This biphasic response and higher response amplitude of donitriptan 
appears to be at variance with findings in the canine isolated coronary artery, where both 
donitriptan and sumatriptan showed a similar efficacy and sigmoidal shape of the 
concentration response curve (John et al., 2000).  However, in contrast to the predominant 
role of 5-HT2A over 5-HT1B receptors in the human coronary artery (Connor et al., 1989; 
Kaumann et al., 1994; Ishida et al., 1999; Nilsson et al., 1999), the 5-HT2 receptor 
antagonist ketanserin was unable to block 5-HT-induced contractions in the canine 
coronary artery, suggesting that the 5-HT2A receptor plays little role in this preparation 
(Cushing and Cohen, 1992).  Therefore, we reasoned that the biphasic response to 
donitriptan in the present experiments could be due to activation of a 5-HT2-like  (possibly 
the 5-HT2A) receptor at high concentrations of donitriptan (pKi: 6.7, John et al., 1999).  
Indeed, the maximal response (Emax as percentage of the response to 100 mM KCl) evoked 
by donitriptan (29±6%) was significantly reduced in the presence of ketanserin (9±2%) to 
a similar level as that of sumatriptan (11±3%); the latter was resistant to ketanserin 
(Table 5.2 and Connor et al., 1989; Kaumann et al., 1994).  Furthermore, the concentration 
response curve to donitriptan in the presence of ketanserin was restored to a sigmoidal 
function and, as expected from their respective affinities at the 5-HT1B receptor 
(Table 5.1), yielded a 37-fold higher potency (pEC50: 7.33±0.21) compared to that of 
sumatriptan (pEC50: 5.76±0.14).  It should be mentioned however, that constriction to 
donitriptan was not blocked by ketanserin (up to 100 µM) in rat isolated aorta (G.W. John, 
unpublished observations), which is considered as a typical 5-HT2A receptor preparation. 
Despite this discrepancy it appears that at low, clinically relevant concentrations 
donitriptan constricts the coronary artery via the 5-HT1B receptor and has similar maximal 
response amplitude as sumatriptan. 
One may argue that in the relatively high concentration employed (10 µM), 
ketanserin can also act as a 5-HT1D receptor antagonist (Zgombick et al., 1995; Pauwels 
and Colpaert, 1996).  This is probably not relevant because 5-HT1D receptor activation is 
not associated with vasoconstriction (Ennis et al., 1998; Bouchelet et al., 2000; Centurión 
et al., 2001). 
 
Cranioselectivity of donitriptan and sumatriptan 
It is known that a number of triptans (sumatriptan, rizatriptan, frovatriptan and eletriptan) 
selectively constrict cranial blood vessels compared to the coronary artery (Longmore et 
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al., 1998; Parsons et al., 1998; MaassenVanDenBrink et al., 2000; Van den Broek et al., 
2000).  In the present investigation also, donitriptan as well as sumatriptan exhibited 
cranioselectivity because they were both more potent in contracting middle meningeal 
artery than coronary artery (see Table 5.2 for pEC50 values).  The cranioselectivity ratio, 
calculated as inverse logarithm of the differences between the respective pEC50 values in 
the middle meningeal and coronary arteries, for donitriptan (7-fold) was smaller than that 
for sumatriptan (50-fold).   However, it must be emphasised that, in view of the predicted 
therapeutic concentration range (Table 5.3), we have used the pEC50 value obtained with 
the high affinity component of the concentration response curve to donitriptan in the 
coronary artery.  Interestingly, after elimination of the low affinity component of 
donitriptan by the 5-HT2A receptor antagonist ketanserin, the cranioselectivity ratio was 
similar to that of sumatriptan (Table 5.2).  This latter finding can be explained by the fact 
that in this preparation, the 5-HT2A receptor is predominant over the 5-HT1B receptor 
(Connor et al., 1989; Kaumann et al., 1994; Ishida et al., 1999; Nilsson et al., 1999). 
 
Prediction of plasma concentration of donitriptan required for therapeutic activity and 
predicted contractions 
Another way to determine cranioselectivity is to calculate predicted contractions at 
therapeutic free (protein-unbound) Cmax of donitriptan and compare them with those for 
sumatriptan (MaassenVanDenBrink et al., 2000).  Since therapeutic free Cmax of 
donitriptan is currently not known, we have attempted to predict this (see Fig. 5.1) using 
two assumptions: (i) cranial vasoconstriction, as reflected by the human isolated middle 
meningeal artery contraction, is the major mechanism of therapeutic action of triptans (De 
Vries et al., 1999; Tfelt-Hansen et al., 2000; Feniuk and Humphrey, 2001) and (ii) data 
obtained in our laboratory setting by and large would apply to the clinical setting.  
Obviously, we cannot be absolutely sure on either count, but predicted therapeutic Cmax of 
donitriptan may also help in determining initial doses to be employed in clinical trials.  In 
any case, a comparison of the predicted and real therapeutic Cmax values of donitriptan 
may be useful in the consideration of the mechanism of action of the drug. 
On the basis of therapeutic free Cmax of 50 mg or 100 mg oral sumatriptan (81 and 
135 nM, see MaassenVanDenBrink et al., 1998; 2000) and the predicted contractions of 
the middle meningeal artery obtained at these concentrations of sumatriptan (79% or 89% 
of the contraction to 1 µM PGF2α), donitriptan would need a free Cmax of ~3-4 nM to be as 
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effective as sumatriptan (see Table 5.3).  The predicted contractions in coronary artery 
(expressed as percentage of the contraction to 100 mM KCl) to donitriptan were small 
(3-4%) and similar to those with sumatriptan at therapeutic concentrations.  Thus, based 
on these predictions, the two drugs have an equal propensity to constrict the coronary 
artery at therapeutic concentrations. 
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Chapter 6 
The Potential antimigraine compound SB-220453 does not contract 
human isolated blood vessels or myocardium; a comparison with 
sumatriptan 
Summary - The mechanistically novel benzopyran derivative SB-220453, which is 
undergoing clinical evaluation in migraine, exhibits a high affinity for a selective, but not 
yet characterised binding site in the human brain.  It inhibits nitric oxide release and 
cerebral vasodilatation following cortical spreading depression as well as carotid 
vasodilatation induced by trigeminal nerve stimulation in the cat.  The aim of our study 
was to investigate the contractile properties of SB-220453 on a number of human isolated 
blood vessels (coronary artery, saphenous vein and middle meningeal artery) as well as 
atrial and ventricular cardiac trabeculae.  While sumatriptan induced marked contractions 
in all blood vessels investigated, SB-220453 was devoid of any effect.  In atrial and 
ventricular cardiac trabeculae, neither SB-220453, nor sumatriptan displayed a positive or 
negative inotropic effect.  Since SB-220453 did not contract the middle meningeal artery, 
we conclude that potential antimigraine effects are not mediated via a direct cerebral 
vasoconstriction.  The lack of activity of SB-220453 in coronary artery, saphenous vein 
and cardiac trabeculae demonstrates the compound is unlikely to display adverse cardiac 
side effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on: MaassenVanDenBrink, A., van den Broek, R.W.M, de Vries, R., Upton, N., Parsons, A.A. & 
Saxena,P.R. (2000). The potential anti-migraine compound SB-220453 does not contract human isolated 
blood vessels or myocardium; a comparison with sumatriptan. Cephalalgia, 20, 538-45. 
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6.1 Introduction 
Sumatriptan, an indole sulphonamide with agonist activity at 5-HT1B/1D receptors, is 
highly effective in aborting attacks of migraine and cluster headache.  The drug is 
generally well tolerated, but up to 15% of patients consistently report chest symptoms, 
including chest pressure, tightness and pain, often mimicking angina pectoris (Brown et 
al., 1991; Polvino et al., 1994; Visser et al., 1996).  Although extracardiac mechanisms 
have been invoked (Houghton et al., 1994), chest symptoms may well be caused by 
coronary vasoconstriction, which has been observed after sumatriptan both in vivo 
(MacIntyre et al., 1993) and in vitro (Bax & Saxena, 1993; Chester et al., 1993; Connor et 
al., 1989; MaassenVanDenBrink et al., 1998).  In some cases, the use of sumatriptan, like 
that of ergotamine (Galer et al., 1991; Yasue et al., 1981), was even associated with 
myocardial infarction (O'Connor & Gladstone, 1995; Ottervanger et al., 1993) and cardiac 
arrest (Kelly, 1995).  'Second generation' sumatriptan-like antimigraine drugs are aimed at, 
in addition to achieving high efficacy and long duration of action, avoiding coronary 
vasoconstrictor activity (Saxena et al., 1996).  However, these drugs also contract human 
isolated coronary artery and seem to have a similar coronary side-effect potential as 
sumatriptan (MaassenVanDenBrink et al., 1998; MaassenVanDenBrink et al., 1999; 
Parsons et al., 1997). 
Due to concerns about cardiac side effects, it would be highly desirable to develop 
antimigraine drugs that act via a mechanism not involving 5-HT1B/1D receptors.  Indeed, 
the mechanistically novel benzopyran SB-220453 (Chan et al., 1999) has no significant 
affinity at 5-HT1B/1D receptors, nor does it show any activity in a large number of 
receptor-, ion channel- and enzyme-assays (Chan et al., 1999).   SB-220453 exhibits a 
high affinity for a selective, but structurally unknown binding site in the human brain 
(Upton et al., 1999) and may be active in the treatment of migraine via blockade of 
excessive cortical excitability.  SB-220453 inhibits neurogenic inflammation in rat brain 
meninges (Chan et al., 1999), nitric oxide release associated with cortical spreading 
depression as well as carotid vasodilatation induced by trigeminal nerve stimulation in the 
cat (Read et al., 1999; Upton et al., 1999).  In the present study, we investigated the 
effects of SB-220453 on a number of human isolated blood vessels (coronary artery, 
saphenous vein and middle meningeal artery) as well as human isolated atrial and 
ventricular cardiac trabeculae.   Sumatriptan was used for comparison. 
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6.2 Patients and methods 
Preparation of tissue 
Human isolated coronary artery  
Right epicardial coronary arteries were obtained from six heart beating organ donors 
(2 male, 4 female; age 37-63 years), who died of non-cardiac disorders (5 of 
cerebrovascular accident, 1 head trauma) less than 24 h before the tissue was taken to the 
laboratory.  Hearts, provided by the Rotterdam Heart Valve Bank (Bio Implant Services / 
Eurotransplant Foundation) after removal of the aortic and pulmonary valves for 
transplantation purposes, were stored at 0ºC to 4ºC in a sterile organ-protecting solution 
immediately after circulatory arrest.   After arrival at the laboratory, the right coronary 
artery was removed and placed in a cold, oxygenated Krebs buffer solution of the 
following composition (mM): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, 
NaHCO3 25 and glucose 8.3; pH 7.4.  The artery was kept overnight before the 
experiment. 
On the following day, the artery was cut into segments of 3-4 mm length, 
excluding distinct, macroscopically visible atherosclerotic lesions.  The vessel segments 
were mounted in 15-ml organ baths filled with oxygenated Krebs buffer solution at 37°C.  
After equilibration for at least 30 min and a wash every 15 min, the vessel segments were 
stretched to a stable tension of about 15 mN.  Changes in tissue tension were measured 
using an isometric transducer (Harvard, South Nattick, Massachusetts, USA) and recorded 
on a flatbed recorder (Servogor 124, Goerz, Neudorf, Austria). 
 
Human isolated saphenous vein 
Human saphenous veins were obtained postoperatively from four patients (2 male, 
2 female; 68-79 years) undergoing coronary bypass surgery.  The tissue was immediately 
placed in cold saline and was brought to the laboratory within 15 min.  Subsequently, the 
vein was cleaned of connective tissue and placed in a cold, oxygenated Krebs buffer 
solution (for composition, see above).  After overnight storage, the vein was cut into 
segments of 3-4 mm length.  The vessel segments were mounted in 15-ml organ baths 
filled with oxygenated Krebs buffer solution at 37°C.  After equilibration for at least 
30 min and a wash every 15 min, the vessel segments were stretched to a stable tension of 
about 10 mN.  Contractions were measured with an isometric transducer (Harvard, South 
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Nattick, Massachusetts, USA) and recorded on a flatbed recorder (Servogor 124, Goerz, 
Neudorf, Austria). 
 
Human isolated middle meningeal artery 
Human middle meningeal arteries were obtained from ten patients (3 male, 7 female; 
30-71 years) undergoing craniotomy during neurosurgical procedures.  In such patients, a 
part of the skull is temporarily removed to gain access to the brain and a small redundant 
portion of a branch of the middle meningeal artery is usually found attached to the dural 
sheath covering the removed piece of the skull.  After careful removal from the dura 
mater, this arterial piece was placed in cold saline and brought to the laboratory 
immediately.  Upon arrival at the laboratory, the artery was cleaned of connective tissue 
and was placed in cold oxygenated Krebs buffer solution of the following composition 
(mM): NaCl 119, KCl 4.7, CaCl2 1.25, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25 and glucose 
11.1; pH 7.4.   Vessel segments of 4 mm length were and mounted in 10-ml organ baths 
filled with oxygenated Krebs buffer solution at 37°C.  After equilibration for at least 
30 min and a wash every 15 min, the vessel segments were stretched to a stable tension of 
about 4 mN.  Contractions of the artery were measured with an isometric force 
displacement transducer and recorded using the IOX 1.103 software (both: EMKA 
Technology, Paris, France). 
To prevent prostaglandin synthesis, the cyclo-oxygenase inhibitor indomethacin 
(0.1 µM) was added to the Krebs solution.  The experiments were performed within 2 h 
after surgery. 
 
Human atrial and ventricular cardiac trabeculae 
As described above (coronary artery section), hearts were obtained from five heart beating 
organ donors (2 male, 3 female; age 36-57 years), who died of non-cardiac disorders (all 
cerebrovascular accident).  Immediately after arrival at the laboratory, right atrial and left 
ventricular trabeculae of approximately 1 mm thickness were carefully dissected and 
mounted in a 15-ml organ bath in the same Krebs buffer solution as used for the coronary 
artery and saphenous vein.  The trabeculae were paced at 1 Hz using electrical field 
stimulation (5 ms, 15-20 V) delivered by a Grass S6 Square Wave Stimulator (Quincy, 
MA, USA).  Resting tension was set to 7.5 mN and 20 mN for atrial and ventricular tissue, 
respectively.  Changes in contraction were recorded with a Harvard force transducer 
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(South Nattick, MA, USA) on a flatbed recorder (Servogor 124, Goerz, Neudorf, Austria).  
The preparation was allowed to stabilise during 1 h with a wash every 15 min (Du et al., 
1994). 
 
Experimental protocol 
Human isolated coronary artery and saphenous vein 
Segments were exposed to K+ (30 mM) twice.  The functional integrity of the endothelium 
was verified by observing relaxation to substance P (1 nM, coronary artery) or bradykinin 
(1 µM, saphenous vein, substance P is nearly inactive in this blood vessel) after 
precontraction with prostaglandin F2α (1 µM).  After washout, the tissue was exposed to 
K+ (100 mM) to determine the maximal contractile response to K+.  After a 30-min 
incubation period, a concentration response curve to sumatriptan (dissolved in distilled 
water or dimethylsulfoxide; DMSO) or SB-220453 (dissolved in DMSO) was constructed.  
In four of the experiments in coronary artery, a concentration response curve to these 
agonists was also constructed after a 30-min incubation with the stable thromboxane A2 
analogue U46619 (3-10 nM, the lowest concentration, determined in half logarithmic 
steps, eliciting a contraction ≥10% of K+-induced contraction).  A paired parallel set-up 
(i.e. all compounds were tested in different segments obtained from the same artery) was 
used for coronary artery experiments.  In the saphenous vein, a paired parallel crossover 
design was used (i.e. similar as in coronary artery, but, in addition, a second concentration 
response curve was constructed to SB-220453 after sumatriptan, or to sumatriptan after 
SB-220453 after a 30-60 min washout period).  Contractions were expressed as a 
percentage of contraction to 100 mM K+. 
 
Human isolated middle meningeal artery 
 Since the addition of K+ frequently increased basal tone (unpublished observations), 
vessel segments were exposed to prostaglandin F2α (0.1 µM) two to three times to prime 
the tissue for stable contractions.  Subsequently, the segments were contracted with 
prostaglandin F2α (1 µM) and the functional integrity of endothelium was assessed by 
observing relaxation to substance P (10 nM).  Due to the limited number of vessel 
segments that could be obtained from one patient, middle meningeal artery experiments 
were performed in an unpaired design, i.e. concentration response curves to sumatriptan 
(dissolved in distilled water) or SB-220453 (dissolved in DMSO) were constructed in 
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different arterial segments, which were in most cases obtained from different patients.  In 
addition, a concentration response curve to sumatriptan (dissolved in DMSO) was 
constructed following a 30-60 min washout period after the concentration response curve 
to SB-220453.  Contractions were expressed as a percentage of contraction to 1 µM 
prostaglandin F2α. 
 
Atrial and ventricular cardiac trabeculae 
A concentration response curve to noradrenaline (10 nM  10 µM) was constructed to 
verify the viability of the tissue.  Trabeculae yielding less than 0.25 mN response to 
10 µM noradrenaline were excluded from further analysis.  After washout, a concentration 
response curve to sumatriptan (dissolved in distilled water or DMSO) or SB-220453 
(dissolved in DMSO) was constructed.  In four out of five experiments, concentration 
response curves were also obtained after precontraction with noradrenaline (10 µM).  
Since this precontraction was not always stable for a period long enough to allow 
construction of a complete concentration response curve (1 nM - 100 µM) to the agonists, 
not all concentrations were studied in these experiments.  Changes in contraction were 
expressed as percentage of increase in contraction to 10 µM noradrenaline). 
 
Compounds 
Sumatriptan succinate was a kind gift from GlaxoWellcome (Dr. H.E. Connor, Ware, 
Hertfordshire, UK).  SB-220453 ((-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoyl amino) 
3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3S-ol) was kindly provided by SmithKline 
Beecham (Dr. A.A. Parsons, Harlow, Essex, UK).  U46619 (9,11-dideoxy-11α,9α-epoxy, 
methanoprostaglandin F2α), prostaglandin F2α (Tris salt), bradykinin acetate, substance P 
acetate and dimethylsulfoxide (DMSO) were purchased from Sigma Chemical Co. 
(St. Louis, Missouri, U.S.A.).  Indomethacin was obtained from the pharmacy of Erasmus 
University Medical Centre Rotterdam (Rotterdam, The Netherlands).  The chemicals used 
for the Krebs buffer solutions were purchased from Merck (Darmstadt, Germany). 
Sumatriptan was dissolved in distilled water or, where indicated, in DMSO and 
further diluted in distilled water.  Indomethacin and SB-220453 were dissolved in DMSO 
and further diluted in distilled water.  The other compounds were dissolved in distilled 
water.   
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Analysis of data 
Concentration response curves analyzed using GraphPad software (GraphPad software 
Inc., San Diego, California, USA) to determine pEC50 values (negative logarithm of the 
concentration eliciting 50% of the maximal contractile response, Emax).  When a plateau in 
the concentration response curve was not reached, the response observed with the highest 
concentration used (100 µM) was considered as Emax. 
At 100 µM, SB-220453 and sumatriptan (dissolved in DMSO) induced a small 
relaxation of the blood vessels, which was not easily quantifiable.  This relaxant response, 
which was also observed with equivalent amounts of the solvent DMSO, has been 
ignored.  For the experiments in the presence of U46619, the precontraction induced by 
U46619 was subtracted from the concentration response curves obtained with the agonists. 
All data in the text and illustrations are presented as mean±s.e.mean, with n 
representing the number of different subjects or, when specifically mentioned, the number 
of vessel segments or trabeculae.  Differences between pEC50 and Emax values of the 
compounds were evaluated with Tukey's test, once an analysis of variance (ANOVA) for 
paired (coronary artery, saphenous vein, myocardial trabeculae) or unpaired data (middle 
meningeal artery) had revealed that the samples represented different populations.  Values 
of P<0.05 were considered to indicate significant differences.   
 
Ethical approval 
The Ethical Committee of the Erasmus University Medical Centre Rotterdam approved 
this study. 
 
6.3  Results 
Human isolated coronary artery 
All coronary artery segments relaxed after substance P (1 nM).  The response amounted to 
48±15% (range: 9-107%) of the precontraction (22±6 mN) to prostaglandin F2α (1 µM).   
Contraction to 100 mM K+ was 55±6 mN (n=6). 
Sumatriptan induced a concentration-dependent contraction, which was 
independent of the solvent  (distilled water and DMSO) used; Emax: 12±3% and 7±1% of 
K+-induced contraction, respectively, pEC50: 6.0±0.2 and 6.4±0.2, respectively.  
SB-220453 induced no response (Figure 6.1, left panel).  After precontraction with 
U46619 (17±3% of K+-induced contraction), the Emax to sumatriptan was substantially 
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augmented in two out of the four experiments.  However, the mean Emax (39±24% for 
sumatriptan dissolved in distilled water and 38±17% for sumatriptan dissolved in DMSO) 
was, as reported previously (MaassenVanDenBrink et al., 1996), not significantly 
different from values in these four experiments in the absence of U46619 (16±3% for 
sumatriptan dissolved in distilled water and 9±1% for sumatriptan dissolved in DMSO).  
The pEC50 of sumatriptan in the presence of U46619 (6.7±0.3 and 6.6±0.3 for sumatriptan 
dissolved in distilled water and DMSO, respectively) was also not significantly increased, 
when compared to those in the absence of U46619 (6.2±0.3% for sumatriptan dissolved in 
distilled water and 6.5±0.2% for sumatriptan dissolved in DMSO).  Similar to the 
experiments performed on quiescent arteries, SB-220453 failed to contract the coronary 
artery in the presence of U46619 (Figure 6.1, right panel). 
 
Figure 6.1 Concentration response curves in human isolated coronary arteries to 
sumatriptan (dissolved in distilled water,  or DMSO, ■) and SB-220453 (∇, dissolved in 
DMSO).  Experiments were performed in the absence of U46619 (left panel, n=6) or after 
precontraction with U46619 (3-10 nM; right panel, n=4, except sumatriptan dissolved in 
distilled water n=3).  The precontraction induced by U46619 was 17±3%, n=15 vessel 
segments. 
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Human isolated saphenous vein 
Saphenous vein segments relaxed after bradykinin (1 µM), the response amounting to 
49±24% (range: 10-107%) of the precontraction (6±3 mN) induced by prostaglandin F2α 
(1 µM).   Contraction to 100 mM K+ was 10±2 mN (n=4). 
In all experiments, sumatriptan (dissolved in DMSO) induced a concentration-
dependent contraction (Emax: 52±5%, pEC50: 6.3±0.1). SB-220453 did not induce a 
contraction in any of the concentrations used (Figure 6.2, left panel).  The concentration 
response curves to sumatriptan that were constructed after the concentration response 
curve to SB-220453 did not differ from those constructed before SB-220453 (Emax: 
59±10%; pEC50: 6.2±0.2).  Also after the concentration response curve to sumatriptan, 
SB-220453 failed to contract the saphenous vein (Figure 6.2, right panel). 
 
 
 
Figure 6.2 Concentration response curves in human isolated saphenous vein to 
sumatriptan (■) and SB-220453 (∇; both dissolved in DMSO; n=4).  Whereas sumatriptan 
induced a concentration-dependent contraction in all experiments, SB-220453 had no 
effect (left panel).  The second concentration response curves (right panel) to sumatriptan 
after SB-220453 (▼) as well as to SB-220453 after sumatriptan (∇; n=4) did not differ 
from the first curve. 
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Human isolated middle meningeal artery 
Middle meningeal artery segments relaxed to substance P (10 nM) with 44±7% (range: 
19-76%) of the precontraction (8±2 mN) induced by prostaglandin F2α (1 µM, n=10). 
Sumatriptan (dissolved in distilled water) induced a concentration-dependent 
contraction in all experiments (Emax: 105±18%, pEC50: 6.9±0.2), whereas SB-220453 
induced no contraction (Figure 6.3, left panel).  After construction of the concentration 
response curves to SB-220453, the contraction to sumatriptan (dissolved in DMSO) did 
not differ significantly from the that to sumatriptan dissolved in distilled water (Emax: 
101±2%; pEC50: 6.8±0.4, Figure 6.3, right panel). 
 
α
 
Figure 6.3 Concentration response curves in human isolated middle meningeal artery 
to sumatriptan (dissolved in distilled water, ●; n=5) and SB-220453 (∇, dissolved in 
DMSO; n=4; left panel).  The second concentration response curves (right panel) to 
sumatriptan (dissolved in DMSO) after SB-220453 (▼, n=4) did not differ from the first 
curve. 
 
 
Human atrial and ventricular cardiac trabeculae 
As we reported earlier (Du et al., 1994), baseline contractile force was significantly lower 
in the atrial (0.64±0.13 mN, n=17 trabeculae) than in ventricular (3.04±0.45 mN, n=20 
trabeculae) tissue.  In both tissues, noradrenaline (10 nM - 10 µM) increased contractile 
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force in a concentration-dependent manner.  After exposure to 10 µM noradrenaline, the 
force of contraction increased to 2.43±0.36 mN (n=17 trabeculae) and 5.02±0.43 mN 
(n=20 trabeculae) in the atrial and ventricular trabeculae, respectively. 
Neither SB-220453, nor sumatriptan displayed a positive inotropic effect on atrial 
and ventricular trabeculae (Figure 6.4).  At concentrations ≥10 µM, SB-220453 and 
sumatriptan (dissolved in DMSO) induced a negative inotropic effect in both atrial 
(sumatriptan: 37±32% of contraction to 10 µM noradrenaline, SB-220453: 34±29%) and 
ventricular (sumatriptan: 18±9%, SB-220453: 55±21%) trabeculae, which were not 
different for these compounds.  This negative inotropic effect may be assigned to the 
solvent DMSO, since it was not observed with sumatriptan dissolved in distilled water 
(Figure 6.4).  After a precontraction with noradrenaline (10 µM) also, none of the 
compounds induced a positive inotropic effect, while a negative effect on contractility was 
observed at concentrations ≥10 µM of SB-220453 and sumatriptan dissolved in DMSO 
(data not shown). 
 
 
 
Figure 6.4 Concentration response curves in human isolated atrial (left panel, n=3-5) 
and ventricular (right panel, n=5) trabeculae to sumatriptan (dissolved in distilled water, ● 
or DMSO, ■) and SB-220453 (∇, dissolved in DMSO).  NA, Noradrenaline. 
 
Part II SB220453 vs Sumatriptan 
106 
6.4  Discussion 
Human isolated blood vessels 
SB-220453 did not induce any significant contraction of the human isolated coronary 
artery, saphenous vein or middle meningeal artery.  In contrast, sumatriptan, investigated 
in parallel, produced marked contractions.  Since contractions to some agonists are 
'unmasked' or augmented in the presence of increased tension (Chester et al., 1993; 
MaassenVanDenBrink et al., 1996), we also investigated the coronary artery contraction 
in the presence of the thromboxane A2 analogue U46619.  Indeed, the contraction to 
sumatriptan was augmented in two of the coronary arteries investigated (in accordance 
with our previous findings (MaassenVanDenBrink et al., 1996)), but even in these 
precontracted segments, SB-220453 failed to elicit any contraction. 
In all blood vessels, a slight relaxation was observed at the highest concentration 
of SB-220453 and sumatriptan (both dissolved in DMSO), but not with sumatriptan 
dissolved in distilled water.  Therefore, this relaxation may be assigned to the solvent 
DMSO.  However, despite this relaxant response, SB-220453 did not affect the 
concentration response curve to sumatriptan (see Figures 6.2 and 6.3). 
It is known that the presence or absence of functional endothelium can influence 
contractile responses in blood vessels (MaassenVanDenBrink et al., 1999; Yang et al., 
1991).  In our study, the endothelial quality of the blood vessels varied, as is illustrated by 
the relaxation to substance P (coronary artery: 9-107%, middle meningeal artery: 19-76%) 
or bradykinin (saphenous vein: 10-107%).  Because in none of the blood vessels 
SB-220453 induced any contraction, our results suggest that the lack of response to these 
compounds is not dependent on the quality of the endothelium. 
 
Atrial and ventricular cardiac trabeculae  
Apart from a negative inotropic effect associated with the solvent DMSO, no inotropic 
response was observed with SB-220453 or sumatriptan in both atrial and ventricular 
cardiac trabeculae.  Sumatriptan did not display any effect on cardiac trabecular 
contractility despite expression of both 5-HT1B and 5-HT1D mRNA in human atrium and 
ventricle (Nilsson et al., 1999).  However, the present results are consistent with the 
observed lack of hemodynamic effects of sumatriptan in patients, where no negative or 
positive inotropic effects were demonstrated (Hood et al., 1997).  These studies are also in 
accordance with in vitro studies performed on guinea pig (Lattimer et al., 1993; Le Grand 
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et al., 1998) and rabbit (Paterna et al., 1995) cardiac tissue.  In fact, the role of 5-HT1B and 
5-HT1D receptors on the human heart is still poorly understood (Saxena & Villalón, 1991), 
although the 5-HT1D receptor has been reported to mediate inhibition of noradrenaline 
release in human atrium (Molderings et al., 1996). 
In conclusion, our results do not provide any evidence for human blood vessel 
contraction or altered myocardial contractility in response to SB-220453.  Since 
SB-220453 did not contract the middle meningeal artery, we conclude that potential 
therapeutic efficacy is independent of cerebral vasoconstriction. SB-220453 did not 
contract coronary artery, saphenous vein or cardiac trabeculae, and is therefore likely to be 
devoid of adverse cardiovascular side effects observed with serotonergic agonists. 
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Et quand le jour arrive 
            Je deviendrais le ciel 
            et je deviendrais la mer 
            et la mer va venir m'embrasser 
            Pour que j'aille à la maison 
            Rien ne pourra plus m'arrêter maintenant  
 
NIN - La Mer 
© Trent Reznor, 2000 
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Chapter 7 
Pharmacological analysis of contractile effects of eletriptan and 
sumatriptan on human isolated blood vessels 
Summary - Eletriptan, a second-generation triptan with high affinity for 5-HT1B/1D 
receptors, is highly effective in migraine, with or without aura.  We compared the effects 
of eletriptan and sumatriptan on the human isolated middle meningeal and coronary 
arteries and saphenous vein, used as models for therapeutic efficacy and potential side 
effects, and have investigated the role of 5-HT1B/1D receptors in contractions induced by 
these triptans.  Concentration-response curves to eletriptan and sumatriptan were 
constructed in the absence or presence of a selective 5-HT1B/1D receptor antagonist, 
GR125743 (N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-methyl-4-(4-pyridyl) 
benzamide).  All three blood vessels constricted in response to eletriptan and sumatriptan, 
but the middle meningeal artery relaxed following the highest concentration (100 µM) of 
eletriptan. In the middle meningeal artery, GR125743 antagonised the contractions 
induced by both eletriptan  (pEC50: 7.34±0.13) and sumatriptan  (pEC50: 6.91±0.17) to a 
similar degree (pA2: 8.81±0.17 and 8.64±0.21, respectively).  In the human coronary 
artery and saphenous vein, sumatriptan-induced contractions (pEC50: 6.24±0.14 and 
6.19±0.12, respectively) were also potently antagonised by GR125743 (pA2: 8.18±0.27 
and 8.34±0.12, respectively).  The eletriptan-induced contractions of the human saphenous 
vein (pEC50: 6.09±0.13) were antagonised less effectively by GR125743 (pKB: 
7.73±0.18), and those of the human coronary artery (pEC50: 5.54±0.22) remained 
unaffected by GR125743 up to a concentration of 100 nM.  These results suggest that (i) 
based on the differences in pEC50 values, the cranioselectivity of eletriptan (63-fold) is 
higher than that of sumatriptan (5-fold) in coronary artery, (ii) the contractile effects of 
sumatriptan and eletriptan (lower concentrations) in the three blood vessels are mediated 
via the 5-HT1B receptor, and (iii) additional mechanisms seem to be involved in coronary 
artery and saphenous vein contractions and middle meningeal artery relaxation following 
high concentrations of eletriptan. 
 
 
Based on: Van den Broek, R.W.M., MaassenVanDenBrink, A., de Vries, R., Bogers, A.J.J.C., Stegmann, 
A.P., Avezaat, C.J. & Saxena, P.R. (2000). Pharmacological analysis of contractile effects of eletriptan and 
sumatriptan on human isolated blood vessels. Eur. J. Pharmacol., 407, 165-73. 
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7.1 Introduction 
Sumatriptan, the first of a new class of compounds with an agonist action at 5-HT1B/1D 
receptors, is effective in the acute treatment of migraine and cluster headaches (Saxena & 
Tfelt-Hansen, 2000).  The high efficacy profile as well as some shortcomings (low oral 
bioavailability, high headache recurrence and chest symptoms) has prompted the 
development of several second-generation triptans, including eletriptan.  Eletriptan 
displays a higher affinity than sumatriptan for the 5-HT1B (pKi: 8.00 and 7.37, 
respectively) as well as 5-HT1D (pKi: 8.94 and 8.04, respectively) receptor (Napier et al., 
1999).  Like sumatriptan, eletriptan constricts porcine carotid arteriovenous anastomoses 
in vivo (Willems et al., 1998) and canine saphenous vein and basilar artery in vitro (Gupta 
et al., 1999) and inhibits c-fos expression in trigeminal nucleus caudalis following 
stimulation of the superior sagittal sinus in the cat (Goadsby & Hoskin, 1999).  Oral 
administration of the highest dose of eletriptan (80 mg) has been shown to be superior to 
sumatriptan (100 mg) in the treatment of migraine in three head-to-head clinical trials 
(Goadsby et al., 2000; Saxena & Tfelt-Hansen, 2000). 
It is now generally accepted that the therapeutic action of sumatriptan and other 
triptans is mainly due to constriction of dilated intra- and extra-cranial blood vessels, 
although other mechanisms interfering with the trigeminovascular system may also be 
involved (De Vries et al., 1999; Saxena & Tfelt-Hansen, 2000).  Indeed, the triptans 
potently contract human isolated middle meningeal (Longmore et al., 1998; Razzaque et 
al., 1999), temporal (Verheggen et al., 1996), middle cerebral (Hamel & Bouchard, 1991; 
Jansen et al., 1992) and basilar (Parsons et al., 1998) arteries.  However, albeit less 
profound, the triptans also have the ability to contract non-cranial blood vessels, such as 
human isolated pulmonary (MacLean et al., 1996) and coronary (Chester et al., 1990; 
Connor et al., 1989; MaassenVanDenBrink et al., 1998) arteries.  Constriction of these 
blood vessels may lead to cardiovascular adverse events, including myocardial ischaemia 
and infarction in predisposed individuals (Kelly, 1995; Main et al., 1998; O'Connor & 
Gladstone, 1995; Ottervanger et al., 1997). 
In the present study, we have investigated the contractile effects of eletriptan, in 
comparison to those of sumatriptan, on human isolated blood vessels used as models with 
relevance to therapeutic efficacy (middle meningeal artery), coronary adverse events 
(coronary artery) and peripheral vasoconstriction (saphenous vein).  Furthermore, we used 
the competitive 5-HT1B/1D receptor antagonist GR125743 (N-[4-methoxy-
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3-(4-methylpiperazin-1-yl)phenyl]-3-methyl-4-(4-pyridyl)benzamide) (Domenech et al., 
1997; Pauwels, 1997) in an attempt to characterise the 5-HT receptors mediating 
contractions to eletriptan and sumatriptan. 
 
7.2 Material and methods 
Tissue collection 
Human isolated middle meningeal artery 
Human middle meningeal arteries were obtained from 10 patients (4 male, 6 female; age 
30-69 years) undergoing craniotomy at the neurosurgical unit of the University Hospital 
'Dijkzigt', Erasmus University Medical Centre, Rotterdam.  During the surgical procedure, 
a part of the skull is temporarily removed and the dura mater, together with a small piece 
of the middle meningeal artery, is intentionally cut to obtain access to the brain.  This 
piece of the artery was placed in a plastic tube filled with ice-cold (0-4 °C) physiological 
saline and immediately transported to the laboratory.  Upon arrival at the laboratory, the 
artery was placed in a cold oxygenated modified Krebs bicarbonate solution of the 
following composition (mM): NaCl 119, KCl 4.7, CaCl2 1.25, MgSO4 1.2, KH2PO4 1.2, 
NaHCO3 25 and glucose 11.1; pH 7.4.  The cyclo-oxygenase inhibitor indomethacin 
(0.1 µM) was added to the Krebs solution to prevent prostaglandin synthesis.  Excess 
tissue surrounding the artery was carefully removed and no attempt was made to remove 
the endothelium.  The middle meningeal artery was used within 2 h of surgery. 
 
Human isolated coronary artery and saphenous vein 
The human right epicardial coronary artery was obtained from 11 heart-beating organ 
donors (6 male, 5 female; 17-52 years), who died of non-cardiac disorders 
(cerebrovascular accidents, 8; brain trauma, 3).  The hearts were provided by the Heart 
Valve Bank, Rotterdam, The Netherlands after donor mediation by Bio Implant Services 
Foundation/Eurotransplant Foundation, Leiden, The Netherlands; for details, see 
MaassenVanDenBrink et al. (1998).  Leftover human saphenous vein was obtained 
postoperatively from 13 patients (7 male, 6 female; age 34-81 years) undergoing coronary 
bypass surgery.  Saphenous vein was immediately placed in cold saline and was brought 
to the laboratory within 15 min. 
Upon arrival in the laboratory, the right coronary artery and saphenous vein were 
cleaned from the surrounding tissue and placed in a cold, oxygenated Krebs bicarbonate 
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solution of the following composition (mM): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, 
KH2PO4 1.2, NaHCO3 25 and glucose 8.3; pH 7.4.  No attempt was made to remove the 
endothelium.  The artery and vein were stored overnight in cold oxygenated Krebs 
solution and were used the following day. 
 
Experimental protocol 
Human isolated middle meningeal artery 
The middle meningeal artery was cut into circular 3 to 4 mm long segments, which were 
mounted on metal prongs in 10-ml organ baths containing Krebs bicarbonate solution, 
aerated with 95% O2 and 5% CO2 and maintained at a temperature of 37 oC.  Changes in 
isometric tension were measured by a force displacement transducer and recorded with 
IOX 1.203h software (both, EMKA Technology, Paris, France).  Segments were stretched 
to a passive tension of 4 mN and were allowed to stabilise at this level for 60 min (with 
replacement of Krebs solution every 15 min).   All segments were then exposed 2-3 times 
to 0.1 µM prostaglandin F2α to demonstrate reproducibility of the evoked contractions.  
Subsequently, the segments were pre-contracted with prostaglandin F2α (1 µM) and the 
relaxation response to substance P (10 nM) was used to evaluate the presence of a 
functional endothelium.  After washing, the segments were allowed to equilibrate for 
60 min, with replacement of buffer every 15 min.  The segments were then used in a 
paired parallel experimental set-up, incubating with the 5-HT1B/1D receptor antagonist 
GR125743 (10 nM and 30 nM) or vehicle for 30 min.  Subsequently, a single cumulative 
concentration response curve to either eletriptan or sumatriptan (both 1 nM to 100 µM) 
was constructed in each segment. 
 
Human isolated coronary artery and saphenous vein 
Vessels were cut into ring segments of approximately 4 mm length and were suspended on 
stainless steel hooks in 15-ml organ baths containing Krebs bicarbonate solution, aerated 
with 95% O2 and 5% CO2 and maintained at a temperature of 37 oC.  Vessel segments 
containing macroscopically visible atherosclerotic lesions were not used.  Changes in 
tension were recorded using a Harvard isometric transducer.  The segments were allowed 
to equilibrate for at least 30 min and were washed every 15 min.   Segments were 
stretched to a passive tension of 15 mN (coronary artery) or 10 mN (saphenous vein), 
respectively.  All segments were then exposed to KCl (30 mM) twice, to demonstrate the 
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reproducibility of the evoked contractions.  Subsequently, the functional integrity of the 
endothelium was verified by observing relaxation to substance P (coronary artery, 1 nM) 
or bradykinin (saphenous vein, 0.1 µM) after pre-contraction with prostaglandin F2α 
(1 µM).  After washout, the tissue was exposed to KCl (100 mM) to determine the 
maximal contractile response to KCl.  The tissue was washed and then was allowed to 
equilibrate for another period of 30 min.  After this equilibration period the segments were 
divided in a paired parallel experimental set-up and were incubated with the 5-HT1B/1D 
receptor antagonist GR125743 (coronary artery: 3 nM to 1 µM; saphenous vein: 3 nM to 
30 nM) or with vehicle for 30 min.  Subsequently, a single cumulative concentration 
response curve to eletriptan or sumatriptan (both 1 nM to 100 µM) was constructed in 
each segment. 
 
Data analysis 
Concentration response curves 
Contractile responses were expressed as percentage of the contractile response to 1 µM 
prostaglandin F2α (middle meningeal artery) or 100 mM KCl (coronary artery and 
saphenous vein).  The occasional spontaneous phasic contractions observed in some 
coronary artery and saphenous vein segments were not considered in the calculations, but 
the respective plateau contraction levels were used.  Initially, we calculated the mean 
value of the individual maximum contractile responses (Emax) to eletriptan or sumatriptan; 
in case the contractions did not reach a plateau in an individual experiment, the 
contraction induced by the highest concentration used (100 µM) was considered as Emax.  
We then analysed mean concentration response curves with a non-linear regression fitting 
technique for sigmoidal functions with variable slope using GraphPad Prism 3.0 
(GraphPad Software Inc., San Diego, CA, USA) to obtain Hill slopes for the agonists in 
the absence or presence of different concentrations of GR125743.  When mean Emax 
values and Hill slopes were not significantly different, we assumed that GR125743 
behaved as a competitive antagonist.  The whole data set was then transformed using 
SPSS 7.5 non-linear regression statistics (SPSS Inc., Chicago, IL, USA) into a dependent 
fitting model, where the Emax values were set to the respective agonist control Emax.  This 
model enabled us to obtain valid S.E.M. and 95% confidence intervals of mean pEC50 
values and dose ratios.  Using the pEC50 values that were significantly different from their 
respective controls, Schild regression analysis was performed (SPSS Inc., Chicago, IL, 
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USA) to calculate antagonist pA2 (≥3 concentrations of GR125743), apparent pA2 
(2 concentrations of GR125743 with slope set to unity) or pKB (1 concentration of 
GR125743 with slope set to unity).  When the ratio between EC50 values in absence or 
presence of antagonist was larger than 1, the dose ratio was calculated. 
 
Statistical analysis 
Differences between Emax, Hill slopes and pEC50 values of vehicle and antagonist-treated 
groups were analysed according to one-way analysis of variance (ANOVA), followed by 
Dunnetts multiple comparison t-test (GraphPad Software Inc., San Diego, CA, USA).  
Differences in potency, efficacy and logarithmically transformed dose ratios between the 
agonists were analysed according to Tukeys unpaired t-test (GraphPad Software Inc., 
San Diego, CA, USA).  Cranioselectivity ratios were calculated as the inverse logarithmic 
difference between pEC50 values of agonists in middle meningeal artery and either 
coronary artery or saphenous vein. The 95% confidence limit (95% CI) of 
cranioselectivity ratios obtained with eletriptan and sumatriptan were calculated and 
compared as described by Steel and Torrie (1980).  In all cases, statistical significance was 
assumed when P<0.05.  Except for dose ratios and cranioselectivity ratios, where the 
geometric means with 95% CI are given, all other data are presented as mean±S.E.M. 
 
Ethical approval 
The Medical Ethics Committee of the Erasmus Medical Centre Rotterdam, dealing with 
the use of human material for scientific experiments, approved the protocols for this 
investigation. 
 
Compounds 
Bradykinin acetate, 5-hydroxytryptamine creatinine sulphate (serotonin; 5-HT), 
indomethacin hydrochloride, prostaglandin F2α tris salt and substance P acetate were 
purchased from Sigma Chemical Co. (St. Louis, MO, USA).  Eletriptan hydrogen 
bromide, sumatriptan succinate and GR125743 (N-[4-methoxy-3-(4-methylpiperazin-
1-yl)phenyl]-3-methyl-4-(4-pyridyl)benzamide) were kindly supplied by Pfizer 
(Sandwich, Kent, UK).  Indomethacin was dissolved in 100% v/v dimethyl sulphoxide and 
further diluted in distilled water.  All other compounds were dissolved in distilled water. 
 
Chapter 7 
117 
7.3 Results 
Human middle meningeal artery 
Both eletriptan and sumatriptan contracted the middle meningeal artery in a concentration 
dependent manner (up to 10 µM) and with similar maxima (Emax: 94±8% and 106±17% of 
contraction to 1 µM prostaglandin F2α, respectively), potency (pEC50: 7.34±0.13 and 
6.91±0.17, respectively) and Hill slopes (0.86±0.20 and 1.27±0.80, respectively) (Fig. 7.1, 
Table 7.1).  However, in contrast to sumatriptan, the highest concentration of eletriptan 
(100 µM) induced a marked vasorelaxation, which was not affected by GR125743.  
Incubation with GR125743 caused a parallel rightward shift, with no alteration in Hill 
slopes, in the concentration response curves to both eletriptan (contractile part) and 
sumatriptan; the maximum contractile responses observed with 10 µM were not 
significantly different after GR125743 compared to the respective control values.  The 
pEC50 values and dose ratios (95% CI) of eletriptan after 10 nM and 30 nM GR125743 
were 6.43±0.13 and 8.2 (4.3-19.4), and 5.48±0.14 and 72 (30-172), respectively.  For 
sumatriptan the pEC50 values and dose ratios (95% CI) yielded 6.11±0.17 and 6.4 
(2.1-19.8) and 5.27±0.18 and 44 (14-137), for 10 nM and 30 nM GR125743, respectively.  
Schild regression analysis revealed similar apparent pA2 values of GR125743 against 
eletriptan (8.81±0.17) and sumatriptan (8.64±0.21) (Table 7.1). 
 
Human coronary artery 
The human coronary artery contracted in response to eletriptan and sumatriptan with equal 
maxima (Emax: 17±4% and 12±2% of contraction to 100 mM KCl, respectively) and Hill 
slopes (0.73±0.26 and 0.96±0.31, respectively).  The potency of eletriptan was 
significantly lower than that of sumatriptan (pEC50: 5.54±0.22 and 6.24±0.14, 
respectively) (Fig. 7.2; Table 7.1).  GR125743 (3 nM-1 µM) did not affect the maxima 
(Emax) and Hill slopes of eletriptan and at concentrations up to 100 nM GR125743 there 
was no shift in the concentration response curves to eletriptan (data not shown).  Due to a 
non-sigmoidal nature of the concentration response curve to eletriptan following high 
concentrations (≥300 nM) of GR125743 (Fig. 7.2, left panel), pEC50 values and dose 
ratios of eletriptan and pA2 of GR125743 were not determined (see Methods).  The 
concentration response curve to sumatriptan was shifted in a parallel manner, with no 
alteration of Hill slopes, by GR125743 (Fig. 7.2, right panel), yielding a significant 
Part III GR125743 
118 
decrease in potency (pEC50: 5.44±0.15, 4.71±0.15, 4.66±0.18 and 3.92±0.20 after 30 nM, 
100 nM, 300 nM and 1 µM GR125743, respectively, with corresponding dose ratios 
(95% CI) of 6.3 (2.5-16), 34 (13-87), 38 (14-107) and 209 (70-624), respectively).  Schild 
regression analysis revealed a pA2 value of 8.18±0.27 for GR125743 against sumatriptan 
with a slope of 0.89±0.15, which was not significantly different from unity.  The dose 
ratios for eletriptan (2.2) and sumatriptan (6.3) after 30 nM GR125743 were similar, 
whereas at 100 nM GR125743 the dose ratio for eletriptan (2.7) was significantly lower 
than for sumatriptan (34). 
 
Human saphenous vein 
Eletriptan and sumatriptan contracted the saphenous vein with equal maxima (Emax: 
71±10% and 80±6% of contraction to 100 mM KCl, respectively), potency (pEC50: 
6.09±0.13 and 6.19±0.12, respectively) and Hill slopes (0.64±0.13 and 0.79±0.14, 
respectively) (Fig. 7.3, Table 7.1).  GR125743 (3-30 nM) did not affect the maxima (Emax) 
and Hill slopes of eletriptan and sumatriptan (Fig. 7.3).  The Hill slope of eletriptan 
control was significantly different from unity, whereas those in presence of antagonist 
were not.  The concentration response curves to eletriptan were shifted to the right only 
after incubation with 30 nM GR125743 (pEC50: 5.56±0.11; dose ratio (95% CI): 3.4 
(1.5-7.7)).  A parallel rightward shift in the concentration response curves to sumatriptan 
was observed with GR125743 (10 and 30 nM), yielding a significant decrease in potency 
(pEC50: 5.66±0.10 and 4.93±0.10, respectively, with corresponding dose ratios (95% CI) 
of 3.3 (1.6-7.0) and 18 (9-34), respectively).  Schild regression analysis revealed an 
apparent pA2 value of 8.34±0.12 for GR125743 against sumatriptan, which was similar to 
the pA2 value found in both middle meningeal and coronary artery (Table 7.1).   The pKB 
of GR125743 obtained at 30 nM against eletriptan (7.73±0.18) appears to be somewhat 
lower compared to the apparent pA2 value found against sumatriptan (8.34±0.12).  This is 
also reflected in the fact that the dose ratio obtained at 30 nM GR125743 for eletriptan 
(3.4) was significantly lower than that for sumatriptan (18).  
 
Cranioselectivity of eletriptan and sumatriptan 
The mean cranioselectivity ratios (inverse logarithm of the difference between the pEC50 
value in the middle meningeal artery and that in the coronary artery or saphenous vein) 
and their respective 95% CI are shown in Table 7.1.  Compared to coronary artery and 
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saphenous vein, both eletriptan (63- and 18-fold, respectively) and sumatriptan (5-fold 
each) were significantly more selective for the meningeal artery.  The cranioselectivity for 
eletriptan in the coronary was significantly higher than that for sumatriptan. 
 
7.4 Discussion 
In the present study, we investigated the effects of eletriptan and sumatriptan on the 
human isolated middle meningeal artery as a model for anti-migraine activity, and 
coronary artery and saphenous vein as models for peripheral vascular side-effect potential.  
In addition, the role of 5-HT1B/1D receptors in the vasoconstrictor responses to the two 
triptans was evaluated using GR125743, a potent and competitive 5-HT1B/1D receptor 
antagonist (Domenech et al., 1997; Pauwels, 1997). 
 
Efficacy profile of eletriptan and sumatriptan in blood vessels 
It is well known that acutely acting antimigraine drugs, such as the triptans, have a 
vasoconstrictor effect, particularly on cranial vessels (De Vries et al., 1999; Saxena & 
Tfelt-Hansen, 2000).  Indeed, eletriptan contracted human isolated blood vessels used in 
this investigation with a maximum response similar to that of sumatriptan (see Emax values 
in Table 7.1).  This is in accordance with our previous study in human vessels, where 
5-HT also showed a similar Emax (MaassenVanDenBrink et al., 1999), but contrasts with 
observations in the canine basilar artery and saphenous vein, where eletriptan behaved as a 
partial agonist (Gupta et al., 1999).  However, it must be pointed out that in our 
experiments the efficacy of eletriptan was not studied after receptor alkylation, thus not 
ruling out the partial agonist nature of eletriptan in human blood vessels. 
Unlike sumatriptan, the highest concentration of eletriptan (100 µM) elicited a 
profound relaxation of the human middle meningeal.  The exact reason for this difference 
between eletriptan and sumatriptan is not known.  However, a possible explanation could 
be that at such high concentrations, which are well beyond the clinically relevant free (i.e. 
protein unbound) plasma Cmax values of around 30 and 65-90 nM obtained after 40 and 
80 mg oral eletriptan, respectively (Personal communication A.D. McHarg, Milton et al., 
1998), the contraction elicited by eletriptan was overruled by vasorelaxation mediated by 
the 5-HT7 receptor (Eglen et al., 1997; Saxena et al., 1998; Terron & Falcon-Neri, 1999).  
The 5-HT7 receptor mRNA has been detected in human meningeal vessels (Schmuck et 
al., 1996) and at this receptor eletriptan (pKi: 6.70±0.06) has a higher affinity than 
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sumatriptan (pKi: 5.86±0.11) (Napier et al., 1999).  Interestingly, eletriptan relaxed neither 
the coronary artery nor saphenous vein; the 5-HT7 receptor mRNA is poorly expressed in 
the human coronary artery (Nilsson et al., 1999). 
 
Effects of GR125743 on contraction elicited by eletriptan and sumatriptan 
The contractions elicited by sumatriptan were competitively antagonised by GR125743 in 
the human middle meningeal and coronary arteries as well as the saphenous vein with 
similar pA2 values (8.64, 8.18 and 8.34, respectively; Table 7.1).  These values resemble 
the affinity estimates of GR125743 at 5-HT1B/1D receptors in radioligand binding (pKi: 
8.2-9.0, Audinot et al., 1997; Domenech et al., 1997) and functional studies against 
sumatriptan-induced contractions of the human isolated middle meningeal artery (pKB: 
9.1, Razzaque et al., 1999).  The results reveal that sumatriptan acts on the same 5-HT 
receptor (most probably 5-HT1B, Kaumann et al., 1993) in all three blood vessels studied.  
Indeed, elegant in situ hybridisation and immunohistochemistry experiments have 
demonstrated that the 5-HT1B but not 5-HT1D receptor mRNA and protein are present in 
the smooth muscles of human middle meningeal and coronary arteries (Bouchelet et al., 
1996; Longmore et al., 1998; Longmore et al., 1997; Nilsson et al., 1999; Nilsson et al., 
1999).   In addition, selective 5-HT1D and 5-HT1F receptor agonists failed to constrict the 
human cerebral arteries, excluding a role for these receptors in vasomotor responses 
(Bouchelet & Hamel, 1999; Cohen & Schenck, 1999; Ennis et al., 1998).  Finally, the 
selective 5-HT1B receptor antagonist SB224289 (2,3,6,7-tetrahydro-1'-methyl-
5-[2'-methyl-4'(5-methyl-1,2,4-oxadiazo-l-3-yl) biphenyl-4-carbonyl]furo[2,3f]indole-
3-spiro-4'-piperidine hydrochloride) antagonises sumatriptan-induced vasoconstrictor 
responses (De Vries et al., 1999; Verheggen et al., 1998).  Thus, there is now 
overwhelming evidence that the 5-HT1B (not 5-HT1D) receptor mediates vasoconstrictor 
responses to the triptans. 
The contraction of the middle meningeal artery by eletriptan was antagonised by 
GR125743 with a pA2 (8.81; Table 7.1) that was similar to that against 
sumatriptan-induced contraction in this artery and eletriptan-induced contractions in the 
dog isolated basilar artery and saphenous vein (pA2 values: 9.1 and 9.4, respectively) 
(Gupta et al., 1999).  However, in the coronary artery and saphenous vein, GR125743 
appeared to block eletriptan-induced contractions in a slightly different manner compared 
to those by sumatriptan.  In the coronary artery, higher concentrations of GR125743 
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(≥300 nM) revealed a non-sigmoidal nature of the concentration response curves to 
eletriptan, whereas lower concentrations (≤100 nM) of GR125743 failed to block 
eletriptan-induced contractions (Fig. 7.2).  In the saphenous vein, the Hill slope of 
eletriptan was significantly different from unity, indicating the involvement of more than 
one mechanism and, accordingly, GR125743 caused a rightward shift in the concentration 
response curve to eletriptan only with the highest concentration used (30 nM; Fig. 7.3).  
Moreover, the dose ratio of eletriptan following 30 nM GR125743 (3.4) was significantly 
lower than that of sumatriptan (18).  The discrepancy between antagonism by GR125743 
against eletriptan-induced contraction in the coronary artery and saphenous vein and the 
results obtained in dog basilar artery and saphenous vein (Gupta et al., 1999) may well be 
species related or could be based on methodological differences, as we have not used the 
mixed 5-HT2/7 receptor antagonist mesulergine in our experiments. 
Overall, these data suggest that the sumatriptan-induced contraction in the three vessels 
examined is mediated by the 5-HT1B receptor.  Furthermore, the contractile effects of 
eletriptan at lower concentrations is largely mediated by the 5-HT1B receptor but an 
additional receptor/mechanism, unaffected by GR125743, contributes to some extent in 
the contractions of the human coronary artery and saphenous vein elicited by high 
concentrations of eletriptan.   This is indirectly supported by our experiments in the 
anaesthetised pigs, where we reported that, unlike sumatriptan (De Vries et al., 1996), the 
eletriptan-induced constriction of carotid arteriovenous anastomoses was not completely 
blocked by GR127935, another potent 5-HT1B/1D receptor antagonist (Willems et al., 
1998).  The exact nature of this additional mechanism involved in eletriptan-induced 
contraction is unknown, but it is conceivable that a part of the contraction to high 
concentrations of eletriptan, particularly after blockade of the 5-HT1B receptor by 
GR125743, may be mediated via the 5-HT2A receptor.  In contrast to the human middle 
meningeal artery that predominantly possesses 5-HT1B receptor population (Jansen et al., 
1992; Razzaque et al., 1999), it is known that both human coronary artery and saphenous 
vein have a mixed population of 5-HT1B and 5-HT2 receptors (Bax et al., 1993; Bax et al., 
1992; Connor et al., 1989; Ishida et al., 1999; Nilsson et al., 1999).  We must, however, 
concede that eletriptan does not differ from sumatriptan with regard to the affinity at the 
5-HT2A receptor (pKi: both <5.5, Napier et al., 1999). 
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Cranioselectivity of eletriptan and sumatriptan 
Eletriptan and sumatriptan contracted the human isolated middle meningeal artery with 
equal efficacy (Emax: 94±8 and 106±17% of the contraction to 1 µM prostaglandin F2α, 
respectively) and potency (pEC50: 7.34±0.13 and 6.91±0.17, respectively).  The two drugs 
exhibited cranioselectivity because they were significantly more potent in contracting the 
middle meningeal artery than coronary artery (pEC50: 5.54±0.22 and 6.24±0.14, 
respectively) or saphenous vein (pEC50: 6.09±0.13 and 6.19±0.12, respectively; 
Table 7.1).  Eletriptan and sumatriptan were equipotent in the saphenous vein, but in the 
coronary artery, as we found earlier with another 5-HT1B/1D receptor agonist GMC2021 
(3-[2-(dimethylanimo)ethyl]-5-[(trifluoromethyl)sulfonyl]oxy][1H]indoleoxalate) (Saxena 
et al., 1996), eletriptan was significantly less potent than sumatriptan.  This latter finding 
appears at variance with the higher binding affinity of eletriptan for the 5-HT1B receptor 
compared to sumatriptan (Napier et al., 1999), but may involve agonist-specific 
differences in stimulus-effector coupling (Kenakin, 1987).  It can perhaps be argued that 
the lower potency of eletriptan on the coronary artery may be due to the involvement of 
the non-5-HT1B/1D mechanism for which eletriptan has a low affinity (see section 7.2).  
However, we believe that the contraction elicited via a high affinity site (in this case, the 
5-HT1B receptor) would overrule that via a low affinity site. 
Based on the difference in pEC50 values, sumatriptan proved 5-fold (95% CI: 2-13) 
more selective for the meningeal artery compared to both coronary artery and saphenous 
vein.  This cranioselectivity ratio of eletriptan in the coronary artery (63, 95% CI 20-200) 
was significantly higher compared to that of sumatriptan (P<0.01), whereas in the 
saphenous vein the cranioselectivity of eletriptan, being 18-fold (95% CI: 8-41), was not 
different from that of sumatriptan (P=0.06).  Admittedly, the data obtained with eletriptan 
are complicated by two factors.  Firstly, the coronary artery contraction has a non-5-HT1B 
receptor component.  However, it is the resultant coronary artery contraction and not its 
underlying mechanism that is important for potential coronary side effects.  Secondly, the 
relaxant response in the middle meningeal artery observed with eletriptan (100 µM) could 
well reduce its Emax and, thus, overestimate its pEC50, compared to sumatriptan.  Our 
results, however, show that the maximal contraction (and Hill slope) by eletriptan is 
similar to that of sumatriptan as well as 5-HT (see Table 1, MaassenVanDenBrink et al., 
1999).  Although, the relaxant response manifests at the highest concentration, it cannot be 
excluded that this response is latently present throughout the concentration range so that 
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the whole concentration-response curve may have been shifted to the right.  In this case, it 
is equally possible that we may have underestimated the pEC50 (and cranioselectivity) of 
eletriptan. 
The cranio-coronary selectivity of eletriptan, together with the clinical data showing that 
the highest dose of eletriptan (80 mg) has a superior efficacy, onset of action and patient 
acceptability in the acute treatment of migraine when compared with oral sumatriptan 
(100 mg) (Goadsby et al., 2000), speak in favour of eletriptan.  However, it cannot be 
overemphasised that eletriptan has the capacity to constrict the human coronary artery and, 
therefore, like the other triptans, must remain contraindicated in patients with coronary 
artery disease. 
 
 
  
Table 7.1 Functional parameters of the agonists eletriptan and sumatriptan, and the antagonist GR125743 in human isolated blood vessels. 
Middle meningeal artery Coronary artery Saphenous vein  
Eletriptan Sumatriptan Eletriptan Sumatriptan Eletriptan Sumatriptan 
Emax 94±8 106±17 17±4a 12±2a 71±10 80±6 
pEC50 7.34±0.13b 6.91±0.17b 5.54±0.22c 6.24±0.14 6.09±0.13 6.19±0.12 
Cranioselectivity ratio  
Mean (95% CI)d 
 
 
 
 
 
63 (20  199)c,e 
 
5 (2-13)e 
 
18 (8-41)e 
 
5 (2-13)e 
pA2 GR125743 8.81±0.17 8.64±0.21 ND 8.18±0.27 7.73±0.18f 8.34±0.12 
Data are presented as means±S.E.M. or as 95% CI (n=4-9).  The Emax values of eletriptan and sumatriptan are presented as percent of 
contraction elicited by either 1 µM prostaglandin F2α (middle meningeal artery) or 100 mM KCl (coronary artery and saphenous vein).  
ND, Not determined because of non-sigmoidal nature of the concentration response curve. 
aEmax eletriptan and sumatriptan significantly lower than the respective Emax in the saphenous vein (P<0.05). 
bpEC50 value significantly higher compared to the respective pEC50 values in the coronary artery and saphenous vein (eletriptan P<0.01, 
sumatriptan P<0.05). 
cSignificantly different from the respective value of sumatriptan (P<0.05). 
dCranioselectivity ratio = Inverse logarithm (pEC50 (middle meningeal artery)  pEC50 (coronary artery or saphenous vein)). 
eSignificantly different from 1 (P<0.05). 
fpKB value. 
  
 
 
 
Figure 7.1  Cumulative concentration response curves to eletriptan (left panel; n=5) and sumatriptan (right panel; n=5) in the
human isolated middle meningeal artery in the absence (■) or presence of GR125743 (∆, 10 nM or ○, 30 nM).  Symbols and
vertical bars represent the means and S.E.M.  PGF2α= prostaglandin F2α. 
  
 
Figure 7.2  Cumulative concentration response curves to eletriptan (left panel; n=4-8) and sumatriptan (right panel; n=4-9) in the
human isolated coronary artery in the absence (■) or presence of GR125743 (∇, 3 nM; ∆, 10 nM; ○, 30 nM; ◊, 100 nM; ▲, 300 nM
or ▼, 1 µM).  Symbols and vertical bars represent the mean and S.E.M. 
  
 
 
 
 
Figure 7.3  Cumulative concentration response curves to eletriptan (left panel; n=6) and sumatriptan (right panel; n=6) in the
human isolated saphenous vein in the absence (■) or presence of GR125743 (∇, 3 nM; ∆, 10 nM or ○, 30 nM).  Symbols and
vertical bars represent the mean and S.E.M.
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Chapter 8 
Characterisation of sumatriptan-induced contractions in human isolated 
blood vessels using selective 5-HT1B and 5-HT1D receptor antagonists and 
in situ hybridisation 
Summary - The 5-HT1B/1D receptor agonist sumatriptan is effective in aborting acute 
attacks of migraine and is known to cause constriction of cranial arteries as well as some 
peripheral blood vessels.   The present study set out to investigate whether 5-HT1B and/or 
5-HT1D receptors mediate contractions of the human isolated middle meningeal and 
temporal arteries (models for antimigraine efficacy) and coronary artery and saphenous 
vein (models for side-effect potential).  Concentration-response curves were made with 
sumatriptan (1 nM-100 µM) in blood vessels in the absence or presence of selective 
antagonists at 5-HT1B (SB224289) and 5-HT1D (BRL15572) receptors.  SB224289 
antagonised sumatriptan-induced contractions in all blood vessels, although the 
antagonism profile was different amongst these blood vessels.  In the temporal artery, 
SB224289 abolished contraction to sumatriptan, whereas in the middle meningeal artery 
and saphenous vein, sumatriptan-induced contractions were blocked in an insurmountable 
fashion.  Moreover, SB224289 acted as a weak surmountable antagonist in the coronary 
artery (pKB: 6.4±0.2).  In contrast, BRL15572 had little or no effect on 
sumatriptan-induced contractions in the four blood vessels investigated.  In situ 
hybridisation revealed the expression of 5-HT1B receptor mRNA in the smooth muscle as 
well as endothelial cells of the blood vessels, whereas the mRNA for the 5-HT1D receptor 
was only very weakly expressed.  These results show that the 5-HT1B receptor is primarily 
involved in sumatriptan-induced contractions of human cranial as well as peripheral blood 
vessels. 
 
 
 
 
Based on: Rémon W.M. van den Broek, Pankaj Bhalla, Antoinette MaassenVanDenBrink, René de Vries, 
Hari S. Sharma and Pramod R. Saxena (2001). Characterisation of sumatriptan-induced contractions in 
human isolated blood vessels using selective 5-HT1B and 5-HT1D receptor antagonists and in situ 
hybridisation  Cephalalgia, accepted. 
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8.1 Introduction 
Sumatriptan, the first of the 5-HT1B/1D receptor agonists, is highly effective in aborting 
migraine headaches (Goadsby, 1998; Tfelt-Hansen et al., 2000).  It is believed that 
migraine headache results from dilation of extracerebral cranial blood vessels and that 
sumatriptan, as well as other triptans, constrict these dilated vessels (Humphrey & Feniuk, 
1991; Tfelt-Hansen et al., 2000).  Although the triptans are known to be cranioselective, 
they all have the propensity to constrict the coronary artery (Longmore et al., 1998; 
MaassenVanDenBrink et al., 2000; Parsons et al., 1998; Van den Broek et al., 2000).  
Constriction of the coronary artery may lead to cardiovascular adverse events, including 
myocardial ischaemia and infarction in predisposed individuals (Ottervanger et al., 1997). 
The triptans are high affinity agonists at 5-HT1B and 5-HT1D receptors, but their 
vasoconstrictor effect seems to be mediated via the 5-HT1B receptor (Tfelt-Hansen et al., 
2000).  Using RT-PCR techniques, it has also been shown that the 5-HT1B receptor mRNA 
is predominant over 5-HT1D receptor mRNA in the human middle cerebral (Bouchelet et 
al., 1996; Hamel et al., 1993), middle meningeal (Schmuck et al., 1996), temporal 
(Verheggen et al., 1998) and coronary (Bouchelet et al., 2000; Nilsson et al., 1999) 
arteries.  The 5-HT1B receptor protein has also been localised in the smooth muscle layer 
as well as endothelium of the human middle cerebral (Nilsson et al., 1999), middle 
meningeal (Longmore et al., 1998; Longmore et al., 1997) and coronary (Longmore et al., 
1998; Longmore et al., 1997; Nilsson et al., 1999) arteries, where the 5-HT1D receptor 
protein is not, or poorly, expressed.  Functional pharmacological in vitro studies suggest 
that sumatriptan behaves as a full agonist in blood vessels (Bax et al., 1992; Jansen et al., 
1992; Kaumann et al., 1994; Kaumann et al., 1993; Verheggen et al., 1996), which do not 
contract in response to selective 5-HT1D receptor agonists (Bouchelet et al., 2000; Ennis et 
al., 1998). 
A more direct evidence for a 5-HT1B receptor-mediated vasoconstriction to 
sumatriptan can be obtained from antagonist studies.  Until now, studies in the human 
isolated middle meningeal (Jansen et al., 1992; Razzaque et al., 1999; Van den Broek et 
al., 2000) and coronary (Bax et al., 1993; Kaumann et al., 1994; MaassenVanDenBrink et 
al., 2000; Van den Broek et al., 2000) arteries and saphenous vein (Bax et al., 1992), have 
used non-selective 5-HT1B/1D receptor antagonists (GR127935, GR55562 and GR125743).  
Recently, SB224289 and BRL15572 have been introduced as selective 5-HT1B and 
5-HT1D receptor antagonists, respectively (Schlicker et al., 1997; Selkirk et al., 1998).  
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The use of these compounds revealed that sumatriptan-induced contractions in human 
isolated temporal (Verheggen et al., 1998) and small pulmonary (Morecroft et al., 1999) 
arteries as well as canine (De Vries et al., 1998) and porcine (De Vries et al., 1999) 
carotid vascular beds are mediated via the 5-HT1B receptor.  Using both functional in vitro 
and in situ hybridisation techniques, we investigated the role of 5-HT1B and 5-HT1D 
receptors in mediating contractions of the human isolated middle meningeal and temporal 
arteries (models for therapeutic efficacy in migraine) and coronary artery and saphenous 
vein (models for peripheral side-effect potential) (MaassenVanDenBrink et al., 1998; 
MaassenVanDenBrink et al., 2000; Van den Broek et al., 2000). 
 
8.2 Material and methods 
Tissue collection 
The middle meningeal (4 male, 5 female; age 30-72 years) and temporal (3 female; age 
45-59 years) arteries and saphenous vein (8 male, 1 female; age 45-78 years) were 
obtained postoperatively from patients undergoing craniotomy (middle meningeal and 
temporal artery: 8 aneurysms; 4 meningiomas) or coronary artery bypass grafting 
(saphenous vein) at the Erasmus University Medical Centre, Rotterdam, The Netherlands.  
The blood vessels were placed in a propylene tube filled with ice-cold (0-4 °C) 
physiological saline, transported immediately to the laboratory and used within 2 hr of 
surgery. 
The right epicardial coronary artery was obtained from 9 heart beating organ 
donors (3 male, 6 female; 37-64 years) who died of non-cardiac disorders (6 
cerebrovascular accident, 2 cerebral infarction, 1 head trauma).  The Rotterdam Heart 
Valve Bank, Rotterdam, The Netherlands provided the hearts, after donor mediation by 
Bio Implant Services Foundation/Eurotransplant Foundation, Leiden, The Netherlands.  
The vessel was stored overnight in a modified Krebs bicarbonate solution (see below) and 
used the next day. 
 
Organ bath experiments 
Measurement of vascular contractions. The methods used were similar to those described 
in detail earlier (MaassenVanDenBrink et al., 2000; Van den Broek et al., 2000).  Briefly, 
approximately 4-mm segments, obtained from pieces of the middle meningeal (n=6), 
temporal (n=3), coronary (n=6) arteries and saphenous vein (n=6), were mounted on metal 
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prongs in organ baths, containing a modified Krebs bicarbonate solution (pH 7.4; 37 oC), 
aerated with 95% O2 and 5% CO2.  The composition (mM) of the Krebs bicarbonate 
solution was NaCl 119, KCl 4.7, CaCl2 1.25 (or 2.5 for coronary artery and saphenous 
vein), MgSO4 1.2, KH2PO4 1.2, NaHCO3 25 and glucose 11.1 (or 8.3 for coronary artery 
and saphenous vein).  The cyclo-oxygenase inhibitor indomethacin (0.1 µM) was added to 
the Krebs solution to prevent prostaglandin synthesis.  In addition, the Krebs solution was 
enriched with the muscarinic receptor antagonist, atropine, the histamine H1 receptor 
antagonist mepyramine, the mixed 5-HT2/7 receptor antagonist mesulergine, the 
α1-adrenoceptor antagonist prazosin, the inhibitor of neuronal uptake1, imipramine (all 
1 µM) and the inhibitor of extra-neuronal uptake2, corticosterone (10 µM) to exclude the 
putative involvement of these receptors/mechanisms.  Changes in isometric tension were 
registered on recording set-ups from either EMKA Technology (Paris, France) for the 
middle meningeal and temporal arteries or Harvard Apparatus (South Natick, MA, USA) 
for the coronary artery and saphenous vein.  The segments were allowed to equilibrate for 
at least 30 min, stretched to a passive tension of 4 mN (middle meningeal and temporal 
arteries), 15 mN (coronary artery) or 10 mN (saphenous vein).  Since sumatriptan is 
metabolised by monoamine oxidase (Dixon et al., 1994), we then treated the segments 
with pargyline (100 µM) for 15 min to prevent its possible breakdown.  After washing, all 
segments were exposed 2-3 times to either 0.1 µM prostaglandin F2α (PGF2α; middle 
meningeal and temporal arteries) or 30 mM KCl (coronary artery and saphenous vein) to 
demonstrate the reproducibility of the evoked contractions.  Subsequently, the relaxation 
response to 10 nM substance P (1 nM in case of coronary artery or 0.1 µM bradykinin in 
the case of saphenous vein) in vessel segments pre-contracted with PGF2α (1 µM) was 
used to verify the functional integrity of the endothelium. 
After washing, the segments were allowed to equilibrate for 60 min, with 
replacement of the Krebs solution every 15 min.  The segments were then studied in a 
paired parallel experimental set-up (MaassenVanDenBrink et al., 2000; Van den Broek et 
al., 2000), where a single concentration response curve to sumatriptan (1 nM-100 µM) 
was constructed in each segment incubated for 60 min with either the vehicle, SB224289, 
BRL15572 or both antagonists together.  Since only 3 segments could be obtained from 
the human temporal artery, addition of both antagonists together was omitted.  In view of 
the affinity of SB224289 and BRL15572 at recombinant h5-HT1B (pKi: 8.0 and 6.1, 
respectively) and h5-HT1D receptors (pKi: 6.2 and 7.9, respectively) (Schlicker et al., 
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1997; Selkirk et al., 1998), we initially employed the two antagonists in a concentration 
range of 10-30 µM in the coronary artery (without the cocktail of inhibitors as mentioned 
above) and saphenous vein.  Since in these concentrations neither antagonist affected the 
concentration response curves of sumatriptan, all experiments were performed with 1 µM 
of SB224289 and BRL15572. 
 
Data presentation 
Contractile responses were expressed as percentage of the contractile response to 1 µM 
PGF2α (temporal and middle meningeal arteries) or 100 mM KCl (coronary artery and 
saphenous vein).  The occasional spontaneous phasic contractions, observed in some 
coronary artery and saphenous vein segments, were ignored where measuring 
contractions.  When the concentration contraction curve to sumatriptan did not attain a 
plateau, the contraction with its highest concentration (100 µM) was considered as the 
apparent maximum contraction (Emax).  Initially, the mean value of Emax of sumatriptan 
observed in individual experiments was calculated.  The mean concentration response 
curves were analysed with a non-linear regression fitting technique for sigmoidal 
functions with variable slope using GraphPad Prism 3.0 (GraphPad Software Inc., San 
Diego, CA, USA) to calculate potency (pEC50) and Hill slopes for the agonists in the 
absence or presence of antagonists.  When mean (apparent) Emax and Hill slopes were not 
significantly different in control and antagonist experiments, a surmountable antagonism 
was assumed.  The whole data set was then transformed using SPSS 7.5 non-linear 
regression statistics (SPSS Inc., Chicago, IL, USA) into a dependent fitting model, where 
the mean maximal-induced contraction was set to the respective agonist control value.  In 
case of a parallel rightward shift, a Schild regression analysis was performed with a slope 
set to unity to calculate the pKB value.  Due to the insurmountable behaviour of SB224289 
in the middle meningeal artery and saphenous vein, pKB values could not be calculated.  
Instead, we calculated the negative logarithm of the mean concentration of sumatriptan 
eliciting a contraction equivalent to 25% of Emax in the individual control experiments 
(pEC25%) in the absence or presence of antagonists.  This parameter enabled us to compare 
the properties of the antagonists in these vascular preparations against low concentrations 
of sumatriptan. 
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Statistical analysis  
Differences between the (apparent) Emax of sumatriptan in the absence or presence of 
antagonists were analysed with a paired t-test, using GraphPad Prism 3.0 (GraphPad 
Software Inc., San Diego, CA, USA).  In case the Emax values in the absence of 
antagonists were similar to those in the presence of antagonist, the differences in Hill 
slopes and pEC50 values of mean concentration response curves between vehicle and 
antagonist groups were analysed with a one-way analysis of variance (ANOVA) followed 
by Dunnetts multiple comparison t-test.  In case Emax values were different between the 
respective groups, we performed a two-way repeated measurement analysis of variance 
(RM-ANOVA) followed by Bonferronis multiple comparison t-test to evaluate the effect 
of treatments (i.e. control or antagonist) at repetitive concentrations of sumatriptan.  
Differences between the pEC25% values of sumatriptan in absence or presence of 
antagonists were calculated according to paired t-test.  In all cases statistical significance 
was assumed when P<0.05.  Data are presented as mean±s.e. mean. 
 
Molecular biological experiments 
In situ hybridisation 
5-HT1B and 5-HT1D receptor mRNAs were localised employing non-radioactive in situ 
hybridisation on the human middle meningeal artery, coronary artery and saphenous vein 
(n=3 each).  After cleaning the surrounding tissue, the blood vessels were fixed for 24 h in 
4% paraformaldehyde dissolved in phosphate buffered saline.  Chinese hamster ovary 
(CHO) cells expressing either the human recombinant 5-HT1B or 5-HT1D receptor served 
as positive controls.  After dehydration with increasing percentage of ethanol in phosphate 
buffered saline, the blood vessels were embedded in paraffin and 5-µm thick sections were 
cut with a microtome (model HM325, Microm GmbH, Walldorf, Germany).  The sections 
were mounted on superfrost plus® glass slides (Menzel-Glaser, Braunschweig, Germany) 
and dried at 37 °C for 48 h. 
 Recombinant plasmid DNAs encoding the human 5-HT1B (Genbank accession 
number D10995, nucleotide 40-390, length 350 bp) or 5-HT1D (Genbank accession 
number M81589; nucleotide 1-400, length 400 bp) receptor were employed for the 
preparation of non-radioactive cRNA probes.  Linearised DNA templates were transcribed 
to synthesise the sense and antisense cRNAs probes, using T7 or SP6 RNA polymerase as 
per protocol described for the DIG-RNA labelling kit.  DIG-labelled cRNA probes were 
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quantified by dot blotting and using serial dilutions of standard DIG-labelled control RNA 
supplied in the kit.  Treatment of tissue sections and cells and subsequent hybridisation 
was performed as described earlier (de Boer et al., 1998).  The tissues were hybridised 
with 25 ng of cRNA probe per slide for 16 h at 55 °C and the DIG-labelled hybrids were 
detected by incubation with antidigoxigenin antibody (1:2000 dilution) conjugated to 
alkaline phosphatase for 2.5 h at room temperature.  The immunodetection of 
DIG-labelled hybrids was done using 4-nitroblue tetrazolium chloride (NBT) as 
chromogen and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) as coupling agent. Slides 
were counter-stained with nuclear red solution, dehydrated with ethanol gradients and 
mounted with Euparal (Chroma-Gesellschaft, Schmid GmbH, Köngen, Germany).  Cells 
and tissue sections were visualised under a light microscope (model Leica DM RBE, Leica 
NL, BV, Rijswijk, The Netherlands) and photographed using a CCD video camera (Sony 
DXC-950, Sony Corporation, Japan). The sense riboprobes were included as negative 
controls, which showed no or little staining compared to antisense riboprobes. 
 
Endothelial staining  
Serial sections of 5-µm thickness were processed for immunohistochemical localisation of 
endothelial cell marker, CD31.  Sections were deparaffinised, rehydrated and incubated 
with pronase (1 mg/ml) at 37 °C for 10 min prior to incubation with specific purified 
mouse monoclonal antibodies raised against human CD31 (Neomarkers, Union City, CA, 
USA).  To block non-specific binding, sections were incubated with 10% normal goat 
serum diluted in 5% bovine serum albumin in phosphate buffered saline (pH = 7.4).  
Subsequently, sections were incubated overnight at 4 °C with primary antibodies, CD31 
(1:75 v/v).  Incubation for 30 min with secondary biotinylated anti-immunoglobulins 
(Multilink, 1:75 v/v, Biogenex, San Ramon, USA) and tertiary complex of streptavidin 
conjugated to Alkaline Phosphatase (Label 1:50 v/v, Biogenex, San Ramon, USA) were 
used to enhance the detection sensitivity.  Colour was developed using New Fuchsine as 
chromogen, while endogenous alkaline phosphatase activity was inhibited by 0.01 M 
levamisole (Sigma, St Louis, USA). Slides were counterstained with Mayer's hematoxylin.  
Positive controls consisted of human cardiac tissue where intense staining was seen in the 
endothelium of all blood vessels.  The optimal dilutions of primary antibody were identified 
by examining the intensity of staining obtained with a series of dilutions, which gave specific 
and easily visible signal on paraffin sections of control tissues.  Slides were mounted and 
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visualised using light-microscopy.  Negative controls consisted of omission of the primary 
antibody. 
 
Ethical approval 
The Medical Ethics Committee of the Erasmus University Medical Centre Rotterdam, 
dealing with the use of the human material for scientific experiments, approved the 
protocols for this investigation. 
 
Compounds and kits 
For pharmacological study, the following compounds were used: atropine sulphate, 
bradykinin acetate, corticosterone, 5-hydroxytryptamine creatinine sulphate (serotonin; 
5-HT), imipramine hydrochloride, indomethacin hydrochloride, mepyramine maleate, 
pargyline hydrochloride, prostaglandin F2α tris salt (PGF2α) and substance P acetate (all 
purchased from Sigma Chemical Co., St. Louis, MO, USA), mesulergine hydrochloride 
(gift: Novartis AG, Basel, Switzerland), prazosin hydrochloride (gift: Pfizer, Sandwich, 
UK), sumatriptan succinate, SB224289 and BRL15572 (gift: SmithKline Beecham 
Pharmaceuticals, Harlow, Essex, UK; courtesy: Dr. A.A. Parsons).  Stock solutions of 
corticosterone (100 mM), indomethacin, mesulergine, prazosin, SB224289 and BRL15572 
(all 10 mM) were dissolved in 100% v/v dimethyl sulphoxide and further diluted in 
distilled water.  All other compounds were dissolved in distilled water. 
For in situ hybridisation, the materials used were: acetic anhydride, diethyl 
pyrocarbonate, levamisol, maleic acid, triethanolamine and xylene (Sigma Chemical Co., 
St. Louis, MO, USA), antidigoxigenin-AP Fab fragments, blocking reagent for nucleic 
hybridisation, DIG-RNA labelling kit, glycine and RNase T1 (Boehringer Mannheim, 
Almere, The Netherlands), bovine serum albumin, dextran sulphate, ethylene 
diaminetetraacetic acid, ficoll, hering sperm DNA, phenol and Tris-HCl (Amersham 
Pharmacia Biotech Benelux, Roosendaal, The Netherlands). BCIP, formamide, NBT, 
proteinase K, sodium citrate and yeast tRNA (Life Technologies, Breda, The 
Netherlands), DNase, RNase inhibitors and Triton-X-100 (Promega Benelux, Leiden, The 
Netherlands) and RNase away solution (Molecular Bio-products, San Diego, CA, USA). 
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8.3 Results 
Relaxation responses to substance P and  bradykinin 
The relaxation to substance P (10 nM) amounted to 29% (range: 17-44%, n=6) and 42% 
(range: 9-86%, n=3) of precontraction with 1 µM PGF2α in the middle meningeal and 
temporal arteries, respectively.  In the coronary artery, relaxation to substance P (1 nM) 
was 46% (range: 30-66%, n=6) of precontraction to 1 µM PGF2α.  In the saphenous vein, 
relaxation to bradykinin (1 µM)  was 54% (range: 26-82%, n=6) of precontraction to 
1 µM PGF2α. 
 
Effects of sumatriptan on cranial arteries 
Concentration response curves to sumatriptan in the middle meningeal and temporal 
arteries are depicted in Fig. 8.1.  In both blood vessels, sumatriptan elicited a 
concentration-dependent contraction.  The Emax values (efficacy) of sumatriptan in the 
middle meningeal and temporal arteries were 83±15% and 68±28% of the contraction to 
1 µM PGF2α, respectively and the pEC50 values (potency) amounted to 6.7±0.2 and 
6.7±0.3, respectively (Table 8.1).  
 
The responses to sumatriptan in both cranial arteries were antagonised by the 5-HT1B 
receptor antagonist SB224289 (1 µM) and the magnitude of antagonism did not correlate 
with the functional integrity of the endothelium (substance P response).  Since SB224289 
decreased the Emax of sumatriptan, the antagonism was apparently insurmountable and 
pEC50 values of sumatriptan were not determined (Fig. 8.1, Table 8.1).  The 5-HT1D 
receptor antagonist BRL15572 (1 µM) had no effect on either the Emax or pEC50 values of 
sumatriptan.  Also, no additional antagonism was observed with the combination of the 
two antagonists (Fig. 8.1, Table 8.1). 
Due to the insurmountable antagonism of sumatriptan by SB224289, pKB values 
could not be estimated.  Alternatively, we calculated the negative logarithm of sumatriptan 
concentration eliciting a response equivalent to 25% of sumatriptan control Emax (pEC25%) 
in the absence or presence of the antagonists in the middle meningeal artery; the temporal 
artery data was not further processed as SB224289 virtually abolished 
sumatriptan-induced contractions (Table 8.2).  While BRL15572 was ineffective, the 
pEC25% of sumatriptan was significantly decreased by SB224289.  No additional 
antagonism was observed with the combination of the two antagonists (Table 8.2). 
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Effect of sumatriptan on peripheral vessels 
Sumatriptan also contracted the human coronary artery and saphenous vein in a 
concentration-dependent manner.  The pEC50 and (apparent) Emax of sumatriptan were, 
respectively, 5.7±0.1 and 13±2% of the response to 100 mM KCl in the coronary artery 
and 6.1±0.1 and 62±1% of the response to 100 mM KCl in the saphenous vein (Fig. 8.2, 
Table 8.1). 
In the coronary artery, SB224289 caused a small parallel rightward shift in the 
concentration response curve to sumatriptan, yielding a significant decrease in the pEC50 
(5.0±0.1) with no change in the apparent Emax (11±3% of the response to 100 mM KCl) of 
sumatriptan.  Schild regression analysis revealed a pKB value of 6.4±0.2 for SB224289 
against sumatriptan.  The shift in the concentration response curve of sumatriptan by 
Figure 8.1  Cumulative concentration response curves to sumatriptan in the
human isolated middle meningeal (n=5-6) and temporal (n=3) arteries in the
absence (control; ○) or presence of SB224289 (1 µM;  ●), BRL15572 (1 µM; ▲) or
both antagonists (1 µM each; ■).  Symbols and vertical bars represent the
means ± S.E.M. *, Significant difference from control contraction elicited by
respective concentrations of sumatriptan (Bonferroni multiple comparison t-test,
P<0.05).
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SB224289 was independent of the functional integrity of the endothelium.  BRL15572 did 
not have any effect on sumatriptan-induced contraction.  Incubation with both antagonists 
together resulted in a small parallel rightward shift as was noticed with SB224289 alone 
(Fig. 8.2, Table 8.1). 
In the saphenous vein, the response to sumatriptan was antagonised by SB224289 
(1 µM).  Although the contraction to sumatriptan increased with concentration, the 
response did not reach a plateau with the highest concentration used and, therefore, pEC50 
and pKB values after SB224289 were not determined.  As observed in the other blood 
vessels, the antagonism of SB224289 was independent of the functional integrity of the 
endothelium. Incubation with BRL15572 (1 µM) resulted in a slight attenuation of the 
response to 10 µM sumatriptan as well as its Emax, but no change was observed in the 
pEC50 value of sumatriptan.  Also, no additional antagonism was observed with the 
Figure 8.2  Cumulative concentration response curves to sumatriptan in the
human isolated coronary artery (n=5-6) and saphenous vein (n=4-6) in the
absence (control; ○) or presence of SB224289 (1 µM;  ●), BRL15572 (1 µM; ▲)
or both antagonists (1 µM each; ■).  Symbols and vertical bars represent the
means ± S.E.M. *, Significant difference from control contraction elicited by
respective concentrations of sumatriptan (Bonferroni multiple comparison t-test,
P<0.05). 
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combination of the two antagonists (Fig. 8.2, Table 8.1).  The pEC25% of sumatriptan was 
not affected by BRL15572, but was reduced after SB224289 alone or in combination with 
BRL15572 (Table 8.2). 
 
In situ hybridisation 
The specificity of mRNA signals and standardisation of the in situ hybridisation 
conditions were first established by the use of specific sense and antisense probes in CHO 
cells expressing either the human 5-HT1B or 5-HT1D receptor.  Strong cytoplasmic and 
nuclear mRNA expression as a dark purple/blue colour for respective antisense riboprobes 
was observed in these cells, whereas sense riboprobes depicted no staining.  Furthermore, 
the sense riboprobes did not show any specific mRNA expression assessed as purple/blue 
staining in the tissue samples included in this study.  If at all staining with sense 
riboprobes was detected, it was always far less than the staining with antisense probes 
(data not shown).  Cellular localisation of mRNAs for the 5-HT1B and 5-HT1D receptors in 
the human middle meningeal and coronary arteries and saphenous vein is depicted in 
Fig. 8.3.  In the middle meningeal artery, hybridisation with antisense riboprobe showed 
5-HT1B receptor mRNA signals in the medial smooth muscle layer as well as in the 
endothelial cells, whereas adventitial cells showed only a faint staining.  Although not so 
intense, the coronary artery and saphenous vein also expressed the 5-HT1B receptor 
mRNA in the vascular smooth muscle cells.  Specific expression for the 5-HT1B receptor 
was seen in the luminal endothelial cells in the case of coronary artery.  In order to verify 
the in situ hybridisation data for the endothelial cell expression of 5-HT1B receptor 
mRNA, CD31 immunohistochemistry was performed and it confirmed a cytoplasmic 
endothelial cell staining (Fig. 8.3).  In contrast to the 5-HT1B receptor mRNA, no signals 
were detected for the 5-HT1D receptor mRNA in both smooth muscle and endothelial cells 
in the middle meningeal artery and saphenous vein.  However, a weak staining for the 
5-HT1D receptor mRNA was noticed in some endothelial cells in the coronary artery and 
in adventitial cells in the case of middle meningeal as well as coronary arteries (Fig. 8.3). 
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Figure 8.3 Photographs of immunohistochemical staining with CD31
endothelial marker (top panels) and in situ hybridisation with DIG-labelled cRNA
probes for h5-HT1B (middle panels) and h5-HT1D (lower panels) receptor mRNAs in
the human middle meningeal and coronary arteries and saphenous vein.  The reddish
colour in the top panels denotes endothelial cells, while the purple precipitates in the
middle panels correspond to 5-HT1B receptor mRNA signals. The 5-HT1D receptor
mRNA (lower panels) as well as the sense riboprobes, as exemplified by the left
middle panel inset, did not show signals in the three blood vessels.  Scale
bar = 50 µm. 
  
Table 8.1 Emax and pEC50 values of sumatriptan in contracting human isolated blood vessels in the absence or presence of antagonists 
Middle meningeal artery Temporal artery Coronary artery Saphenous vein Antagonist 
Emax (%) pEC50 Emax (%) pEC50 Emax (%) pEC50 Emax (%) pEC50 
None 83±15 6.7±0.2 68±28 6.7±0.3 13±2 5.7±0.1 62±4 6.1±0.1 
SB224289 (1 µM) 40±11* ND 2±1* ND 11±3 5.0±0.1* 35±7* ND 
BRL15572 (1 µM) 72±10 6.8±0.2 47±24 6.5±0.2 14±2 5.7±0.1 44±7* 6.1±0.1 
SB224289 (1 µM) + 
BRL15572 (1 µM) 
53±14 ND - - 10±2 5.0±0.2* 32±4* ND 
Data are presented as means±s.e.m. (n=3-6).  Emax is presented as % of contraction elicited by either 1 µM PGF2α (middle meningeal and 
temporal artery) or 100 mM KCl (coronary artery and saphenous vein).  ND, Not determined because of insurmountable nature of the 
antagonism;  -, not investigated.  *, Significantly different from sumatriptan control  (P<0.05). 
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Table 8.2 pEC25% of sumatriptan in contracting the middle meningeal artery 
and saphenous vein in the absence or presence of antagonists 
Antagonist Middle meningeal 
artery 
Coronary artery 
 
Saphenous vein 
 
None 6.8±0.2 6.3±0.1 6.4±0.1 
SB224289 (1 µM) 5.6±0.4* 5.7±0.3 5.3±0.2* 
BRL15572 (1 µM) 7.0±0.5 6.1±0.1 6.3±0.1 
SB224289 (1 µM) + 
BRL15572 (1 µM) 
6.0±0.5 5.7±0.2* 5.7±0.3* 
Data are presented as mean±s.e.m. (n=4-6).  pEC25% represents the negative 
logarithm of the concentrations of sumatriptan eliciting a contraction equivalent to 
25% of individual control Emax (middle meningeal artery, 20.8±3.8% of the response 
to 1 µM PGF2α;  coronary artery, 3.3±0.4% of the response to 100 mM KCl; 
saphenous vein, 15.2±0.9% of the response to 100 mM KCl).  * Significantly 
different from sumatriptan control (P<0.05). 
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 8.4 Discussion 
Craniovascular selectivity of sumatriptan 
Sumatriptan contracted in a concentration-dependent manner both cranial and peripheral 
blood vessels, used as models for antimigraine activity (middle meningeal and temporal 
artery) and possible peripheral side-effect potential (coronary artery and saphenous vein), 
respectively.  The potency of sumatriptan was higher at the middle meningeal and 
temporal arteries (pEC50: 6.7 each) than at the coronary artery (pEC50: 5.7) and saphenous 
vein (pEC50: 6.1).   Compared to the other vessels, the efficacy (Emax) of sumatriptan in the 
coronary artery was clearly lower (see Table 8.1).  These data, which confirm the 
cranioselectivity of sumatriptan, are in accordance with other studies dealing with middle 
meningeal (Jansen et al., 1992; Longmore et al., 1998; MaassenVanDenBrink et al., 2000; 
Razzaque et al., 1999), temporal (Jansen et al., 1992; Verheggen et al., 1998) and 
coronary (Connor et al., 1989; Kaumann et al., 1994; MaassenVanDenBrink et al., 1998; 
MaassenVanDenBrink et al., 2000; Nilsson et al., 1999; Van den Broek et al., 2000) 
arteries and saphenous vein (Bax et al., 1992; MaassenVanDenBrink et al., 2000; Van den 
Broek et al., 2000). 
 
Receptors mediating sumatriptan-induced contractions 
The data obtained in in vitro functional studies show that the 5-HT1B receptor antagonist 
SB224289 clearly attenuated sumatriptan-induced contractions, while the 5-HT1D receptor 
antagonist BRL15572 had little effect on the concentration response curves to 
sumatriptan; the combination of SB224289 and BRL15572 did not reveal any additional 
antagonism.  These results establish that the 5-HT1B receptor mediates the contractile 
effects of sumatriptan in both cranial and peripheral blood vessels, while the 5-HT1D 
receptor does not seem to play any role.  The latter conclusion is also supported by the fact 
that selective 5-HT1D receptor agonists (PNU-109291 and L775,606) did not contract 
isolated blood vessels (Bouchelet et al., 2000; Ennis et al., 1998; Longmore et al., 2000) 
and, interestingly, one such compound (PNU-142633) was also found ineffective in 
migraine (Cutler et al., 2000).  Based on the high affinity of sumatriptan for the 5-HT1F 
receptor (pKi: 7.9, Leysen et al., 1996), it has been argued that this receptor might play a 
role in the therapeutic action of sumatriptan (Johnson et al., 1997).  Although we cannot 
rule this out, the 5-HT1F receptor is not involved in vasoconstriction, since selective 
5-HT1F receptor agonists (LY344864 and LY334370) show no vasoconstrictor effect 
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(Bouchelet et al., 2000; Cohen & Schenck, 1999; Shepheard et al., 1999).  In addition, 
Verheggen et al. (1998) have suggested that in the presence of SB224289 high 
concentrations of sumatriptan can elicit contractions of the human isolated temporal artery 
via the 5-HT2A receptor.  This was not the case in the present studies, probably because we 
included the mixed 5-HT2/7 receptor antagonist mesulergine (pKB: 9.1 and 8.2, 
respectively, Hoyer et al., 1994) in the Krebs solution.  However, the 5-HT2 receptor 
antagonist ketanserin was unable to block sumatriptan-induced contractions in the human 
middle meningeal (Jansen et al., 1992) and coronary (Connor et al., 1989; Kaumann et al., 
1994) arteries as well as the saphenous vein (Bax et al., 1992). 
It may be noted that SB224289 antagonised the responses to sumatriptan in an 
insurmountable manner in the middle meningeal artery, whereas in the temporal artery the 
contractions were virtually abolished.  In the coronary artery, there was a weak 
competitive (surmountable) antagonism, whilst in the saphenous vein an intermediate 
antagonistic response was observed. The nature of the difference in the antagonistic 
behaviour of SB224289 in these blood vessels is not clear.  A possible explanation (Schutz 
& Freissmuth, 1992) could be that SB224289, which acts as an inverse agonist in cells 
expressing recombinant 5-HT1B receptors (Gaster et al., 1998), may also do so at 
constitutive 5-HT1B receptors.  Another explanation for the observed differences could be 
the influence of receptor density and receptor reserve, but, in view of considerably higher 
5-HT1B receptor density in meningeal artery as compared to coronary artery (Longmore et 
al., 1997), we should have observed a surmountable antagonism in the middle meningeal 
artery and insurmountable antagonism in the coronary artery.  Finally, in view of the 
localisation of the 5-HT1B receptor on the endothelium (see below), the effect of 
SB224289 may be influenced to a different degree by endothelial factors (either 
contractile or relaxing) released upon activation of the 5-HT1B receptor.  Whatever the 
mechanism, differences in the nature of antagonism have also been observed between 
sumatriptan and the non-selective 5-HT1B/1D receptor antagonist GR127935 (Bouchelet et 
al., 2000; Razzaque et al., 1999). 
It is surprising that SB224289 proved to be a weak antagonist in our experiments 
as its pKB (6.4±0.2) against sumatriptan in the coronary artery resembled more its pKi 
(6.2) at the 5-HT1D receptor and was far less than its pKi at the 5-HT1B receptor (8.2) 
(Schlicker et al., 1997; Selkirk et al., 1998).  However, if 5-HT1D receptors were involved, 
we would have found BRL15572 to be an even more potent antagonist than SB224289; 
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this was obviously not the case.  The involvement of 5-HT1B receptor in the 
sumatriptan-induced coronary artery contraction is also supported by previous 
investigations using non-selective 5-HT1B/1D receptor antagonists (Bax et al., 1993; 
Connor et al., 1989; MaassenVanDenBrink et al., 2000; Nilsson et al., 1999; Van den 
Broek et al., 2000).  However, the weaker antagonism by SB224289 than these 
non-selective antagonists suggests that an additional mechanism is partly responsible for 
the coronary contraction induced by sumatriptan.  The nature of this additional mechanism 
is not known, but it cannot be related to 5-HT2 receptors in view of the presence of 
mesulergine in the organ bath.  Certainly, this additional mechanism is of interest in 
regard to the sumatriptan related cardiac side effects and may prove relevant in future 
antimigraine drug development. 
 
Vascular localisation of 5-HT1B and 5-HT1D  receptor mRNA 
Although RT-PCR studies have shown the presence of 5-HT1B receptor mRNA in the 
human middle meningeal (Schmuck et al., 1996) and coronary (Bouchelet et al., 2000; 
Nilsson et al., 1999) arteries, the cellular localisation of 5-HT receptor subtypes at mRNA 
level has not been demonstrated.  Our results of in situ hybridisation showed the mRNA 
expression of 5-HT1B receptor in both smooth muscle and endothelium, whereas the 
expression of 5-HT1D receptor mRNA was weak, if any, in the three human blood vessels 
investigated (Fig. 8.3).  These results are in agreement with the 5-HT1B and 5-HT1D 
receptor protein localisation in coronary and middle meningeal arteries (Longmore et al., 
1998; Longmore et al., 1997; Nilsson et al., 1999).  The localisation of 5-HT1B receptor 
mRNA within the smooth muscle cells of these blood vessels, and the lack of 5-HT1D 
receptor mRNA, strongly suggest that contraction to sumatriptan is mediated via the 
5-HT1B receptor rather than the 5-HT1D receptor.  Although the exact role of the 
endothelial 5-HT1B receptor in these vessels is not well understood, we cannot rule out the 
release of relaxing and/or contractile substances upon stimulation  
 
Conclusion 
In conclusion, our data show that sumatriptan contracts the human middle meningeal, 
temporal and coronary arteries and saphenous vein via the 5-HT1B receptor, but not 
5-HT1D receptor.  In the human coronary artery, the contraction may also be mediated by 
an unknown, SB224289-resistant, mechanism. 
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Chapter 9 
General Discussion  
9.1 Human isolated middle meningeal artery in relation to therapeutic 
efficacy of antimigraine drugs 
The main objective of this thesis was to study the effects of current and prospective 
antimigraine drugs in vitro, with the emphasis on the therapeutic site of action: the cranial 
vasculature.  Even though the underlying mechanisms for the pathophysiology of migraine 
attacks still remain a black box, several findings suggest a predominant role for the 
cranial vasculature, either primary (Humphrey, 1991) or secondary in nature (Goadsby 
and Hoskin, 1998).  As discussed in previous chapters, the most probable cause of a 
migraine headache is dilatation of cranial arteries.  The 5-HT1B/1D receptor agonist 
sumatriptan was designed to selectively reverse this craniovascular dilatation 
(Humphrey et al., 1988; Humphrey et al., 1989) via vasoconstriction leading to subsequent 
relief of migraine headache.  Not surprisingly, sumatriptan and the since then developed 
second-generation triptans all are effective in migraine relief (Limmroth and Diener, 
1998; Deleu and Hanssens, 2000; Roon, 2000).  Ever since the introduction of sumatriptan 
the research in migraine accelerated, leading to better insights in its pathophysiology.  One 
such a pathway is characterising the mode of action of these antimigraine drugs in the 
isolated middle meningeal artery, used as a predictive therapeutic model.  Using organ 
bath techniques we have investigated sumatriptan, eletriptan and donitriptan using 
isometric contraction measurements in isolated artery segments.   As was observed in vivo 
for sumatriptan (Henkes et al., 1996), these compounds potently constricted the human 
isolated middle meningeal artery, as is the case with other triptans (see Table 1.4).   
To validate whether cranial vasoconstriction is the main mechanism of the 
therapeutic action of triptans we re-analysed concentration response curves to triptans in 
the middle meningeal artery, obtained from previous published studies.   First we 
recalculated the concentration response curves to various second-generation triptans as 
percentage of maximal contraction to sumatriptan, which was derived from the same study 
as the respective compound (with Emax values of sumatriptan fixed at 100%).  Secondly, 
we predicted the relative magnitude of contraction from the concentration response curves 
at free plasma concentrations (i.e. plasma protein unbound; free Cmax) of the compounds 
for dosages currently on the market.  Finally, we calculated the predicted contraction at its 
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respective free Cmax and correlated the predicted contractions to the therapeutic gain 
(defined as reduction of pain from severe or moderate to mild or none, 2 hours postdosing) 
of the triptans versus placebo.  To make a valid comparison between predicted 
contractions by triptans we have considered the fact that some triptans may have 
pharmacologically active metabolites.  This is particularly the case with zolmitriptan since 
its main metabolite, N-desmethyl zolmitriptan is present in a 1:2 concentration ratio at 
Cmax, (Seaber et al., 1996; Peck et al., 1998), which is twice as potent in mediating human 
isolated cerebral artery contraction (Nilsson et al., 1999a).  With the assumption that 
zolmitriptan and its active metabolite have a similar efficacy, equilibrium and plasma 
protein binding the predicted contraction by zolmitriptan would be at twice the 
concentration of its free Cmax.  It should be mentioned that active metabolites of rizatriptan 
and eletriptan have been reported (Cooper et al., 1999; Goldberg et al., 2000) but their 
concentrations are rather low (<10% of original dosage) and therefore, they are unlikely to 
cause a significant additional pharmacological effect.  As depicted in Figure 9.1, all 
triptans constricted the middle meningeal artery at free Cmax to a similar extent (between 
50-75%), except for zolmitriptan (25-40%).  To correlate predicted contraction in middle 
meningeal artery in vitro with clinical observations we used the well defined clinical 
endpoint of therapeutic gain over placebo at two hours postdosing (International Headache 
Society Committee  on Clinical Trials in Migraine, 1991), since all triptans included have 
a Tmax lower than two hours (Table 1.3).  As can be seen in Figure 9.2, predicted 
contraction in middle meningeal artery correlated well with the therapeutic gain of the 
respective triptan, which strongly indicates that the therapeutic efficacy of the triptans is 
mediated by cranial vasoconstriction.  Interestingly, this conclusion is strengthened by the 
low therapeutic gain of the two dosages of zolmitriptan (2.5 and 5 mg), which resulted in 
low predicted contractions of the middle meningeal artery. 
 As discussed in Chapter 3, it appears that the 5-HT1B receptor is the predominant 
receptor mediating middle meningeal artery contraction and thus, the therapeutic effects 
by the triptans.   Although most triptans display a high affinity for the 5-HT1D as well as 
the 5-HT1F receptor, several lines of pharmacological evidence confirm that the 
vasoconstrictor activity of the triptans is mediated by the 5-HT1B receptor.  First of all we 
showed that the non-selective 5-HT1B/1D receptor antagonist GR125743 and the selective 
5-HT1B receptor antagonist SB224289 blocked sumatriptan-induced contractions, whereas 
the selective 5-HT1D receptor antagonist BRL15572 was without effect.  Secondly, 
molecular techniques revealed dense 5-HT1B receptor mRNA (Chapter 8) and protein 
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(Longmore et al., 1997; Longmore et al., 1998) present in middle meningeal artery 
whereas little or no 5-HT1D receptor mRNA (Chapter 8) and protein (Longmore et al., 
1997; Longmore et al., 1998) was detected.  Thirdly, several triptans (i.e. alniditan, 
donitriptan and IS-159) display a low affinity for the 5-HT1F receptor (see Table 1.2), but 
still constricted cranial blood vessels (Chapter 5 and Bouchelet et al., 2000).  Fourthly, 
specific 5-HT1D (PNU109291) and 5-HT1F (LY334370) receptor agonists were devoid of 
vasoconstrictor activity in vitro (Bouchelet et al., 2000).  Therefore, for the therapeutic 
efficacy of the triptans, 5-HT1D and 5-HT1F receptor activity seems not to be required.  
Nonetheless, several other mechanisms (such as those affecting the trigeminovascular 
system or cortical spreading depression), which do not require the 5-HT1B receptor, have 
also been implicated in migraine relief.  As will be discussed below, the 5-HT1F receptor 
agonist LY334370 may provide migraine relief, but needs further study.  As for the 
cortical spreading inhibitor SB220453, no vasoconstrictive properties in human isolated 
middle meningeal artery were observed (Chapter 6).  However, by inhibiting cortical 
spreading depression, SB220453 could prevent the subsequent cranial vasodilatation.   
 
9.2 Human isolated peripheral blood vessels in relation to side-effect 
potential of antimigraine drugs 
As previously discussed, sumatriptan has the propensity to cause side effects, such as 
chest pain, in a substantial percentage of migraine patients (Brown et al., 1991; Plosker 
and McTavish, 1994).  Most probably the side effects are caused by constriction of 
peripheral blood vessels such as the coronary artery.  Indeed, sumatriptan constricted this 
artery both in vivo and in vitro, which, together with the observed cardiac side effects, led 
to its contraindication in migraine patients with coronary artery diseases.  Apart from the 
success of sumatriptan, these cardiovascular effects prompted several pharmaceutical 
companies to develop safer triptans.  To predict whether these compounds will constrict 
coronary arteries in vivo, these compounds can be studied in the human isolated coronary 
artery.  In parallel with measuring contraction in middle meningeal artery we measured 
contraction to sumatriptan, eletriptan and donitriptan in human isolated coronary artery.  
Overall, these compounds constricted this artery with a potency that is lower than in 
middle meningeal artery, confirming that these compounds are cranioselective. Using the 
concentration response curves we predicted that these antimigraine drugs will only cause a 
small constriction of the coronary artery in vivo at clinical free plasma concentrations, as 
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is the case for other triptans investigated in this preparation (MaassenVanDenBrink et al., 
1998).  However, these results, together with the chest-related adverse events observed in 
clinical trials, point out that all triptans still remain contraindicated in patients with 
coronary artery diseases.  As described in Part III, we also investigated via which 
receptors the triptans induced constriction in human isolated coronary artery.  The most 
probable candidate is the 5-HT1B receptor, which (in contrast to the 5-HT1D receptor) is 
expressed in the smooth muscle and endothelium (Nilsson et al., 1999b), although far less 
abundant than in the middle meningeal artery.  The low 5-HT1B receptor expression is 
most probably the reason that all triptans have a similar lower intrinsic efficacy as 
compared to 5-HT, which induces an additional vasoconstriction via the ample expressed 
5-HT2A receptor (Connor et al., 1989; Bax et al., 1993; Kaumann et al., 1994).  
Interestingly, donitriptan, which has a moderate affinity for the 5-HT2A receptor 
(John et al., 1999), displays a higher intrinsic efficacy than sumatriptan.  This intrinsic 
activity was reduced to the sumatriptan level after incubation with the 5-HT2 receptor 
antagonist ketanserin (see Chapter 5).  Our data confirmed the role for the 5-HT1B receptor 
in sumatriptan-induced coronary artery constriction since this response was blocked by the 
non-selective 5-HT1B/1D receptor antagonist GR125743 and partly by the 5-HT1B receptor 
antagonist SB224289, while the 5-HT1D receptor antagonist BRL15572 was without 
effect. However, our results suggest that apart from the 5-HT1B receptor, other 
mechanisms may be involved in triptan-induced coronary artery contraction as was 
observed for eletriptan (Chapter 7) and sumatriptan (Chapter 8).  
Besides the isolated coronary artery we also used the human isolated saphenous 
vein as a model for peripheral blood vessel constriction.  In general, the investigated 
triptans revealed a potency profile similar to the results found in coronary artery, whereas 
the efficacy profile showed a closer resemblance to the middle meningeal artery.   
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Figure 9.1 Predicted contraction in middle meningeal artery of various triptans 
dosages at their respective free plasma concentrations in human.  Predicted contractions 
were calculated from concentration response curves in middle meningeal artery 
(Longmore et al., 1998; Razzaque et al., 1999; Maassen VanDenBrink et al., 2000b), for 
calculation see Chapter 9.1.  Free plasma concentrations (free Cmax) were obtained from 
MaassenVanDenBrink et al., 1998; MaassenVanDenBrink et al., 2000a. Data points 
represent individual triptans with oral dosage in mg between brackets. s.c.: subcutaneous.  
In case of zolmitriptan the predicted contraction is given with (■) and without (□) 
participation of the active metabolite.  Dotted lines represent the predicted contraction 
window. 
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Figure 9.2 Correlation analysis of predicted contraction in middle meningeal artery of 
various triptans dosages and their respective therapeutic gain.  Predicted contractions were 
calculated from concentration response curves in middle meningeal artery 
(Longmore et al., 1998; Razzaque et al., 1999; MaassenVanDenBrink et al., 2000b), for 
calculation see Chapter 9.1.  Therapeutic gain (defined as reduction of pain from severe or 
moderate to mild or none 2 hours postdosing) of the triptans versus placebo, obtained from 
Deleu and Hanssens, 2000; Millson et al., 2000. Data points represent individual triptans 
with oral dosage in mg between brackets. s.c.: subcutaneous. Pearsons correlation 
analysis revealed a significant correlation, p=0.04 with r=0.77).  
 
9.3 Limitations of in vitro blood vessel models 
Experiments described in this thesis were performed in organ baths, where segments of the 
blood vessels were suspended for isometric tension measurements under conditions where 
the in vivo situation is most closely mimicked.  These models per se are straightforward 
methods to predict antimigraine efficacy and side-effect potential as well as to resolve the 
mechanisms involved in contraction mediated by these drugs.  Obviously, extrapolation of 
the results obtained from these in vitro studies to the clinical situation introduces 
uncertainties and limitations.  First of all the material itself does not necessarily reflect the 
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in vivo situation in man due to the lack of systemic hemodynamic responses, such as blood 
pressure changes, in isolated preparations.  Secondly, in the organ bath set-up, the drugs 
reach both intraluminal and extraluminal cells whereas in vivo, only the intraluminal side 
of the blood vessel is directly exposed.  One possible way to avoid extraluminal exposure 
is to use perfused blood vessel segments.  Another disadvantage could be the source of the 
material since storage and transportation can damage the tissue.  To minimise this risk we 
opted for post-operative material, which was transported immediately to the laboratory in 
sterile, ice-cold, physiological buffers and processed as soon as possible.  Since 
post-operative coronary artery material often contains atherosclerotic lesions we used the 
right epicardial coronary arteries from heart-beating organ donors, which were obtained 
within 24 hours after explantation.  Before starting experiments we have examined 
whether the blood vessels are intact by challenging them first with substances such as KCl 
or PGF2α.  Intact segments were then tested for the functional integrity of the endothelium 
by observing relaxations to endothelium-dependent compounds, such as substance P or 
bradykinin.  Despite the limitations mentioned above, experiments on human isolated 
blood vessels provide unique possibilities for more detailed and in depth investigations 
than would otherwise be possible in patients.  One such advantage is the possibility to 
investigate a number of segments from the same preparation in parallel. 
 
9.4 Interpretation of concentration response curves 
With our experimental set-up we can measure contractions to current and prospective 
antimigraine drugs in blood vessel segments important for therapeutic activity and 
side-effect potential.  Since sumatriptan was the first triptan with 5-HT1B receptor agonist 
activity, the newly developed triptans or other possible antimigraine compounds were 
compared against this golden standard.  As described in Chapter 3, concentration 
response curves can be constructed after applying cumulative concentrations of the drugs 
in question.  If possible, by applying different drugs to different segments from the same 
preparation pharmacologically important parameters such as efficacy and potency of a 
drug can be compared in a paired manner.  The primary goal in these types of experiments 
is to predict what these drugs will do in migraine patients and not per se via which 
mechanisms (i.e. via which receptors) these drugs act.  Hence, the definition of potency is: 
that concentration of the drug eliciting half-maximal overall effect, and not necessarily the 
potency of a compound at a certain receptor (see Chapter 3).  In this case we calculated 
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cranioselectivity ratios by taking the ratio of potency in middle meningeal artery and 
coronary artery.  Interestingly, eletriptan was found to be slightly more cranioselective 
than sumatriptan since it had a lower potency in the coronary artery than sumatriptan, 
while it was equally potent in middle meningeal artery.  A few concerns, regarding these 
results in coronary artery, were raised when these results were published (see Chapters 4 
and 7).  These concerns were mainly based on the misconception that the potencies in 
question were compared on the basis of receptor classification and not for the overall 
effects per se.  It was questioned whether the concentration response curves of sumatriptan 
and eletriptan should be compared since the curves to eletriptan did not reach a plateau 
and the curves themselves were indistinguishable (see Chapter 4.6, letter to Neurology).  
Since our experiments were performed in parallel we believe that comparisons between 
two drugs can be made, in our case by constructing concentration response curves with an 
Emax set to the maximum-induced contraction by the drug at the highest concentration of 
agonist used (i.e. fixed Emax).  Furthermore we recalculated the potency and efficacy 
using the concentration response curves to eletriptan and sumatriptan.  By fitting 
concentration response curves to both drugs into a different model, without setting the 
Emax to the level of maximum-induced contraction of the agonist (i.e. free Emax), we did 
not observe any differences in efficacy between eletriptan and sumatriptan.  Still, even if 
the efficacy of both compounds would differ, a comparison of potencies is still valid since 
this parameter is discernible from efficacy.  Another issue that can be raised is consistency 
of the results throughout the different studies.  As depicted in Table 9.1, only marginal 
differences in potency of sumatriptan were observed within the middle meningeal or the 
coronary artery in the studies included in this thesis.  However, these small differences can 
lead to a large variation in cranioselectivity ratios.  Therefore, to compare the 
cranioselectivity ratio of newer triptans to sumatriptan (Chapters 5 and 7) a head-to-head 
parallel comparison is required to justify the conclusions.  In any case, conclusions based 
on cranioselectivity ratios alone should be made with caution since these drugs still 
contract the coronary artery at therapeutic concentrations. 
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Table 9.1 Sumatriptan potency (pEC50) in middle meningeal and coronary artery and 
respective cranioselectivity ratio obtained from studies included in this thesis. 
 
Middle meningeal 
artery pEC50 
Coronary artery 
pEC50 
Cranioselectivity ratio 
(95%CI) 
 
Chapter 
7.26±011 6.06±0.21 16 (5-47) 4 
 
7.41±0.08 5.71±0.16 50 (22-113) 
 
5 
6.9±0.2 6.0±0.2 8 (2-28) 6 
 
6.91±0.12 6.24±0.14 5 (2-13) 7 
 
6.7±0.2 5.7±0.1 10 (4-28) 8 
 
 
 An additional way of using concentration response curves is to predict the 
contraction of various blood vessels and relate them to the clinical situation.  By 
interpolating the concentration response curves the level of contraction in vitro at clinical 
free plasma concentrations can be calculated and correlated to therapeutic efficacy or 
potential side-effects in vivo.  Certainly, one should be cautious with extrapolating in vitro 
findings to the clinical situation, but the results obtained can be of help in the evaluation of 
antimigraine drugs.  As described above, we predicted the contraction at therapeutic 
concentrations for the second-generation triptans in comparison with that of sumatriptan 
using the isolated middle meningeal artery.  Overall the results indicated that, although 
there are differences in potency and efficacy, all compounds, except zolmitriptan, yielded 
similar predicted contractions at therapeutic concentrations.  Similarly, we predicted 
side-effect potential in vivo using in vitro coronary artery contraction.  Overall it becomes 
clear that the triptans investigated in this thesis have a small propensity to constrict the 
coronary artery at therapeutic concentrations as was observed with other triptans 
previously described.  All triptans therefore, remain contraindicated in patients with 
coronary artery diseases. 
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9.5 Implication for future research 
The results described in this thesis do raise questions that can be of interest for future 
research.  Our data, and those of others, show that vasoconstriction to triptans is 
predominantly mediated via the 5-HT1B receptor.  Since this receptor is most abundant in 
the cranial vasculature these compounds are cranioselective, but there is a catch.  
Although not as densely present in the coronary artery, the 5-HT1B receptor is active at 
therapeutic concentrations and may cause unwanted coronary artery related side effects. 
What is clear from our results is that a higher affinity for the 5-HT1B receptor does not 
necessarily mean that the compound is more cranioselective, as was found with 
donitriptan (Chapter 5).  One notable finding was that eletriptan, which has a higher 
affinity for the 5-HT1B receptor as compared to sumatriptan, had a significant lower 
potency in coronary artery (Chapters 4 and 7).  Furthermore, although the contraction to 
eletriptan was potently blocked in middle meningeal artery by the 5-HT1B/1D receptor 
antagonist GR125743, this antagonist failed to block eletriptan-induced contractions at the 
expected concentration in coronary artery (Chapter 7).  In contrast, this antagonist potently 
blocked sumatriptan-induced contractions in both middle meningeal and coronary arteries.  
Hence, further investigations into this yet unknown vasoconstrictor mechanism could 
clarify this controversy.  Since all triptans to date have a high affinity for the 5-HT1B 
receptor it is unlikely that such compounds will not affect the cardiovasculature and 
remain contraindicated in patients with coronary artery syndromes.  Thus, it would be of 
value to search for cranioselective compounds that do not affect peripheral blood vessels.  
On the other hand, it may be argued whether cranial vasoconstriction by triptans per se is 
required for therapeutic efficacy since all triptans are also known to affect peripheral and 
central trigeminal neuronal pathways.  As described in Chapter 2, activation of trigeminal 
afferents leads to vasodilatation and agonist activity at 5-HT1B, 5-HT1D and/or 5-HT1F 
receptors can lead to inhibition of this process at concentrations that lack vasoconstriction.  
Furthermore, brain-penetrant triptans such as zolmitriptan, eletriptan and naratriptan are 
known to inhibit action potentials generated in the trigeminus nucleus caudalis, a possible 
site of action in migraine.  As noted before, sumatriptan does not cross the blood brain 
barrier due to its low lipophilicity and poorly penetrates the brain, but further studies have 
to be fulfilled to see whether this blood brain barrier is disrupted during a migraine attack.  
In order to challenge the different hypotheses it could be of interest to appraise the 
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antimigraine activity of a non-brain-penetrant selective 5-HT1B receptor agonist, but such 
a compound is not yet available.  
 
9.6 Beyond the triptans 
One of the key goals in designing antimigraine drugs is the success rate of the treatment. 
Interestingly, the highest antimigraine efficacy to date is observed with subcutaneous 
injections of sumatriptan (Dahlöf and Saiers, 1998; Tfelt-Hansen et al., 2000).  Oral 
sumatriptan revealed a lower efficacy and the second-generation triptans only marginally 
improved this level, despite improved pharmacokinetics (Goadsby, 1998; Saxena and 
Tfelt-Hansen, 2000).  To improve on efficacy using such serotonin agonists, the way 
forward is probably not by designing drugs with a selective affinity for a specific 5-HT1 
receptor subtype.  The specific 5-HT1D receptor agonist PNU142633 was ineffective in 
migraine, although better results might be expected if such compounds can penetrate the 
brain (McCall, 1999) or have a full efficacy (May & Goadsby, 2001). The selective 
5-HT1F receptor agonist LY334370 (a modified triptan, withdrawn because of liver 
toxicity) did show antimigraine efficacy but with no improvement over the 
second-generation triptans (Roon, 2000).  No cardiovascular adverse effects were noted at 
clinical effective doses, but larger trials have to be performed to conclusively exclude 
cardiovascular symptoms.  Interestingly, significant central nervous system adverse events 
were observed (Roon, 2000).  Further research has to be performed since these agonists 
also have moderate affinity for the 5-HT1B receptor, furthermore, no data are known 
regarding active metabolites, which are known to exist with other triptans (Seaber et al., 
1996; Goldstein et al., 1997) and may have vasoconstrictor properties.  
 Overall, to achieve safer antimigraine efficacy, newly developed drugs should be 
designed to act via several mechanisms including the trigemino-vascular system and 
cranial artery constriction without effecting the peripheral vasculature.  Further research 
should be employed, like clarifying if there could be a cross-talk between the different 
5-HT1 receptor subtypes and its effectors (Berg et al., 1998), which can be important in 
further understanding of migraine pathophysiology and possible improvement in 
antimigraine efficacy.  
 Another important issue in designing future antimigraine drugs is consistency in 
treatment and prevention.  One of the drawbacks of the triptans is the high recurrence of 
the headache after initial successful treatment.  This recurrence can be explained by the 
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fact that these antimigraine drugs are agonists.  When administering agonists one can 
expect desensitisation at the receptor level which could cause the recurrence of headache, 
moreover, desensitisation may lead to drug abuse (Bruynzeel et al., 1985; Freedman and 
Lefkowitz, 1996).  A simple way to avoid this phenomenon is by designing antagonists 
that counter vasodilatation and thus, avoid a migraine headache. As described in 
Chapter 2, various prophylactic antimigraine drugs have some 5-HT2B or 5-HT7 receptor 
antagonistic properties.  Consequently, it may be worth assessing whether selective 
5-HT2B or 5-HT7 receptor antagonists are effective in the prevention of migraine.  In this 
light, the human isolated middle meningeal artery can be used as a suitable model by 
designing experiments where these antagonists can block vasodilatory-induced responses.  
Another pathway to counter vasodilatation is by blocking the effects or release of the 
vasodilator neuropeptide CGRP, which is elevated during a migraine attack (see 
Chapter 2).  Currently several new CGRP antagonists are under clinical investigation such 
as BIBN4096BS (Doods et al., 2000), Compound 1 (Edvinsson et al., 2001) and 
SB273779 (Aiyar et al., 2001).  Interestingly, several new avenues are currently being 
explored that involve mediation of CGRP release from trigeminal neurones, which, upon 
stimulation, induce a vasodilatation of meningeal arteries and neurogenic inflammation 
(Williamson et al., 1997; Hargreaves and Shepheard, 1999).  As was postulated for 
sumatriptan, which inhibits CGRP release via prejunctional 5-HT1B/1D receptors 
(Humphrey and Feniuk, 1991; Goadsby and Edvinsson, 1993), other receptors are 
involved in mediating CGRP release.  One such example is the adenosine A1 receptor, 
which, after activation with the highly selective A1 receptor agonist GR79236, inhibits 
trigeminal neurones and their release of CGRP both in vitro and in vivo (Humphrey et al., 
2001).  Early indications from a human experimental study suggest that GR79236 may 
have antimigraine action by inhibiting nociceptive trigeminal neurones (Giffin et al., 
2001).  Another class of receptors that are also implicated in mediating CGRP release are 
the prostanoid receptors.  Exposure to the prostaglandines PGE2, carbaprostacyclin 
(cPGI2) and PGD2 results in increased CGRP release from trigeminal neurones of the rat 
mediated via the E-, I- and D- prostanoid receptors, respectively (Jenkins et al., 2001). 
These observations suggest that certain prostanoid receptor antagonists could be potential 
antimigraine drugs. Overall, inhibition of CGRP release is an interesting and challenging 
approach to unravel certain aspects of the pathophysiology of migraine. For this purpose, 
the human isolated middle meningeal artery can be used as a very suitable preparation 
since it is richly innervated with CGRP containing fibres.  As discussed in Chapter 2, an 
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additional level of interest in the acute treatment of migraine is the trigeminus nucleus 
caudalis, which transduces intracranial nociceptive information to higher centres in the 
brain.  Apart from the binding sites that recognise 5-HT1 receptor ligands various other 
receptors, which also modulate c-fos expression in the trigeminus nucleus caudalis, have 
been identified (Mitsikostas and Sanchez del Rio, 2001).  Particularly, the non-NMDA 
ionotropic glutamate GluR5 (an AMPA/kainate subtype) receptor appears to be an 
interesting new target.  The GluR5 receptor antagonist LY293558 potently blocks 
electrically-induced c-fos expression in the rat trigeminus nucleus caudalis.  A high 
intravenous dose (1.2 mg/kg) of LY292558 is effective in migraine patients 
(Ramadan et al., 2001) with no vasoconstrictor properties in rabbit saphenous vein 
(Johnson et al., 2001).  It can be argued whether the role for this GluR5 receptor is specific 
for migraine since it is involved in general pain processing (Zhou et al., 1996).  LY293558 
is known as an analgesic by reducing spinal neurone sensitisation and is also effective for 
post-operative and clinical pain (Sang et al., 1998; Gilron et al., 2000). 
 Inhibition of cortical spreading depression is yet another way to target migraine, as 
described earlier, SB220453 is such a compound currently under clinical investigation.  
SB220453, after intravenous administration of glyceryltrinitrate, however, did not delay a 
migraine attack in migraine patients implicating no acute antimigraine activity 
(Tvedskov et al., 2001).  Another way in developing antimigraine drugs is linking genetic 
factors to migraine.  Several investigators have shown mutations on the α1A subunit of a 
brain specific P/Q type calcium channel in patients with hemiplegic migraine 
(Ophoff et al., 1998; Terwindt et al., 1998).  The full understanding of this calcium 
channelopathy is not know but at least one compound has been investigated with 
promising results.  The P/Q type calcium channel blocker α-eudesmol potently inhibits 
presynaptic neuropeptide release from perivascular trigeminal terminals and attenuated 
neurogenic vasodilatation in rat (Asakura et al., 2000).  Whether this compound will be 
effective in migraine remains to be elucidated. It should be noted though that in a 
substantial group of migraine patients no genetic mutations have been found.  In any case, 
various different pathways are currently being explored, all with a different angle but with 
the same goal; the development of safer and better antimigraine drugs. 
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Chapter 10 
Summary – Samenvatting 
10.1 Summary 
Chapter 1 discusses the clinical symptoms of migraine as well as the current antimigraine 
drugs available.  Although the pathophysiology of migraine has not been fully elucidated, 
this neurological disorder can be divided in distinct phases.  The initial trigger phase most 
probably involves a brainstem ‘generator’ which upon activation causes a reduction of 
cerebral blood flow. If this reduction of cerebral blood flow falls below a critical value a 
migraine aura can be experienced. In response to this blood flow reduction, vasodilatation 
of large cranial arteries occurs, inducing the headache phase. 
 This vasodilatation is one of the key targets in acute migraine treatment, ergot 
alkaloids were the first non-selective vasoconstrictors effective in migraine. With the aim 
of craniovascular selectivity, sumatriptan and its followers, the second-generation triptans, 
were designed to exclusively counter cranial vasodilatation.  These, co-called 5-HT1B/1D 
receptor agonists are all effective in migraine with similar pharmacotherapeutic but 
different pharmacokinetics properties.  Despite their success, all triptans to date have the 
propensity to contract the human coronary artery and are therefore, contraindicated in 
patients with coronary artery disease. 
 
In Chapter 2 the mechanisms of action of current and future antimigraine drugs are 
reviewed.  Originally designed to act on postsynaptic vascular 5-HT1 receptors, the 
triptans demonstrated high affinities for the 5-HT1B, 5-HT1D and 5-HT1F receptors. 
Various studies did show that the triptans constrict cranial blood vessels via the 5-HT1B 
receptor and not via the 5-HT1D or 5-HT1F receptor.  Other mechanisms of action of the 
triptans have been postulated, which include the trigeminovascular system.  Activated 
trigeminal fibres release vasodilatory neuropeptides and the triptans are believed to block 
the subsequent plasma protein extravasation via the presynaptic 5-HT1D receptor.   
However, plasma protein extravasation has only been demonstrated in animal models and 
selective blockers failed to demonstrate antimigraine activity in patients.  Another 
suggested pathway in the action of the triptans lays within the central nervous system.  
Brain penetrant triptans inhibit action potentials from the trigeminus nucleus caudalis and 
thus, block the nociceptive information towards higher brain centres. The exact nature of 
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the receptor involved in this pathway needs to be further investigated, but a role for the 
5-HT1D or 5-HT1F receptor is suggested.  Interestingly, but still under debate, agonists with 
a selectivity towards the 5-HT1F receptor, devoid of vasoconstrictive properties, are 
effective in migraine and active in the trigeminovascular models.  Specific 5-HT1D 
receptor agonists are inactive in migraine. 
 Preventing vasodilatation of cranial blood vessels can be a target in antimigraine 
therapy. Various receptors mediate relaxation in blood vessels and are implicated in 
migraine, the 5-HT2B and 5-HT7 receptors are such targets and antagonists against these 
receptors can be effective in migraine therapy.  The role of the neuropeptide CGRP is also 
discussed, released during a migraine attack it dilates cranial arteries and relief of migraine 
headache by sumatriptan is accompanied by normalisation of CGRP levels.  To prevent 
CGRP release or block the CGRP receptors may prevent or counter a migraine headache.  
Currently, several CGRP antagonists are under clinical investigation to elucidate 
antimigraine efficacy.  
 Yet another way to target migraine is by early interception of the cascade that leads 
to a migraine attack.  Cortical spreading depression can lead to cranial vasodilatation and 
thus, by preventing this event a migraine attack can be blocked.  The potent cortical 
spreading depression inhibitor SB220453 is under clinical investigation and the results can 
further unravel the importance of this phenomenon in migraine. 
 
Chapter 3 provides an overview of the human blood vessels used as in vitro models in 
migraine.  By using organ bath techniques and measuring mechanical responses to 
antimigraine drugs we can determine certain pharmacological parameters such as potency 
(pEC50) and efficacy (Emax).  The potency and efficacy of different antimigraine drugs 
(with particular interest in the triptans) can be compared or can reveal an insight in the 
receptors involved in the measured responses by using selective antagonists.  Various 
blood vessels used as models for the therapeutic activity or side-effect potential of triptans 
are described.  The human isolated middle meningeal artery is considered the most 
important in vitro model depicting the therapeutic site of action.  Measuring potency and 
efficacy of current and newly developed triptans clearly indicates that the 5-HT1B receptor 
mediates the contraction and thus, the therapeutic activity. Other cranial arteries such as 
the cerebral and temporal arteries reveal similar results. As further discussed, the triptans 
also have the propensity to constrict the coronary artery causing unwanted coronary 
related side effects.  In order to predict whether antimigraine drugs cause coronary adverse 
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events, peripheral blood vessels, such as the isolated coronary artery and saphenous vein, 
can be studied. The results obtained clearly indicate that the triptans constrict the isolated 
coronary artery, albeit with a profound lower potency and efficacy as compared to cranial 
blood vessels. A well as was the case for contraction in cranial blood vessels, the triptans 
constrict the peripheral blood vessels most probably via the 5-HT1B receptor.  The 
differences between the therapeutic and side effect models can be explained by the fact the 
5-HT1B receptor is more densely expressed in the cranial vasculature as opposed to the 
peripheral blood vessels, supporting the craniovascular selectivity of the triptans. Despite 
this cranioselectivity, all triptans to date will remain contraindicated in patients with 
coronary artery disease. 
 
The aims of the thesis therefore, were (i) to determine the effects of several current and 
prospective antimigraine drugs on human isolated blood vessels of relevance to 
therapeutic activity and side-effect potential, and (ii) to investigate and characterise which 
receptors/mechanisms are involved in vascular responses elicited by antimigraine drugs. 
 
In Chapter 4, we investigated contraction to eletriptan, sumatriptan and 5-HT in blood 
vessel models predictive of clinical efficacy (human middle meningeal artery) and side-
effect potential (human coronary artery and saphenous vein). By constructing cumulative 
concentration response curves, using organ bath techniques, we derived EC50 (potency) 
and Emax (efficacy) values. Using these parameters we predicted the contraction of 
eletriptan and sumatriptan at clinical plasma concentrations. The potency of eletriptan and 
sumatriptan was higher in middle meningeal artery than in coronary artery and saphenous 
vein, indicating cranioselectivity.  In coronary artery the potency of eletriptan was lower 
as compared to sumatriptan, whereas the compounds were equipotent in middle meningeal 
artery and saphenous vein. The efficacy of eletriptan and sumatriptan was similar within 
tissues.  The predicted contractions by sumatriptan (100 mg p.o.) and eletriptan (40 mg 
and 80 mg p.o.) at free plasma concentrations were similar in middle meningeal artery, but 
in the side-effect potential models they appear to be lower for 40 mg eletriptan than for 
sumatriptan.  In conclusion, both eletriptan and sumatriptan contract middle meningeal 
artery at therapeutic concentrations more than coronary artery. While both drugs have a 
limited propensity to cause adverse coronary side effects in patients with healthy coronary 
arteries, they must remain contraindicated in patients with coronary artery disease. 
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In Chapter 5, we studied the contractile effects of donitriptan and sumatriptan on the 
human isolated blood vessels of relevance to therapeutic efficacy in migraine (middle 
meningeal artery) and coronary adverse events (coronary artery).  Furthermore, using the 
concentration response curves in the middle meningeal artery, we have predicted the 
plasma concentration needed for therapeutic effect of donitriptan.  Both triptans contracted 
the middle meningeal artery with similar efficacy, but the potency of donitriptan was 
significantly higher than that of sumatriptan.  In the coronary artery, the contraction to 
donitriptan was biphasic with a significantly higher efficacy than sumatriptan, yielding 
two distinct pEC50 values.  Incubation with the 5-HT2 receptor antagonist ketanserin 
(10 µM) eliminated the low-affinity, high-efficacy component of the concentration 
response curve of donitriptan.  Ketanserin was without effect on the sumatriptan-induced 
contraction.  Both triptans had similar selectivity for the middle meningeal over coronary 
artery.  The predicted therapeutic concentration for donitriptan amounted to ~4.5 nM, 
which is likely to induce only a small contraction of the coronary artery.  In conclusion, 
the results suggest that donitriptan would be effective in aborting migraine attacks with 
similar coronary side-effect profile as sumatriptan. 
 
The aim of the investigation in Chapter 6 was to study the effects of the benzopyran 
derivative SB220453 in human isolated blood vessels important in migraine (middle 
meningeal, coronary artery and saphenous vein) and atrial and ventricular cardiac 
trabeculae.  SB220453, inhibits the cortical spreading depression and is undergoing 
clinical evaluation in migraine, exhibits a high affinity for a selective, yet unknown, 
binding site in the human brain. Previous studies revealed that SB220453 inhibits nitric 
oxide release and cerebral vasodilatation induced by trigeminal nerve stimulation. While 
the 5-HT1B/1D receptor agonist sumatriptan induced a marked contraction in all blood 
vessels studied, SB220453 was devoid of any effect.  In atrial and ventricular cardiac 
trabeculae, neither sumatriptan nor SB220453 displayed any inotropic effect.  Since 
SB220453 did not contract the middle meningeal artery, we conclude that should 
SB220453 prove effective in migraine, its therapeutic efficacy, unlike that of sumatriptan, 
will be independent of cranial vasoconstriction.  Because SB220453 also did not contract 
the coronary artery, saphenous vein or cardiac trabeculae, the compound is unlikely to 
display adverse cardiac side effects. 
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In Chapter 7 we further characterised which receptor is involved in eletriptan-induced 
contraction in comparison to that of sumatriptan.  We compared the effects of eletriptan 
and sumatriptan on the human isolated middle meningeal and coronary arteries and 
saphenous vein, used as models for therapeutic efficacy and potential side effects, and 
have investigated the role of 5-HT1B/1D receptors in contractions induced by these triptans.  
Concentration-response curves to eletriptan and sumatriptan were constructed in the 
absence or presence of a selective 5-HT1B/1D receptor antagonist, GR125743.  All three 
blood vessels constricted in response to eletriptan and sumatriptan, but the middle 
meningeal artery relaxed following the highest concentration (100 µM) of eletriptan. In 
the middle meningeal artery, GR125743 antagonised the contractions induced by both 
eletriptan and sumatriptan to a similar degree (pA2: 8.81±0.17 and 8.64±0.21, 
respectively).  In the human coronary artery and saphenous vein, sumatriptan-induced 
contractions were also potently antagonised by GR125743 (pA2: 8.18±0.27 and 8.34±0.12, 
respectively).  The eletriptan-induced contractions of the human saphenous vein were 
antagonised less effectively by GR125743 (pKB: 7.73±0.18), and those of the human 
coronary artery remained unaffected by GR125743 up to a concentration of 100 nM.  In 
conclusion, these results suggest that based on the differences in pEC50 values, the 
cranioselectivity of eletriptan (63-fold) is higher than that of sumatriptan (5-fold) in 
coronary artery. Furthermore, the contractile effects of sumatriptan and eletriptan (lower 
concentrations) in the three blood vessels are mediated via the 5-HT1B receptor, but 
additional mechanisms seem to be involved in coronary artery and saphenous vein 
contractions and middle meningeal artery relaxation following high concentrations of 
eletriptan. 
 
 
Chapter 8 set out to investigate whether 5-HT1B and/or 5-HT1D receptors mediate 
contractions of the human isolated middle meningeal and temporal arteries (models for 
antimigraine efficacy) and coronary artery and saphenous vein (models for side-effect 
potential).  Concentration-response curves were made with sumatriptan in blood vessels in 
the absence or presence of selective antagonists at 5-HT1B (SB224289) and 5-HT1D 
(BRL15572) receptors.  SB224289 antagonised sumatriptan-induced contractions in all 
blood vessels, although the antagonism profile was different amongst these blood vessels.  
In the temporal artery, SB224289 abolished contraction to sumatriptan, whereas in the 
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middle meningeal artery and saphenous vein, sumatriptan-induced contractions were 
blocked in an insurmountable fashion.  Moreover, SB224289 acted as a weak 
surmountable antagonist in coronary artery (pKB: 6.4±0.2).  In contrast, BRL15572 had 
little or no effect on sumatriptan-induced contractions in the four blood vessels 
investigated.  In situ hybridisation revealed the expression of 5-HT1B receptor mRNA in 
the smooth muscle as well as endothelial cells of the blood vessels, whereas the mRNA 
for the 5-HT1D receptor was only very weakly expressed.  These results show that the 
5-HT1B receptor is primarily involved in sumatriptan-induced contractions of human 
cranial arteries, but indicate that possible other mechanisms may as well be part of this 
contraction in peripheral blood vessels. 
 
10.2 Samenvatting 
Hoofdstuk 1 beschrijft de klinische symptomen van migraine, alsmede de huidige 
antimigraine middelen op de markt.  De pathofysiologie van migraine is nog niet geheel 
bekend, maar deze neurologische ziekte kan worden opgedeeld in verschillende fases. De 
initiële fase bestaat uit een stimulans waarbij hoogst waarschijnlijk een hersenstam 
generator betrokken is, die na activatie een verlaging geeft van cerebrale bloedstromen.  
Als deze cerebrale bloedstroom lager wordt dan een bepaalde kritieke waarde kan er een 
migraine aura optreden.  Als reactie op de verlaging van de bloedstroom gaan de grote 
craniale bloedvaten verwijden, die vervolgens de migraine hoofdpijn fase bewerkstelligen. 
 Deze dilatatie is een van de belangrijkste aanknooppunten in de acute antimigraine 
behandeling, ergot alkaloïden waren de eerste niet-selectieve vaatvernauwers effectief 
tegen migraine.  Met als doel om een betere selectiviteit voor craniale bloedvaten te 
bewerkstelligen werd sumatriptan, en zijn opvolgers, de tweede generatie triptanen, 
ontwikkeld om deze craniale vasodilatatie tegen te gaan.  Deze zogenaamde 5-HT1B/1D 
receptor agonisten zijn allen effectief tegen migraine met vergelijkbare 
farmacotherapeutische, maar verschillende farmacokinetische eigenschappen.  Ondanks 
hun succes kunnen huidige triptanen ook de humane coronair arterie contraheren, 
waardoor zij gecontraïndiceerd zijn in patiënten met coronaire arterie ziekten. 
 
In Hoofdstuk 2 worden de werkingsmechanismen van huidige en toekomstige 
antimigraine middelen beschreven.  Oorspronkelijk ontwikkeld om op postsynaptische 
vasculaire 5-HT1 receptoren aan te pakken, is gebleken dat de triptanen voornamelijk een 
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hoge affiniteit voor de 5-HT1B, 5-HT1D en 5-HT1F receptoren hebben. Uit verschillende 
studies is gebleken dat de triptanen craniale bloedvaten contraheren via de 5-HT1B 
receptor, en niet via de 5-HT1D of 5-HT1F receptoren.  Er zijn suggesties voor andere 
werkingsmechanismen van de triptanen waarbij het trigemino-vasculaire systeem 
betrokken is.  Geactiveerde trigeminale zenuwvezels geven vasodilatoire neuropeptiden af 
en men denkt dat de triptanen de hierop volgende plasma eiwit extravasatie blokkeert via 
de presynaptische 5-HT1D receptoren.  Echter, plasma eiwit extravasatie is alleen 
aangetoond in proefdier modellen en selectieve blokkers zijn ineffectief gebleken tegen 
een migraine aanval.  Een derde mogelijk werkingsmechanisme van de triptanen ligt 
binnenin het centrale zenuwstelsel. Triptanen die de bloed-hersen barrière kunnen 
passeren blokkeren actiepotentialen, die ontstaan in de trigeminus nucleus caudalis, 
waardoor ze de pijn transmissie naar hogere hersencentra remmen.  Het is nog niet precies 
bekend welke receptoren dit laatste mechanisme mediëren, maar een rol voor de 5-HT1F of 
5-HT1D receptor wordt gesuggereerd.  Opvallend, maar nog steeds betwist, zijn de 
agonisten met affiniteit voor de 5-HT1F receptor die, zonder vasoconstrictieve 
eigenschappen, effectief zijn in de trigeminovasculaire modellen en ook effectief in 
migraine. Specifieke 5-HT1D receptor agonisten zijn ineffectief in migraine. 
 Het voorkomen van dilatatie van craniale bloedvaten kan een streefpunt zijn in 
antimigraine therapie.  Verscheidene receptoren mediëren relaxatie van bloedvaten en zijn 
betrokken in migraine, zoals de 5-HT2B en 5-HT7 receptoren, en antagonisten tegen deze 
receptoren kunnen effectief zijn tegen migraine.  De rol van de neuropeptide CGRP wordt 
ook bediscussieerd, welke wordt afgegeven tijdens een migraine aanval, waarna het 
dilatatie van craniale bloedvaten veroorzaakt.  Verlichting van de hoofdpijn door 
sumatriptan gaat samen met het normaliseren van de CGRP waarden.  Het voorkomen van 
CGRP afgifte of het blokkeren van de CGRP receptoren zou een migraine aanval kunnen 
tegengaan of stoppen.  Momenteel worden er verschillende CGRP antagonisten getest in 
de kliniek om antimigraine activiteit op te helderen. 
 Nog een andere manier om een migraine aanval tegen te gaan is door een vroege 
onderbreking van de cascade, die leidt tot de uiteindelijke migraine aanval.  Corticale 
spreidingsdepressie kan leiden tot craniale vasodilatatie en dus door het voorkomen van 
dit fenomeen kan een opkomende migraine aanval geblokkeerd worden.  De potente 
corticale spreidingsdepressie blokker SB220453 wordt momenteel onderzocht in de 
kliniek en de resultaten kunnen de rol van dit fenomeen in migraine verduidelijken. 
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Hoofdstuk 3 geeft een overzicht van de humane bloedvaten, die gebruikt worden als in 
vitro modellen in migraine.  Door middel van het gebruik van orgaanbad technieken en het 
meten van responsen van antimigraine medicijnen kunnen we verschillende 
farmacologische parameters bepalen, zoals potency (pEC50) en efficacy (Emax).  De 
potency en efficacy van verschillende antimigraine middelen (met name de triptanen) kan 
vergeleken worden of inzichten verschaffen in de receptoren, die betrokken zijn bij de 
gemeten responsen, bijvoorbeeld door middel van het gebruik van selectieve antagonisten.  
Verscheidene bloedvaten die als therapeutische- of als mogelijke bijwerkingsmodellen 
gebruikt kunnen worden, worden beschreven in dit hoofdstuk.  De geïsoleerde humane 
arteria meningea media wordt beschouwd als het belangrijkste therapeutische in vitro 
model.  De gemeten potency en efficacy van huidige en nieuw ontwikkelde triptanen geeft 
een duidelijke indicatie dat de 5-HT1B receptor verantwoordelijk is voor de contractie en 
dus de therapeutische werking.  Andere craniale bloedvaten, zoals de cerebrale en 
temporale arteriën, vertonen vergelijkbare resultaten. Verder wordt nog bediscussieerd dat 
de triptanen de neiging hebben om de coronair arterie te contraheren, wat ongewenste 
coronair gerelateerde bijwerkingen geeft. Om te voorspellen of antimigraine medicijnen 
coronaire bijwerkingen veroorzaken kunnen perifere bloedvaten, zoals de geïsoleerde 
coronair arterie of vena saphena magna, gebruikt worden.  De resultaten laten duidelijk 
zien dat de triptanen de geïsoleerde coronair arterie contraheren, alhoewel met een 
onmiskenbaar lagere potency en efficacy in vergelijking tot craniale bloedvaten.  Zoals het 
in sterke mate gold voor de craniale bloedvaten, veroorzaken de triptanen contractie van 
perifere bloedvaten via de 5-HT1B receptoren.  De verschillen tussen de therapeutische- en 
bijwerkingsmodellen kunnen verklaard worden door het feit dat de 5-HT1B receptor veel 
sterker tot expressie wordt gebracht in de craniale vasculatuur ten opzichte van de perifere 
bloedvaten, wat de stelling van cranioselectiviteit van de triptanen ondersteunt.  Ondanks 
deze cranioselectiviteit zijn alle huidige triptanen gecontraïndiceerd in patiënten met 
coronair arterie ziekten. 
 
Het doel van dit proefschrift was daarom tweeledig. Ten eerste wilden wij de effecten van 
bestaande en nieuw ontwikkelde antimigraine middelen bepalen met behulp van 
verschillende in vitro modellen relevant voor therapeutische activiteit en mogelijke 
bijwerkingen. Ten tweede wilden we de receptoren/mechanismen karakteriseren van de 
door deze antimigraine middelen gemedieerde responsen. 
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In Hoofdstuk 4 onderzochten we de contractie van eletriptan, sumatriptan en 5-HT in 
bloedvaten, die gebruikt worden voor het bepalen van therapeutische activiteit (humane 
arteria meningea media) of mogelijke bijwerkingen (humane coronair arterie en vena 
saphena magna).  Door middel van het construeren van concentratie respons curven, met 
behulp van orgaanbadjes, hebben we EC50 (potency) en Emax (efficacy) waarden bepaald.  
Met deze parameters hebben we de verwachte contractie van eletriptan en sumatriptan 
bepaald van klinische plasma concentraties.  De potency van eletriptan en sumatriptan was 
hoger in de arteria meningea media in vergelijking tot die in de coronair arterie en vena 
saphena, dat cranioselectiviteit impliceert.  In de coronair arterie was de potency van 
eletriptan lager dan die van sumatriptan, terwijl de middelen een gelijke potency hadden in 
de arteria meningea media en vena saphena.  De efficacy van eletriptan en sumatriptan 
was gelijk binnen alle bloedvaten. De voorspelde contracties van sumatriptan (100 mg 
oraal) en eletriptan (40 mg en 80 mg oraal) bij vrije plasma concentraties waren gelijk, 
maar in de bijwerkingsmodellen leek het erop dat de voorspelde contractie lager was voor 
40 mg eletriptan dan die voor sumatriptan.  Samenvattend, zowel eletriptan als 
sumatriptan contraheren de arteria meningea media bij therapeutische concentraties meer 
dan de coronair arterie.  Alhoewel beide medicijnen weinig neiging hebben om coronaire 
bijwerkingen te veroorzaken, zullen ze gecontraïndiceerd blijven in patiënten met 
coronaire arterie ziekten. 
 
In Hoofdstuk 5 hebben we de contraherende effecten van donitriptan en sumatriptan 
bestudeerd in de geïsoleerde humane bloedvaten, die relevant zijn voor de therapeutische 
effectiviteit (arteria meningea media), en coronaire bijwerkingen (coronair arterie) in 
migraine. Verder hebben we getracht om, met behulp van de concentratie respons curven 
in de arteria meningea media, de plasma concentratie van donitriptan te berekenen, 
waarbij klinische activiteit te verwachten is.   Beide triptanen contraheerden de arteria 
meningea media met een zelfde efficacy, maar de potency van donitriptan was significant 
hoger dan die van sumatriptan.  In de coronair arterie bestond de contractie door 
donitriptan uit twee fasen, elk met een eigen pEC50 waarde, met een significant hogere 
efficacy dan sumatriptan.  Incubatie met de 5-HT2 receptor antagonist ketanserine (10 µM) 
elimineerde het ‘lage affiniteit, hoge efficacy’-gedeelte van de concentratie response curve 
van donitriptan.   Ketanserine had geen effect op de sumatriptan geïnduceerde contracties.  
Beide triptanen hadden vergelijkbare selectiviteit voor de arteria meningea media ten 
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opzichte van de coronair arterie.  De voorspelde therapeutische concentratie voor 
donitriptan bedroeg ~4.5 nM, die waarschijnlijk voor een kleine contractie zorgt in de 
coronair arterie. Samenvattend suggereren de resultaten dat donitriptan effectief zal zijn 
tegen migraine, waarbij een vergelijkbaar coronaire bijwerkingsprofiel als sumatriptan te 
verwachten is. 
 
Het doel van de studie in Hoofdstuk 6 was het bestuderen van de effecten van de 
benzopyran derivaat SB220453 in geïsoleerde humane bloedvaten belangrijk in migraine 
(arteria meningea media, coronair arterie en vena saphena magna), alsmede cardiale atriale 
en ventriculaire trabekels.  SB220453, een corticale spreidingsdepressie blokker dat 
momenteel een klinische evaluatie in migraine ondergaat, heeft een hoge affiniteit voor 
een selectieve maar nog onbekende bindingsplaats in de humane hersenen.  Eerdere 
studies hebben laten zien dat SB220453 zowel de afgifte van stikstof oxide, maar ook 
cerebrale vasodilatatie, na trigeminale zenuw stimulatie, remt.  Terwijl de 5-HT1B/1D 
receptor agonist sumatriptan alle onderzochte bloedvaten duidelijk contraheerde, had 
SB220453 geen effect. In cardiale atriale en ventriculaire trabekels had noch sumatriptan, 
noch SB220453 enig inotroop effect.  Omdat SB220453 de arteria meningea media niet 
contraheert kunnen wij concluderen dat, indien SB220453 effectief blijkt te zijn in 
migraine, het therapeutisch effect, in tegenstelling tot sumatriptan, onafhankelijk zal zijn 
van craniale vasoconstrictie.  Omdat SB220453 ook de coronair arterie, de vena saphena 
en de cardiale trabekels niet contraheert, is het onwaarschijnlijk dat deze stof cardiale 
bijwerkingen veroorzaakt. 
 
In Hoofdstuk 7 hebben we een verdere karakterisatie gemaakt van de receptor die 
betrokken is bij de eletriptan geïnduceerde contractie en deze vergeleken met sumatriptan.  
We hebben de effecten van eletriptan en sumatriptan vergeleken in de geïsoleerde humane 
arteria meningea media, coronair arterie en vena saphena magna, die gebruikt worden als 
modellen voor therapeutische effectiviteit en mogelijke bijwerkingen. Verder hebben we 
de rol van de 5-HT1B/1D receptoren, die deze contractie mediëren, onderzocht.  
Concentratie response curven van eletriptan en sumatriptan werden geconstrueerd in af- en 
aanwezigheid van de selectieve 5-HT1B/1D receptor antagonist GR125743. Alledrie de 
bloedvaten contraheerden in respons op eletriptan en sumatriptan, maar in de arteria 
meningea media volgde er een relaxatie bij de hoogste concentratie (100 µM) van 
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eletriptan.  In de arteria meningea media antagoneerde GR125743 zowel de eletriptan, 
alsmede de sumatriptan geïnduceerde contractie op een zelfde manier (pA2: 8.81±0.17 and 
8.64±0.21, respectievelijk).  In de humane coronair arterie en vena saphena werd de 
sumatriptan geïnduceerde contractie ook potent geblokt door GR125743 (pA2: 8.18±0.27 
and 8.34±0.12, respectievelijk). De eletriptan geïnduceerde contractie in de vena saphena 
werd minder effectief geblokkeerd door GR125743 (pKB: 7.73±0.18) en die in de coronair 
arterie bleven onaangetast door GR125743 tot en met een concentratie van 100 nM.  
Concluderend, suggereren de resultaten dat, gebaseerd op de verschillen in pEC50 
waarden, eletriptan (63-keer) cranioselectiever is dan sumatriptan (5-keer) in de coronair 
arterie.  Verder is gebleken dat de contractie geïnduceerde effecten van sumatriptan 
worden gemedieerd via de 5-HT1B receptor, terwijl er aanvullende mechanismen 
betrokken zijn in de coronair arterie en vena saphena constrictie, en arteria meningea 
media relaxatie, na hoge concentraties eletriptan. 
 
Hoofdstuk 8 had als doel te onderzoeken of de 5-HT1B of 5-HT1D receptor 
verantwoordelijk is voor het mediëren van geïsoleerde humane arteria meningea media en 
temporalis (modellen voor antimigraine effectiviteit), en coronair arterie en vena saphena 
magna (modellen voor mogelijke bijwerkingen).  Concentratie response curven werden 
geconstrueerd met behulp van sumatriptan in de af- en aanwezigheid van selectieve 
antagonisten voor de 5-HT1B (SB224298) en 5-HT1D (BRL15572) receptoren.  SB224289 
antagoneerde sumatriptan geïnduceerde contracties in alle bloedvaten, alhoewel het soort 
antagonisme verschillend was tussen de bloedvaten.  In de arteria temporalis werd 
sumatriptan volledig geblokkeerd door SB224289, terwijl in de arteria meningea media en 
vena saphena de sumatriptan geïnduceerde contractie niet competitief geblokkeerd was.  
Bovendien antagoneerde SB224289 op een zwakke niet-competitieve manier in de 
coronair arterie (pKB: 6.4±0.2).  In tegenstelling tot SB224289 had BRL15572 weinig tot 
geen effect op de sumatriptan geïnduceerde contracties in de vier bloedvaten die waren 
onderzocht. In situ hybridisatie toonde aan dat er expressie van 5-HT1B receptor mRNA 
aanwezig was in zowel het gladde spierweefsel als het endotheel, terwijl er zeer weinig 
expressie gevonden werd voor de 5-HT1D receptor.  Deze resultaten laten zien dat de 
5-HT1B receptor primair betrokken is bij sumatriptan geïnduceerde contracties in humane 
craniale bloedvaten, maar suggereren dat er mogelijk andere mechanismen 
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medeverantwoordelijk zijn voor een gedeelte van deze contracties in de perifere 
bloedvaten.
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List of Abbreviations 
5-HIAA 5-hydroxyindole acetic acid 
5-HT  5-hydroxytriptamine, serotonin 
AMPA alpha-amino-3-hydroxy-5-methyl-4-propionate 
ANOVA analysis of variance 
BIBN4096BS a CGRP antagonist 
BMS181885 a discontinued triptan 
BRL15572 a selective 5-HT1D receptor antagonist 
c-fos  an early expression gene 
cAMP  cyclic adenosine monophosphate 
CGRP  calcitonin gene related peptide 
CHO cells Chinese hamster ovary cells 
CI confidence interval 
Cmax maximum plasma concentration 
CP122288 a PPE inhibitor, restricted analogue of sumatriptan 
cPGI2 carbaprostacyclin I2 
DIG digoxigenine 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
EC50  concentration of agonist at half maximal effect  
Emax  maximum induced effect of an agonist 
F11356 donitriptan HCl 
F12640 donitriptan mesylate 
GMC2021 a discontinued triptan 
GR125743 a reversible 5-HT1B/1D receptor antagonist 
GR127935 an irreversible 5-HT1B/1D receptor antagonist 
GR79236 an adenosine1 receptor agonist 
IHS  international headache society 
IS-159  a novel triptan  
L775,606 a 5-HT1D receptor agonist 
LY292558 a glutamate R5 receptor antagonist 
LY334370 a 5-HT1F receptor agonist 
LY344864 a 5-HT1F receptor agonist 
mCPP  meta-chlorophenylpiperazine 
(m)g (milli)gram 
min minute 
mm millimeter 
(m)N  (milli) Newton 
(m)RNA (messenger) ribonucleic acid 
NA noradrenaline 
(n/µ/m)M (nano/micro/milli) molar 
NK-1  neurokinin 1 
nH  Hill coefficient  
NMDA N-methyl-D-aspartate 
NO  nitric oxide 
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NPY neuropeptide Y 
NSAIDs non-steroid anti-inflammatory drugs 
pA2 negative logarithm of the concentration of antagonist to produce a two-fold 
shift to the right of an agonist concentration response curve. 
pEC25% negative logarithm of agonist concentration eliciting a response equivalent 
to 25% of (control) Emax 
pEC50  negative logarithm of EC50 
PGF2α/E2/D2 prostaglandin F2α/E2/D2 
pKi  negative logarithm of binding affinity constant 
pKB negative logarithm of antagonist-receptor dissociation equilibrium constant 
PNU-109291  a 5-HT1D receptor agonist 
PNU-142633 a 5-HT1D receptor agonist 
p.o. per os (orally) 
PPE plasma protein extravasation 
RNase ribonuclease 
RT-PCR reverse transcriptase polymerase chain reaction 
SB220453 a cortical spreading depression inhibitor 
SB224289 a selective 5-HT1B receptor antagonist 
SB273779 a CGRP antagonist 
s.c. subcutaneous 
s.e.mean standard error of the mean 
T1/2 plasma half life time 
Tmax time to reach maximal plasma concentration 
U46619 tromboxane A2 analogue 
VIP vasoactive intestinal peptide 
 
 
 
 
